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Abstract
Abstract
The epidermal growth factor receptor (EGFR) and its family of ligands may be 
associated with the progression of atherosclerosis by mediating the proliferation and 
migration of endothelial cells and vascular smooth muscle cells. However there is 
some evidence that EGFR is expressed by cells of the monocytic lineage. This study 
was undertaken to investigate the expression of the EGFR on monocytes and 
macrophages and explore its potential function. The expression of the EGFR was 
studied using the monoclonal antibody ICR62. Flow cytometry revealed that the 
monocytic THP-1 cell line expressed EGFR on its surface and specific EGFR 
reactivity was also observed by western blotting analysis. Whilst PMA differentiated 
THP-1 cells failed to show cell surface expression of the receptor, 
immunocytochemical analysis revealed the receptor was localized to the nucleus. 
Human peripheral blood-derived monocytes and monocyte-derived macrophages 
showed minimal cell surface expression of EGFR. EGFR gene transcription in 
monocytic THP-1 cells was induced 2.7 fold following treatment with 50nM HB- 
EGF for 12 hours and this was statistically significant (PO.Ol). Differentiated THP- 
1 cells showed a 1.5 fold increase in gene expression following treatment with 50nM 
TGFa for 12 hours; this increase was also highly significant (PO.Ol). Gene 
expression was also significantly increased in both monocytic and differentiated 
THP-1 cells following 12 hours treatment with lOOU/ml IFNy [3.7 fold (PO.Ol) and
1.8 fold (PO.Ol) respectively] and 2.5ng/ml IL-lp [3.6 fold (PO.Ol) and 1.7 fold 
(PO.05) respectively)]. Newly isolated human peripheral blood-derived monocytes 
displayed very low EGFR mRNA expression. However, during maturation in vitro,
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gene expression peaked following 48 hours in culture and returned to baseline after 
96 hours. Exposure of THP-1 cells to HB-EGF (0.1 nM) resulted in a 3 fold increase 
(PO.Ol) in maximum chemotactic activity. This response was found to be greater 
than the 2 fold increase seen with the well established monocyte chemokine MCP-1 
at InM (PO.05). Peripheral blood-derived monocytes had a statistically significant 
(PO.Ol) 2.4 fold increase in their chemotactic response compared to unstimulated 
control cells when exposed to lOnM HB-EGF. This was equivalent to the response 
seen for O.lnM MCP-1 with these same cells. Interestingly, as the monocyte 
matured into an 8 day old macrophage-like cell the chemotactic response to O.lnM 
MCP-1 decreased, whereas peak chemotactic activity to HB-EGF occurred at lower 
concentrations. Incubation of peripheral blood-derived monocytes with the 
inhibitory monoclonal antibody ICR62 significantly (P<0.05) reduced chemotactic 
activity towards HB-EGF (O.lnM) in a dose dependent manner. 
Immunohistochemical analysis of human arterial sections revealed EGFR expression 
within atherosclerotic lesions. Further analysis showed that EGFR expression co­
localised with macrophages. It therefore appears that the EGFR is expressed by the 
THP-1 cell line and human peripheral blood-derived monocytes and may play a role 
in the pathogenesis of human atherosclerosis.
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Chapter One 
Introduction
Cardiovascular disease (CVD) is the major cause of death globally. An estimated
17.5 million people died from CVD in 2005, representing 30% of all global deaths. 
Of these deaths, an estimated 7.6 million were due to coronary heart disease and 5.7 
million were due to stroke (The WHO, 2008).
CVD, encompassing coronary heart disease (CHD) and stroke, is also the main cause 
of mortality in the UK and accounts for 38% of all deaths. In 2003, CHD caused 
over 38,000 premature deaths in the UK (BHF Statistics Database).
1.1 Atherosclerosis
Atherosclerosis is a multi-factorial disease with a complex aetiology. It is a 
progressive disease characterised by the accumulation of lipids, cellular components 
and fibrous material within the large arteries (Libby, 2002; Stary et aL, 1994). The 
initiation of the atherosclerotic process is believed to begin with a protective 
response to injury of the endothelium and the smooth muscle cells (SMCs) of the 
artery wall which is usually accompanied by an inflammatory response (Ross, 1993). 
Over time the artery wall can become thickened and calcified, and looses its 
elasticity. Although advanced lesions can grow sufficiently large to block the arterial 
lumen, the most prevalent clinical complication occurs if  the plaque ruptures or 
becomes ulcerated. In this situation, platelets adhere and aggregate creating a
1
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thrombus over the site of the rupture further increasing plaque size (Lusis, 2000). 
The luminal narrowing which follows can lead to ischemia of the heart, brain or 
extremities resulting in infarction (Ross, 1999).
Many epidemiological studies have revealed numerous risk factors associated with 
CVD {Table 1.1). They can in general terms be classed as unmodifiable, for example 
gender and age, or modifiable, for example smoking and hypertension. Due to the 
complex nature of atherosclerosis it is difficult to define a one particular factor as the 
major inducer o f the disease (Patel & Kent, 1998). However, elevated levels of 
serum cholesterol are probably unique in being sufficient to drive plaque 
development in humans and experimental animals, even in the absence of other 
known risk factors (Glass & Witztum, 2001). One increasingly prevalent clinical 
scenario involves the intertwining o f the development of atherosclerosis with an 
underlying insulin resistance and its associated metabolic abnormalities (Plutzky, 
2003).
2
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Table 1.1 Risk factors associated with cardiovascular disease (CVD).
Unmodifiable Factors References
Advancing age (Aronow, 2006)
Gender (Nathan & Chaudhuri, 1997)
Menopausal Status (Wenger, 2006)
Familial hypoalphalipoproteinemia (Vega & Grundy, 1996)
Family history (Watkins & Farrall, 2006)
Ethnicity/Race (Forouhi & Sattar, 2006;
Watson & Topol, 2004)
Autoimmune disease (Sherer & Shoenfeld, 2006)
e.g. lupus, rheumatoid arthritis
Major Modifiable Factors
Obesity (Grundy, 2004)
Smoking (Lakier, 1992)
Hypercholesterolemia (Tulenko & Sumner, 2002)
Increased Lipoprotein(a) (Seman et al., 1999)
Hypertriglyceridemia (Austin et al., 1998)
Diabetes/insulin resistance (Lebovitz, 2006)
Hypertension (Kannel, 1996)
High dietary saturated fat (Griel & Kris-Etherton, 2006)
Hypothyroidism (Dorr & Volzke, 2005)
Physical Inactivity (Wannamethee et al., 2002)
Raised levels of clotting factors (Kannel, 2005)
e.g. fibrinogen
Minor Modifiable Factors
Low antioxidant status (Aviram et al., 2005)
Infection -  bacterial or viral (Lowe, 2001)
Hyperhomocysteinemia (Fanapour et al., 1999)
Alcohol intake (Emberson et al., 2005)
Certain medication e.g. contraceptive pill (Farley et al., 1998)
Mental ill-health inc. psychosocial stress (Andre-Petersson et al., 2006)
Obstructive sleep apnea (Parish & Somers, 2004)
3
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1.1.1 Pathogenesis
In regions of arterial branching or curvature, blood flow is disturbed and non- 
laminar. In these areas, the endothelial cells (ECs) lining the arterial wall have 
polygonal shapes and no particular orientation. This may be associated with an 
increased permeability to macromolecules such as low density lipoprotein (LDL) and 
triglycerides (Lusis, 2000; Staiy et al., 1992). This process formed the basis of the 
response-to-injury hypothesis which now contributes to the understanding that 
endothelial dysfunction is the first step in atherocslerosis (Ross, 1999). Other causes 
of endothelial dysfunction include elevated and modified LDL, free radicals caused 
by cigarette smoking, hypertension, diabetes mellitus, elevated plasma homocysteine 
levels and infectious microorganisms such as Chlamydia pneumonia (Ross, 1999).
Due to increased endothelial permeability, LDL enters and becomes trapped within 
the vessel wall (Mora et al., 1987). Accumulations within the vessel wall have been 
observed in humans (Morton et al., 1986; Hoff & Gaubatz, 1982) and experimental 
animal models (Rosenfeld et al., 1990; Haberland et al., 1988; Hoff & Bond, 1982). 
These observations led to the formation o f the response-to-retention hypothesis 
which stated that sub-endothelial lipid retention within the vessel wall leads to a 
cascade of responses which results in disease in a previously non-lesional artery 
(Williams & Tabas, 1998). Once retained, the lipoproteins undergo modifications 
(Aviram, 1993), i.e. oxidation (Palinski et al., 1989; Yla-Herttuala et al., 1989) and 
acetylation (Goldstein et al., 1979), which contributes to an inflammatory response 
(Yla-Herttuala et al., 1994). Both of these processes are also regarded to be 
important steps in the initiation process of atherosclerosis (Ross, 1999; Witztum & 
Steinberg, 1991).
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It is proposed that cardiovascular risk factors enhance endothelial oxidative stress. 
Superoxide anions are released locally from ECs, attached monocytes or from 
macrophages and SMCs contained within the sub-endothelial space (Sattar et al.,
1998). Oxidised low density lipoprotein (oxLDL) has been shown to reduce nitric 
oxide (NO) synthesis and promote its destruction. Oxidative stress thus limits the 
endothelial cell to produce NO and its ability to promote vasodilation leading to 
endothelial dysfunction and loss o f its anti-atherogenic abilities (Sattar et al., 1998).
Once dysfunctional, ECs begin to produce a number of chemotactic and pro- 
inflammatory molecules including monocyte chemotactic protein-1 (MCP-1) (Navab 
et al., 1991) and macrophage colony stimulating factor (M-CSF) (Rajavashisth et al., 
1990). T lymphocytes and monocytes are subsequently attracted to the area and 
adhere in clusters to the endothelial cell surface. After rolling over the endothelium, 
the monocytes and T lymphocytes are tethered to the endothelium via specific 
adhesion molecules e.g. vascular cell adhesion molecule-1 (VCAM-1), intercellular 
adhesion molecule-1 (ICAM-1) and P & E Seleetin (Glass & Witztum, 2001; Lusis, 
2000). Under the influence o f chemoattractants, such as MCP-1, oxLDL and 
transforming growth factor p (TGFp) released by the endothelium, adherent 
leukocytes and possibly SMCs, the leukocytes penetrate the endothelial cell junctions 
and accumulate in the subendothelial space (Ross, 1993). High density lipoprotein 
(HDL) has been shown to inhibit this migration by inhibiting lipoprotein oxidation 
(Navab et al., 1991).
Beneath the surface o f the endothelium the monocytes differentiate into tissue 
macrophages. Under the influence of M-CSF the macrophages proliferate and begin
5
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to express the scavenger receptors SR-A, SR-B, CD36 and CD68 (Libby, 2002). 
These receptors mediate the uptake and accumulation of oxLDL which results in the 
formation of foam cells and increased release o f inflammatory mediators such as 
tumour necrosis factor a (TNFa), interleukin lp (IL-lp), IL-8 and M-CSF. This in 
turn leads to the increased transcription of the LDL-receptor gene which results in 
enhanced binding of LDL to the endothelium and SMCs. The monocyte is possibly 
primed for this outcome by its strong association with extracellular matrix 
components such as collagen I as it enters the intima. Together with the T 
lymphocytes in the intima, the foam cells form the first recognisable lesion of 
atherosclerosis, the fatty streak (Osterud & Bjorklid, 2003).
The transition from the fatty streak to the more complex lesion is characterised by
the immigration of SMCs from the media, through the internal elastic lamina and
into the developing intima (Glass & Witztum, 2001). The medial SMCs are attracted
into the intima by chemotactic factors such as platelet derived growth factor (PDGF)
and basic fibroblast growth factor (bFGF). Here, the SMCs produce extracellular
matrix which forms the fibrous cap overlaying the lipid-rich core and with this the
lesion is classified as advanced (Plutzky, 2003; Stary et al., 1995; Ross, 1993). With
time, the macrophage foam cells die, contributing their lipid-filled contents to the 
*
necrotic core of the lesion. This is thought to result from cell-cell interactions and 
the local cytokine environment within the arterial wall, involving the actions o f pro- 
and anti-apoptotic proteins that include death receptors, proto-oncogenes and tumour 
suppressor genes (Glass & Witztum, 2001). As a consequence, the lesion expands, 
initially towards the adventitia through vascular remodelling until a critical point is 
reached, after which it begins to expand outwards, encroaching into the luminal
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space. At this point the plaque may become stable and subsequently pose no further 
clinical threat The necrotic core remains small and is separated from the lumen by a 
thick fibrous cap containing SMCs and type I and III collagen fibres. However, if  
the lesion continues to undergo further insult, the migration o f new mononuclear 
cells from the blood may occur. These then accumulate at the shoulder region of the 
plaque and lead to the destabilisation of the plaque (Plutzky, 2003; Lusis, 2000).
Although advanced lesions can lead to ischemia due to the progressive narrowing of 
the lumen, acute cardiovascular events that result in myocardial infarction, stroke and 
in some cases death, are generally thought to result from plaque rupture and 
thrombosis (Glass & Witztum, 2001). The forces that maintain the stability o f the 
fibrous cap on an advanced lesion are in a fine balance between the synthesis of 
matrix materials and their degradation. The products of inflammatory cells are likely 
to influence both processes. For example, macrophages are known to secrete matrix 
metalloproteinases (MMP-1, MMP-3 and MMP-9) in response to several mediators 
secreted from T lymphocytes and monocytes e.g. TNFa, and IL-lp. T cells also 
produce interferon y (IFNy) which inhibits matrix production by SMCs (Lusis, 
2000). Apoptosis can also play an important role in plaque rupture. SMC death can 
be harmful because it may weaken the fibrous cap through a decrease in the 
production of collagen fibres. However, apoptosis of macrophages and T 
lymphocytes can be beneficial as removal o f inflammatory cells from the plaque 
could attenuate the inflammatory response and decrease the production o f MMPs. 
Unfortunately, apoptosis o f these cells can also lead to an increased inflammatory 
response and a decrease in the uptake o f other apoptotic bodies leading further to the 
formation o f an acellular necrotic core (Tabas, 2005; Martinet & Kockx, 2004;
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Martinet & Kockx, 2001; Libby et al., 1996). Due to the nature o f cells involved in 
these processes most plaque ruptures occur within the macrophage-rich shoulder 
region of the lesion (Glass & Witztum, 2001).
The stability of atherosclerotic lesions may also be influenced by calcification and 
neovascularisation. The process of calcification is regulated by cytokines and 
oxysterols acting on pericyte-like cells. These cells secrete a matrix scaffold which 
subsequently becomes calcified, akin to bone formation. Plaques may also become 
vascularised during the process o f remodelling with large numbers o f capillaries and 
venule-like channels maybe as a result of bFGF and/or other angiogenic molecules. 
These vessels may act as conduits for further entry of inflammatory cells (Lusis, 
2000; Ross, 1993).
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1.2 The Monocytic Lineage
It is clear from the evidence in the previous section that monocytes and macrophages 
are present during all stages of atherogensis and play a vital role in the development 
and stability o f the plaque.
1.2.1 The Monocyte
From its production in the bone marrow, under the influence of various cytokines 
including M-CSF, the monocyte circulates within the blood both as a defence cell 
and as a precursor to the tissue macrophage. In response to pathogens, monocytes 
and macrophages play a key role in cell-mediated immunity. Cross-linking of these 
receptors by immobilized immunoglobulin (IgG) or immune complexes results in the 
production of cytokines, i.e. MCP-1, IL-8, TNFa and M-CSF, and reactive oxygen 
species (ROS) (Baran et al., 2004).
The recruitment and translocation o f monocytes to and within the intima is an 
important determinant of plaque development (Lessner et al., 2002). Many 
chemokines are thought to be involved in this process. MCP-1, considered the 
principal cytokine in attracting monocytes to the intima has been found to be 
abundantly expressed in human lesions and has been extensively investigated within 
in vivo models (Ikeda et al., 2002; Reape & Groot, 1999; Han et al., 1998). Its 
effects are mediated through the CC-motif chemokine receptor-2 (CCR2) which is 
expressed on circulating monocytes. Other chemokines include macrophage 
inflammatory protein-1 alpha (MIP-la), MIP-ip and regulated on activation, normal 
T-cell-expressed and secreted (RANTES). Their common receptor, CCR5, is
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expressed during monocyte differentiation into macrophages. As CCR2 expression 
has been found to be decreased during monocyte maturation (Phillips et al., 2005), it 
has been speculated that these chemoattractants play their main role in the migration 
of macrophages already established within the main lesion (Osterud & Bjorklid, 
2003; Reape & Groot, 1999; Cross et al., 1997; Uguccioni et al., 1995). 
Lysophosphatidylcholine (lysoPC), formed by the oxidation of LDL particles, is also 
a potent chemoattractant (Quinn et al., 1988) as are oxLDL, TGFp and the colony 
stimulating factors (CSFs) (Ross, 1993).
Once attracted to the endothelium they adhere and roll over the cellular membrane 
with the aid of VCAM-1, ICAM-1 and the P and E-selectins (Osterud & Bjorklid, 
2003). Monocytes migrate through the endothelial barrier at junctional sites, with 
the assistance o f platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) and 
CD99 (Schenkel et al., 2002; Muller & Randolph, 1999). Once in the intimal space, 
monocytes interact with components o f the extracellular matrix (ECM), thought to be 
a prerequisite for the formation of foam cells and modified LDL particles (Ross,
1999). Monocytes also differentiate into tissue macrophages under the influence of 
M-CSF. This process is thought to depend on many transcription factors including 
nuclear factor-icB (NFkB), which has been shown to accumulate in the cytoplasm of 
differentiated macrophages (Osterud & Bjorklid, 2003).
1.2.2 The Macrophage
Macrophages are present in all stages of atherogenesis carrying out roles such as 
acting as antigen-presenting cells to T-lymphocytes, acting as scavenger cells to 
remove noxious materials, and as a source o f growth-regulatory molecules,
10
Chapter 1 -  Introduction
cytokines, chemokines, metalloproteinases and other hydrolytic enzymes. The 
macrophage is therefore considered to be the principal inflammatory mediator of 
cells in the atheromatous plaque microenvironment (Ross, 1999).
Sub-populations of macrophages appear to develop in part as a result o f the different 
stimuli that they encounter within a tissue microenvironment. Macrophages can be 
‘classically activated’ in response to a priming signal from IFNy produced by type-1 
T helper (Thl) cells and a secondary signal from lipopolysaccharide (LPS) inducing 
TNF production through toll-like receptors (TLRs). These activated macrophages 
migrate to sites of inflammation and act as effector cells in Thl cellular responses, 
i.e. cell mediated immunity. They are characterised by an increased expression of 
interleukins (IL-1, IL-6 and IL-12), NO and chemokines (MIP-la and MCP-1). 
These cells are highly microbicidal and proinflammatory. ‘Alternatively activated’ 
macrophages or type-II activated macrophages mediate type-2 T helper (Th2) cell 
adaptive immune responses, i.e. antibody production. These macrophages develop 
following exposure to IL-4 and IL-13 and appear to be involved in tissue repair and 
immunosuppression and could serve a more regulatory and recovery function. Under 
these conditions they fail to produce NO but do produce IL-1, IL-10 and high levels 
of fibronectin. (Mosser, 2003; Ma et al., 2003; Gordon, 2003). Both Thl and Th2 
responses regulate each other; IFNy inhibits the Th2 pathway and IL-10 inhibits the 
Thl pathway (Linton & Fazio, 2003). There are several other factors that can either 
induce or enhance monocyte/macrophage activation. These are summarised in Table 
1.2.
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Table 1.2 Agents that induce/enhance monocyte/macrophage activation that 
have been associated with the development of atherosclerosis (Ma et al., 2003; 
Osterud & Bjorklid, 2003).
Immune Stimulatory Agents Cytokines
Bacteria - LPS IL-lp, IL-6, IL-12, IL-8
Immune Complexes TNFa
Complement Factors (C3a & C5a) IFNy
Lectins
Virus Platelet-derived activation products 
P-selectin
Growth Factors Platelet microparticals
PDGF Platelet factor 4
M-CSF
G-CSF Proteins
Fibrinogen
Lipids Proteoglycans
Oxidised LDL Proteases
Lipoproteins
Reactive oxygen species
Eicosanoids 0 2~, #OH
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IL-10 and TGFp play an important role in dampening macrophage activation. IL-10 
is a broad spectrum inhibitor of macrophage function, effecting cytokine, chemokine, 
NO and MMP production. It also inhibits the expression of major histocompatibility 
complex (MHC) class II molecules. TGFp has similar effects as IL-10. However, its 
most important function is in limiting the production of ROS and nitrogen 
intermediates by cells either activated by IFNy or LPS (Ma et al., 2003).
Recent work on the phenotyping of macrophage subsets has indicated that 
macrophages are capable of adapting to their microenvironment and do not 
terminally differentiate into one particular phenotype. Instead, unless the signal 
initiates an apoptotic cascade, the macrophage will eventually revert to its original, 
functional status after the cytokine signalling ceases (Stout & Suttles, 2004).
1.2.3 The Macrophage Foam Cell
Macrophages are capable o f internalising LDL through the surface LDL receptor 
(LDLR). They are protected from accumulating LDL through the down regulation of 
the LDL receptors and through the trafficking o f cellular cholesterol to 
apolipoprotein A l (ApoAl), a constituent o f HDL, in the blood via the ATP-binding 
cassette transporter A l (ABCA1). However, by taking up modified LDL particles, 
macrophages turn into fat-loaded macrophages or foam cells. Modified LDL, either 
oxidised, myloperoxidased or acetylated, has an affinity for the series of 
aforementioned transmembrane scavenger receptors. These receptors have been 
found to be induced during the differentiation o f monocytes into macrophages 
(Osterud & Bjorklid, 2003). The expression o f the scavenger receptors is regulated 
by peroxisome proliferator-activated receptor y (PPARy), whose ligands include
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oxidised fatty acids, and by cytokines such as TNFa and IFNy (Linton & Fazio, 
2003; Linton & Fazio, 2001; Lusis, 2000). Since IFNy has been found to 
downregulate ABCA1 and cholesterol efflux from foam cells, this cytokine cascade 
may promote cholesterol accumulation in the lesion, and may be responsible for the 
accelerated transformation of macrophages into foam cells (Wang et al., 2002). 
Foam cells are capable o f releasing further amounts o f inflammatory mediators such 
as IL-lp, IL-6, TNFa, IL-8 and M-CSF. This can result in increased monocyte 
recruitment, further LDL oxidation and production o f MMPs consequently leading to 
plaque instability and possible rupture (Osterud & Bjorklid, 2003; Libby, 2000).
1.2.4 Macrophage Apoptosis
Macrophage death in atherosclerotic lesions is almost certainly multifactorial 
involving high levels o f oxLDL, oxysterols, TNFa, Fas ligand, NO, growth factor 
withdrawal, hypoxia/ATP depletion, and intracellular accumulation of unesterified, 
or ‘free’, cholesterol. It is likely that some o f the death inducers in early lesions are 
different from those in the more advanced lesions (Tabas, 2005). In the early lesion, 
the phagocytic clearance o f apoptotic macrophages is very efficient and 
physiologically beneficial. However, in advanced lesions apoptotic macrophages are 
more numerous suggesting that the phagocytic clearance is defective (Tabas, 2005). 
Here, the inefficient clearance leads to secondary necrosis of the macrophage which 
leads to the generation of the necrotic core, increased inflammation, plaque 
instability and acute lesional thrombosis (Tabas, 2005; Li & Glass, 2002).
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1.3 The Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR) is a 170-kDa glycoprotein and is the 
prototype of the type-1 growth factor receptor family with tyrosine kinase activity. 
The complete amino acid sequence of the EGFR was deduced from its gene sequence 
in the 1980’s (Hunter & Cooper, 1985; Ullrich et al., 1984). These data also 
revealed that the EGFR is homologous to the v-erb-B oncogene of avian 
erythroblastosis virus (Downward et al., 1984b).
The EGFR family consists of four members: ErbBl (also termed EGFR, HER1), 
ErbB2 (also termed HER2, pl85, or neu), ErbB3 (also termed HER3 or pl60) and 
ErbB4 (also termed HER4 or p i80). All four family members are expressed by a 
wide variety o f cell types and tissues throughout the body (Casalini et al., 2004; 
Yano et al., 2003), including the vasculature (Table 1.3).
1.3.1 EGFR Structure
The extracellular region or ectodomain o f the EGFR is responsible for the binding of 
epidermal growth factor (EGF) and the other ligand family members. This region 
consists of four domains which provide the receptor with its ligand specificity and 
contact with the plasma membrane (Jorissen et al., 2003; Lax et al., 1991; Lax et al., 
1989) (figure 1.1 A). Evidence has indicated that in order to create the ligand binding 
site, all four regions would fold into a configuration that forms a ligand binding 
pocket (Cadena & Gill, 1992; Ullrich & Schlessinger, 1990) (figure LIB).
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Table 1.3 Expression and sites of action of the EGF family of growth factors 
with reference to atherogenesis.
Ligand Cells & Tissues 
of Production
Receptor Sites of Action References
Epidermal
Growth
Factor
Receptor
(EGF)
Platelets (bone 
marrow)
EGFR Vascular smooth 
muscle and 
endothelial cells
(Styren et al., 1993; 
Oka & Orth, 1983; 
Bhargava et al., 1979; 
Gospodarowicz et ah, 
1978)
Heparin-
Binding
Epidermal
Growth
Factor
(HB-EGF)
Macrophages,
monocytes,
T lymphocytes, 
smooth muscle 
and endothelial 
cells
EGFR, ErbB4 Vascular smooth 
muscle cells
(Matsumoto et al., 
2002; Blotnick et al., 
1994; Nakano et al., 
1994; Yoshizumi et 
a l,  1992;
Higashiyama et al., 
1991)
Transforming 
Growth 
Factor a 
(TGFa)
Macrophages, 
vascular smooth 
muscle cells
EGFR Endothelial cells (Lee et al., 1995; 
Derynck, 1992; 
Mueller et al., 1990; 
Rappolee et al., 1988; 
Madtes et a l,  1988)
Betacellulin
(BTC)
Vascular smooth 
muscle cells, 
macrophages
EGFR, ErbB4, 
ErbB2:ErbB3
Vascular smooth 
muscle cells
(Dunbar & Goddard, 
2000; Riese et al., 
1996; Shing et a l, 
1993)
Amphiregulin
(AR)
Activated human 
monocytes
EGFR;
EGFR:ErbB2
Vascular smooth 
muscle cells
(Shin et al., 2003; 
Mograbi et al., 1997)
Epiregulin
(EPR)
Peripheral blood 
macrophages, 
vascular smooth 
muscle cells
EGFR, ErbB4 Smooth muscle 
cells
(Koo & Kim, 2003; 
Toyoda et a l,  1997)
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CR1 L2 CR2 KINASE CT
JMTM
EGFDOMAIN FUNCTION
Ligand binding 
DimerizationExtracellular
Transmembrane
Juxtamembrane
Membrane anchor 
Negative Control (Thr 654)
ATP
ATP binding (Lys 721) 
Substrate binding 
Catalytic activities
Tyrosine
Carboxy-terminal tail Signal regulation
Figure 1.1 Schematic representations of the domains and proposed structure- 
function topology of the EGF Receptor. (A) EGF receptor domains with amino 
acid positioning. Abbreviations used: L for ligand binding domain and CR for 
cysteine-rich domain. The 4 domains are also known as I(L1), II(CRl), III(L2) and 
IV(CR2). TM - transmembrane domain, JM - juxtamembrane domain and CT - 
carboxy-terminus (Jorissen et al., 2003). (B) Subdomains I and IV represent the 
cysteine-rich regions of the extracellular domain. Left: side view. Right: top view. 
S and R represent the proposed interaction sites for substrates and regulatory 
molecules (Ullrich & Schlessinger, 1990).
17
Chapter 1 -  Introduction
The transmembrane domain o f the EGFR consists of a single alpha-helix and its 
main function is to anchor the receptor in the plasma membrane (Ullrich & 
Schlessinger, 1990; Kashles et al., 1988). The juxtamembrane domain is conserved 
between members of the EGFR family. It has been suggested that this region is 
involved in regulatory functions such as receptor downregulation (via threonine 654), 
ligand-dependent internalization events, basolateral sorting and interaction with 
proteins such as calmodulin and heterotrimeric G proteins (Jorissen et al., 2003; 
Wells, 1999; Ullrich & Schlessinger, 1990).
The cytoplasmic domain has been found to carry the structural determinants that 
define kinase specificity, high affinity binding, mitogenic and transforming potential, 
and receptor trafficking (Van der Heyden et al., 1997; Riedel et al., 1989). All four 
EGFR family members have one uninterrupted tyrosine kinase domain in the 
cytoplasmic region however, ErbB3’s region is inactive as a result o f three point 
mutations which disable the receptor’s ability to facilitate the transfer of phosphates 
between ATP and the receptors substrates (Wells, 1999; Guy et al., 1994). This 
domain is the most highly conserved region of all the receptor tyrosine molecules 
(Fantl et al., 1993; Carpenter & Cohen, 1990). There is a consensus sequence, 
GlyXGlyXXGlyX(15-20)Lys, that functions as part o f the binding site for ATP. 
Replacement o f the consensus Lys721 residue completely abolishes kinase activity 
(Ullrich & Schlessinger, 1990; Moolenaar et al., 1988; Honegger et al., 1987). 
Various receptor mutants have been developed to investigate the importance o f the 
tyrosine kinase domain (Prywes et al., 1986). Although kinase activity was not 
found to be essential for receptor expression and targeting to the cell membrane, it 
was essential for signal transduction and induction o f both early and late cellular
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responses, including mitogenesis and transformation (Chen et al., 1987). Protein 
tyrosine kinase activity was also found to be important for EGFR targeting to 
lysosomes upon ligand-induced activation. This implied that lysosomal targeting 
requires the phosphorylation o f specific substrates, or that components o f the 
intracellular routing system may only recognise the conformation of an activated 
receptor (Ullrich & Schlessinger, 1990). The binding of EGF to its receptor in vitro 
is associated with the generation of hydrogen peroxide (H2O2) through 
phosphoinositol 3-kinase (PI3-K) in a variety o f cell types (Gamou & Shimizu,
1995). H2O2 has been found to reversibly oxidize protein tyrosine phosphatases 
(PTPases) which can lead to a more sustained receptor phosphorylation (Lee et al., 
1998; Bae et al., 1997; Gamou & Shimizu, 1995).
The carboxy-terminal tail sequences of the EGFR family are among the most 
divergent o f the known receptor tyrosine kinases (Ullrich & Schlessinger, 1990). 
Phosphorylation sites have been mapped to the carboxy-terminal tail o f the EGFR at 
tyrosine residues 992, 1068, 1086, 1148 and 1173 (Fantl et al., 1993; Walton et al., 
1990; Margolis et al., 1989; Downward et ah, 1984a). Autophosphorylation of the 
receptor is mediated by the intrinsic kinase activity through an intermolecular 
process. This involves the catalytic domain o f one receptor partner phosphorylating 
its neighbouring receptor partner (Moriki et al., 2001; Yarden & Schlessinger, 
1987b).
1.3.2 EGFR Localisation
All receptors are synthesized and directed to specific cellular locations on the cell 
membrane. Their distribution is a dynamic event, which can be dependent on the
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type of cell (Wiley, 2003). Experiments have shown that a region in the extracellular 
juxtamembrane domain of the receptor targets it to caveolae/raft regions (Yamabhai 
& Anderson, 2002). However, it is still unclear as to where precisely the 
unstimulated receptors are directed. Some studies indicate that more than half of the 
unstimulated EGFRs on the cell surface are located within caveolae; these are 
cholesterol- and sphingolipid-rich invaginations o f the plasma membrane containing 
the protein caveolin-1 (Jorissen et al., 2003; Lai, 2003; Anderson, 1998). However, 
other studies have shown that they are located in non-caveolar membrane domains 
(Roepstorff et al., 2002; Waugh et al., 1999). It has been observed that with short 
exposure to ligand, receptors become associated with lipid rafts, whereas, with 
longer stimulation, the receptors are associated with caveolae where they became 
dephosphorylated. This is consistent with the fact that caveolin is a negative 
regulator of the receptor (Matveev & Smart, 2002; Couet et al., 1997), and that 
cholesterol affects the function of the receptor. Cholesterol depletion increases 
ligand binding, the signalling activity of the receptor and decreases internalization 
(Roepstorff et al., 2002; Pike & Casey, 2002). It has also been proposed that a 
variety o f proteins that are involved in cell signalling are concentrated in cholesterol- 
rich microdomains known as membrane rafts. It is thought that membrane rafts 
function as sites of assembly o f proteins involved in cell signalling including the 
receptors (Lai, 2003; Schlessinger, 2000; Simons & Ikonen, 1997).
1.3.3 Receptor Activation
The EGFR family is activated by a family of peptide growth factors {Table 1.4). 
Among these are: epidermal growth factor (EGF), transforming growth factor a 
(TGFa), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR),
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betacellulin (BTC), epiregulin (EPR), epigen, and the four neuregulins (NRGs). 
NRG-1 is also known as Neu differentiation factor (NDF), heregulin (HRG), 
acetylcholine receptor-inducing activity (ARIA) and glial growth factor (GGF) 
(Harris et al., 2003; Falls, 2003; Massague & Pandiella, 1993).
EGF family members are commonly grouped with respect to their structural 
homology and biological activity. All members contain one or more repeats of a 
conserved six cysteine-containing motif in their extracellular domain. These six 
cysteine residues are contained within a sequence of 35-40 amino acids CX7CX4. 
5CX10-13CXCX8GXRC (C, cysteine; G, glycine; R, arginine; X, any amino acid), and 
have the potential to form three intra-molecular disulfide bond pairings between C l- 
C3, C2-C4 and C5-C6 to produce three loops that are essential for high-affinity 
binding to the receptor (Harris et al., 2003; Lee et al., 1995; Massague & Pandiella,
1993).
The EGF family of growth factors are derived from type-I transmembrane 
glycoprotein precursors. These precursor molecules comprise an extracellular region 
containing the growth factor sequence, a hydrophobic trans-membrane domain and a 
cytoplasmic domain. Within the plasma membrane they undergo proteolytic 
cleavage resulting in the release of soluble, biologically active growth factors 
(Massague & Pandiella, 1993). This cleavage is achieved by members o f the family 
of a disintegrin and metalloproteinase (ADAMs) which have a wide tissue 
distribution and are essential for mammalian development (Primakoff & Myles, 
2000; Peschon et al., 1998). Certain factors are capable o f enhancing growth factor 
shedding. Treatment of cells with the phorbol ester 12-0-tetradecanoyl-phorbol-13-
21
Chapter 1 -  Introduction
acetate (TPA), an activator of protein kinase C (PKC), induces a strong increase in 
the level of TGFa synthesis in keratinocytes and other cells as well as increased 
cleavage of the membrane bound form (Lee et al., 1995).
Some membrane-bound forms of EGF and TGFa have been found to be biologically 
active by promoting juxtacrine stimulation of EGFR receptors on adjacent cells 
(Singh & Harris, 2005; Lee et al., 1995; Massague & Pandiella, 1993; Anklesaria et 
al., 1990). It has also been suggested that proHB-EGF can promote juxtacrine 
stimulation o f the EGFR through its association with CD9 and integrin a3pl, and 
that this may generate a different EGFR-mediated signal than that generated by the 
soluble form (Harris et al., 2003; Iwamoto & Mekada, 2000). For example, a trans­
membrane HB-EGF has been found to protect rat hepatoma cells from TGFp- 
induced apoptosis, whereas the soluble mature HB-EGF has no protective effect 
(Raab & Klagsbrun, 1997).
The biological activities of the different members o f the EGF family o f growth 
factors are similar. All the members have been shown to induce cell migration, 
differentiation and gene expression, and are involved in processes such as 
angiogenesis, wound healing, bone reabsorption, atherosclerosis, blastocyst 
implantation and tumour growth (Lee et al., 1995).
Ligands that bind to the EGFR family o f receptors can be divided into two classes 
{Table 1.4). The first group includes EGF, TGFa, HB-EGF, BTC, AR, EPR and 
epigen; these bind to ErbBl homodimers. Unlike the other members o f this group, 
BTC, HB-EGF and EPR are also able to bind and activate ErbB4 (Piepkom et al.,
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1998; Elenius et al., 1997; Beerli & Hynes, 1996). Furthermore BTC is also capable 
of activating all possible combinations of heterodimeric receptors (Riese et al., 
1996). The second group of ligands are the NRG family. They are known to bind 
ErbB3 and ErbB4 homodimers but are unable to bind ErbBl (Falls, 2003).
Ligand-induced receptor oligomerization of the EGF receptor family has been 
demonstrated in living cells (Sako et al., 2000; Cochet et al., 1988), intact isolated 
cell membrane (Sako et al., 2000), in detergent-solubilized (Ge et al., 2002; Hurwitz 
et al., 1991) and purified receptor preparations (Yarden & Schlessinger, 1987a). The 
binding affinity of ligands for the EGF receptor may be high or low, and this may be 
determined in part by the presence of pre-existing bound ligand, or whether the 
receptor is in a dimerized form (Jorissen et al., 2003; Hurwitz et al., 1991; Prywes et 
al., 1986). There is still controversy as to how the ligand-receptor complexes form. 
Many theories have been presented including the conjugation o f ligand-bound 
receptor monomers (Schlessinger, 2000; Lemmon et al., 1997; Sherrill & Kyte, 
1996), asymmetric ligand binding mechanisms (Ge et al., 2002) and conformational 
changes in the extracellular region with ligand binding, with subsequent cytoplasmic 
domain conformational changes (Tanner & Kyte, 1999). It has also been suggested 
that inactive EGFR monomers are in equilibrium with active receptor dimers without 
bound ligand (Moriki et al., 2001; Lemmon et al., 1997).
Once the receptor-ligand dimers are formed, autophosphorylation occurs. The 
catalytic domain adopts an open configuration that permits access to ATP and 
substrates, and enables phosphotransfer from MgATP to tyrosines on the receptor 
itself and on cellular proteins involved in signal transduction (Schlessinger, 2000).
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Table 1.4 The discovery of the epidermal growth factor receptor family of 
major ligands and the ErbB homodimers and heterodimers they bind.
Ligand Cells of Discovery Receptor Reference
EGF Submaxillary glands of 
adult male mice
ErbBl (Carpenter & Cohen, 
1990; Starkey et al., 
1975; Cohen, 1962)
TGFa Murine 3T3 fibroblasts ErbBl (Anzano et al., 1983; De 
Larco & Todaro, 1978)
AR Human breast 
adenocarcinoma cell line 
(MCF-7)
ErbBl,
ErbBl :ErbB2
(Johnson et al., 1993; 
Shoyab et al., 1989; 
Shoyab et al., 1988)
HB-EGF Human U937 macrophage­
like cells
ErbBl, ErbB4 (Raab & Klagsbrun, 
1997; Higashiyama et 
al,, 1991)
BTC Mouse pancreatic p cell 
tumours
ErbBl, ErbB4, 
ErbB2:ErbB3
(Miura et al., 2002; 
Shingeta l., 1993)
EPR Mouse fibroblast-derived 
tumour cell line NIH3T3
ErbBl, ErbB4 (Toyoda etal., 1997; 
Toyoda et al., 1995)
Epigen Mouse keratinocytes ErbBl (Strachan et al., 2001)
NRG-1 Conditioned medium of 
human MDA-MB-231 
breast carcinoma cells
ErbB3, ErbB4 (Holmes et al., 1992)
NRG-2 Sequence analysis & 
molecular cloning
ErbB3, ErbB4 (Carraway, III et al., 
1997; Busfield et al., 
1997)
NRG-3 Sequence analysis & 
molecular cloning
ErbB4 (Zhang et al., 1997)
NRG-4 Sequence analysis & 
molecular cloning
ErbB4 (Harari et a l,  1999)
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The EGFR was the first protein tyrosine kinase (PTK) to be shown to dimerize after 
ligand binding. Since then, many studies have demonstrated the combinatorial 
hetero-oligomerization of different pairs of members o f the EGFR family 
(Schlessinger, 2000). This ability to heterodimerize firstly increases the diversity of 
cellular signalling pathways that can be activated by PTKs, and secondly, increases 
the repertoire o f ligands that can be recognised by each receptor on its own (Lemmon 
& Schlessinger, 1994). Since no ligand has yet been identified for ErbB2, it has been 
proposed that it functions as a promiscuous heterodimeric partner of the other EGFR 
family members providing a platform for the recruitment o f more diverse 
intracellular signalling pathways as a result o f differences in their C-terminal 
domains (Qian et al., 1994). It also appears that ErbB2 is the preferred partner of all 
ErbB proteins. If all the receptors are present then ErbB3 and ErbB4 will 
preferentially bind ErbB2. However, if  ErbB2 is not present, only then will the two 
receptors interact with ErbBl (Graus-Porta et al., 1997). ErbB3 lacks kinase activity 
and so this receptor also serves as a docking protein to recruit a broader spectrum of 
signalling molecules after phosphorylation by EGFR or ErbB2 (Wells, 1999).
1.3.4 Receptor Signalling
Ligation of the EGFR has pleiotropic biological effects. Cellular responses, that 
include mitogenesis, apoptosis, chemotaxis and differentiation, depend on the 
context o f the cell and include cell density, extracellular matrix composition, and 
priming by other cytokines (Wells, 1999) {Figure 1.2). Autophosphorylation allows 
the receptor to recruit adapter proteins such as Grb2 (Lowenstein et al., 1992) and 
She (Batzer et al., 1994) which bind via their Src homology 2 (SH2) (Koch et al., 
1991) and phosphotyrosine-binding (PTB) domains (Schlessinger & Lemmon,
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2003). These adapter proteins further recruit other molecules such as the guanine 
nucleotide exchange factor Sos which activates the small G-protein Ras (Lowy & 
Willumsen, 1993). Once in its active GTP-bound state, Ras interacts with other 
effector proteins leading to the activation o f the MAP (mitogen activated protein) 
kinase pathway. This pathway is highly conserved in evolution and results in the 
control o f metabolic processes, cell cycle, migration, proliferation and differentiation 
(Nishida & Gotoh, 1993). The binding of c-Cbl to the activated bound Grb2 targets 
the EGFR for degradation in the lysosome (Duan et al., 2003; Fukazawa et al.,
1996).
Phospholipase C y (PLCy) binds directly to the activated EGFR via its two SH2 
domains (Chattopadhyay et al., 1999; Meisenhelder et al., 1989). Once active, PLCy 
catalyses the hydrolysis o f phosphatidylinositol 4,5-bisphosphate (PIP2) to produce 
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Toker, 1998). IP3 
mediates calcium release from intracellular stores which, amongst activating a host 
of Ca2+-dependent enzymes such as NFkB (Sun & Carpenter, 1998), has been found 
to be responsible for inducing cellular motility (Chen et al., 1994). DAG however, is 
known to activate PKC (Crotty et al., 2006) which in turn phosphorylates the EGFR 
inhibiting its activity (King & Cooper, 1986).
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Figure 1.2 EGFR signalling pathways. The EGFR, once activated by its family of 
ligands, is capable of activating numerous signalling pathways leading to essential 
cellular processes. The recruitment of the adapter proteins She, Grb2 and Gabl leads 
to the activation of c-Src, known to be involved in mitogenesis; c-Cbl, which targets 
the receptor for degradation and the MAP kinase pathway leading to proliferation. 
The EGFR can also directly bind the STAT transcription factors, which are involved 
in the transcription of numerous target genes, and PLCy, which via IP3 liberates 
calcium resulting in actin reorganisation and migration, and via DAG activates PKC 
which is involved in the downregulation of EGFR activation. Adapted from (Oda et 
al., 2005).
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Activated EGF receptors are also able to activate the signal transducer and activator 
of transcription (STAT) transcription factors, notably STAT-1, 3 and 5. After 
causing rapid tyrosine phosphorylation, they migrate to the nucleus where they are 
involved in the transcription of many target DNA genes such as caspase-1 and the 
cell cycle inhibitor p21WAF/CIP (Darnell, Jr., 1997). This could be a means by which 
PTKs play a role in the negative control o f cell proliferation, as seen sometimes in 
A431 epithelial cells (Jorissen et al., 2003; Hackel et al., 1999).
2.3.5 Receptor Regulation
Receptor tyrosine kinases (RTKs) must be tightly regulated in order to mediate their 
normal control over cellular tasks and physiological responses. Therefore, there are 
many mechanisms that exist that attenuate and terminate the activity of the receptor 
induced by stimulatory ligands including PKC (Lund et al., 1990), protein tyrosine 
phosphatases (PTPases) (Tiganis, 2002) and receptor internalisation (Sweeney & 
Carraway, III, 2004). PKC is capable of phosphorylating Thr654 located in the 
juxtamembrane domain. This results in the abolition o f EGF high-afflnity binding 
and receptor kinase activity in the same cell, as well as inhibition of internalisation 
and downregulation (Lund et al., 1990). Protein tyrosine phosphatases 
dephosphorylate regulatory phosphotyrosine residues which results in the inhibition 
of tyrosine kinase activity and the biological responses mediated by downstream 
effectors that rely on tyrosine activity. In the presence o f PTPase inhibitors, virtually 
all RTKs can be activated, even with the absence of ligand (Schlessinger, 2000).
Growth factor stimulation results in receptor localization to plasma membrane 
clathrin-coated pits, internalization o f coated pits and delivery to endosomes, and
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sorting of receptors for trafficking back to the cell surface or to the lysosomes for 
degradation (Sweeney & Carraway, III, 2004). Following ligand binding and 
dimerization, activated receptors serve as a docking site for Cbl. This protein 
contains a phosphotyrosine binding domain and a RING finger E3 ubiquitin ligase 
domain. Cbl-mediated EGFR ubiquitination is required for efficient sorting of 
activated EGFR to the lysosome for its degradation (Duan et al., 2003).
After internalization, activated receptors are sorted into the lysosomal pathway 
(Wiley, 2003). The ligand-receptor complexes dissociate in acidic endocytotic 
vesicles (Sorkin & Carpenter, 1991) with the ligand then being degraded in the 
lysosomes. The receptor is either degraded or recycled back to the cell surface 
(Massague & Pandiella, 1993). This difference in sorting pathways is thought to 
depend upon protein tyrosine kinase activity, as kinase-negative receptor mutants 
have been shown to recycle back to the cell surface for reutilization, even when 
coexpressed in the same cell as wild-type receptors (Schlessinger, 2000; Ullrich & 
Schlessinger, 1990). It has also been shown to depend upon the receptors 
heterodimerization status. EGFR homodimers are quickly endocytosed and degraded 
in the lysosomes, whereas, a heterodimeric complex with EGFR and either ErbB2 or 
ErbB3 reduces the internalization rate and causes dissociation o f the complex in the 
early endosome resulting in the EGFR being recycled back to the plasma membrane 
(Lenferink et al., 1998).
There is the possibility that internalization is required for signalling as certain critical 
substrates may not be located at the cell surface but further within the cytoplasm 
(Cadena & Gill, 1992). It has been documented that an endosomal fraction is the
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primary site for the EGF-stimulated She phosphorylation and Grb2 recruitment 
(Leof, 2000). It has also been suggested that the receptor could signal in multiple 
locations depending on the particular signalling pathway activated. For example, 
PLCyl -stimulated hydrolysis of PIP2 is restricted to the plasma membrane, whereas 
Ras activation can occur at both the membrane and within an internal compartment 
(Leof, 2000).
1.3.6 Biological Effects
Previous studies have shown that all members of the group one family o f ligands 
compete with each other for binding to the EGFR. TGFa is capable o f competing 
with EGF for the EGFR (Massague, 1983). However, it has been suggested that 
these ligands bind in different manners to the receptor and that this may account for 
the differences in the biological activities (Winkler et al., 1989). For example, TGFa 
is a more potent stimulus for keratinocyte migration and angiogenesis than EGF (Lee 
et al., 1995). Both HB-EGF (Thompson et al., 1994) and AR (Thome & Plowman, 
1994) contain a heparin-binding domain, which allow binding to cell surface 
heparin-sulphate proteoglycans which may in turn modulate their biological activity. 
For example, HB-EGF is a more potent smooth muscle cell mitogen than EGF or 
TGFa (Massague & Pandiella, 1993). Also, although HB-EGF is able to stimulate 
proliferation and chemotaxis in cells expressing EGFR, only chemotactic responses 
have been demonstrated in cells expressing ErbB4 alone (Iwamoto & Mekada, 2000; 
Elenius et al., 1997; Thompson et al., 1994). Hence, HB-EGF can bind and activate 
two different types o f receptors leading to different biological outcomes.
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Many cells that synthesise TGFa also possess EGF receptors, allowing the possibility 
of autocrine responses (Derynck, 1992). This can also been seen in some cells 
responsive to AR (Johnson et al., 1993). In addition to interactions between the 
soluble forms of growth factor with the EGFR, membrane bound forms of TGFa and 
EGF are known to exist, and these appear to promote juxtacrine stimulation which 
causes the autophosphorylation of EGF receptors in adjacent cells (Lee et al., 1995; 
Massague & Pandiella, 1993; Anklesaria et al., 1990). It has also been suggested 
that proHB-EGF can promote juxtacrine stimulation of the EGFR through its 
association with CD9 and integrin asPi and that this may generate a different EGFR- 
mediated signal than that generated by the soluble form (Harris et al., 2003; Iwamoto 
& Mekada, 2000). For example, transmembrane HB-EGF has been found to protect 
a rat hepatoma cell line from TGFp-induced apoptosis, whereas soluble mature HB- 
EGF had no protective effect (Raab & Klagsbrun, 1997).
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1.4 The Role of the EGFR Family in Atherogenesis
The EGFR and the EGF family o f growth factors are expressed by cells involved in 
atherogenesis and appear to mediate important biological effects relevant to the 
atherogenic process (figure 1.3).
EGF receptors have been identified immunocytochemically on intimal smooth 
muscle cells within human atherosclerotic plaques (Tamura et al., 2001) as well as 
vascular endothelial cells (Styren et al., 1993). EGF receptors have also been 
demonstrated on cultured rat aortic smooth muscle cells and can mediate both cell 
proliferation and DNA synthesis (Nanney et al., 1988; Tomita et al., 1986).
In some cases, the ligands elicit their actions on the same cells to produce the same 
biological outcome. For example, EGF, TGFa, HB-EGF, BTC and EPR can all 
mediate the transformation of SMCs from a differentiated non-proliferative 
phenotype into a dedifferentiated proliferative and migratory phenotype. This 
change is associated with the development and progression of atherosclerosis 
(Yamanaka et al., 2001).
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Figure 1.3 The expression of the EGFR and its ligands within the atherosclerotic 
plaque. The EGFR is expressed on endothelial cells, smooth muscle cells (SMCs) 
and monocytes/macrophages. These cells also express the EGFR ligands, most 
notably HB-EGF, TGFa, BTC and EPR.
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1.4,1 Heparin-Binding Epidermal Growth Factor
Since its discovery in 1991, HB-EGF has been considered to play an important role 
in atherosclerosis. It was found to be a SMC chemoattractant and mitogen 
(Higashiyama et al., 1993; Higashiyama et al., 1991) mediating its effects via the 
MAP Kinase and PI3-K pathways leading to DNA synthesis (Reynolds et al., 2002). 
HB-EGF is expressed by monocytes (Nakano et al., 1994; Higashiyama et al., 1991), 
SMCs (Dluz et al., 1993; Temizer et al., 1992; Yoshizumi et al., 1992), T cells 
(Blotnick et al., 1994) and endothelial cells (Yoshizumi et al., 1992), and their 
expression o f this growth factor is upregulated by several factors associated with 
atherogenesis (Table 7.5).
HB-EGF mRNA has also been found to be abundantly expressed in human adipose 
tissue. Plasma HB-EGF levels increase with increasing body fat content and this 
appears to be associated with risk o f coronary artery disease in human subjects 
(Matsumoto et al., 2002). In 1995, Miyagawa (Miyagawa et al., 1995) reported the 
expression of HB-EGF protein in SMCs and macrophages associated with human 
atherosclerotic plaques as well as the expression o f the EGF receptor in SMCs. The 
existence o f HB-EGF protein was thereafter discovered in human coronary arteries, 
and its presence was closely associated with the progression o f coronary 
atherosclerosis. It was suggested that HB-EGF protein produced by SMCs and 
macrophages could be involved in the atherosclerotic process, especially in the 
migration and proliferation o f SMCs and in the interaction between SMCs and 
macrophages through the EGFR-mediated signalling pathway (Nakata et al., 1996). 
This was supported by Reape and colleagues, who reported that HB-EGF mRNA and 
protein was present in macrophage rich areas of atherosclerotic human carotid
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Table 1.5 Factors stimulating the production of HB-EGF expression in cells 
associated with atherogenesis. Heparin-binding epidermal growth factor is 
expressed by all the major cell types involved in atherogenesis.
Cell Type and Factor Reference
Smooth Muscle Cells
Angiotensin II (Temizer et al., 1992)
Thrombin (Nakano et al., 1993)
Phorbol ester (Dluz et al., 1993; Temizer et al., 1992)
Serum (Dluz et al., 1993)
HB-EGF (Dluz et al., 1993)
bFGF (Dluz et al., 1993)
PDGF (Dluz et al., 1993)
Vessel injury (Raab & Klagsbrun, 1997)
Endothelial Cells
TNFa (Yoshizumi et al., 1992)
LysoPC (Raab & Klagsbrun, 1997)
High glucose (Asakawa et al., 1996)
Hyperosmolarity (Asakawa et al., 1996)
Sheer stress (Raab & Klagsbrun, 1997)
IL-ip (Yoshizumi et al., 1992)
VEGF (Arkonac et al., 1998)
Monocytes/macrophages
OxLDL (Ouchi et al., 1997)
LysoPC (Nakano et al., 1994)
LPS (Nakano et al., 1994)
Platelet activating factor (PAF) (Pan et al., 1995)
T Lymphocytes
LysoPC (Nishi et al., 1997)
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arteries, as well as the expression of HB-EGF mRNA in both normal and 
atherosclerotic human arteries (Reape et al., 1997). Furthermore, in differentiated 
macrophages and SMCs, HB-EGF and CD9 mRNA and protein are upregulated in 
response to oxLDL or lysoPC which could lead to juxtacrine stimulation (Nishida et 
al., 2000; Ouchi et al., 1997). In SMCs, HB-EGF was found to cause an 
upregulation of PDGF and bFGF mRNA, as well as M-CSF receptor gene expression 
which suggests a possible role in the phenotypic transformation o f SMCs to 
‘macrophage-like’ smooth muscle cell-derived foam cells in atherosclerotic lesions 
(Raab & Klagsbrun, 1997; Peifley et al., 1996). HB-EGF has also been shown to 
mediate the transactivation of EGFR by G-protein coupled receptors (GPCRs) and 
remnant lipoproteins in cultured vascular SMCs, thus suggesting that the EGFR may 
be important in the regulation o f vascular SMCs (Kawakami et al., 2003; Kalmes et 
al., 2001).
1.4.2 Betacellulin
Betacellulin (BTC) and its receptors were reported to be present in the human aortic 
wall (Tamura et al., 2001). The percentage o f BTC-positive medial SMCs increased 
significantly in the aorta in individuals with atherosclerosis. Intimal SMCs also 
showed strong BTC immunoreactivity indicating that this growth factor may be 
involved in intimal SMC proliferation as the two known receptors for BTC, EGFR 
and ErbB4, were also found to be expressed in SMCs with the same distribution 
patterns. This study suggested that BTC is produced by macrophages, and it has also 
been detected in the human monocytic THP-1 cell line. It was also speculated that 
macrophages or foam cells could stimulate or modulate the proliferation o f SMCs by
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secreting BTC. This evidence strongly suggests that BTC may be one of the factors 
involved in atherosclerotic plaque formation.
1.4.3 Epidermal Growth Factor
Although platelets are a putative source o f EGF during atherogenesis, they lack 
protein biosynthetic capability, and are involved late in the atherogenic process. It is 
possible that EGF is synthesized in megakaryocytes and stored in platelets, or that 
EGF is derived from some other source and is subsequently taken up by platelets. It 
has also been suggested that EGF originates from the bone marrow and is released 
into the plasma during the coagulation process (Oka & Orth, 1983).
EGF has been shown to possess mitogenic activity for smooth muscle cells in vitro 
(Thyberg et al., 1990), the effects o f which can be enhanced by TGFp, angiotensin II 
and insulin growth factor-1 (IGF-1), and inhibited by HDL (Ko et al., 1993a; Ko et 
al., 1993b). Furthermore it appears that intimal SMCs are more sensitive to the 
mitogenic effects o f EGF compared to medial smooth muscle cells (Mitsumata et al.,
1994). EGF stimulation o f the EGFR in vascular SMCs activates the MAPK 
pathway, and inhibits angiotensin II action (Gui & Zheng, 2003; Ullian et al., 1997).
1.4.4 Transforming Growth Factor a
There is limited evidence for the role o f TGFa in atherogenesis. It was discovered 
that TGFa could stimulate arterial blood flow (Gan et al., 1987), angiogenesis 
(Schreiber et al., 1986) as well as prostacyclin (PGI2) release from endothelial cells 
which plays a role in vasodilation and inhibition o f platelet aggregation (Ristimaki,
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1989). Since then TGFa has been reported to be produced by activated macrophages 
and vascular smooth muscle cells and as it can promote endothelial proliferation 
TGFa could contribute to the pathogenesis o f atherogenesis (Mueller et ah, 1990; 
Rappolee et al., 1988; Madtes et al., 1988).
1.4.5 Others
Recent data also suggest that amphiregulin and epiregulin may play a role in 
atherogenesis. These growth factors have been found to be produced by human 
monocytes and peripheral blood macrophages respectively, and stimulate smooth 
muscle cell mitogenesis both in vitro and in vivo (Shin et al., 2003; Kato et al., 2003; 
Mograbi et al., 1997; Toyoda et al., 1997). Epiregulin, produced by SMCs, can be 
induced by angiotensin II, endothelin-1 and thrombin (Taylor et al., 1999). It has also 
been found to be the major mediator in factor Xa-induced rat aortic smooth muscle 
cell mitogenesis and can be considered as an autocrine growth factor (Koo & Kim, 
2003).
38
Chapter 1 -  Introduction
1.5 EGFR, Monocytes, Macrophages and Atherogenesis
Although there is already evidence of the expression of three distinct families of 
receptor tyrosine kinases (RTKs) (M-CSF-1R, Axl/Tyro3/Mer and murine 
STK/human RON) in the monocyte/macrophage lineage, there is limited evidence 
for the expression of the EGF receptor family (Correll et al., 2004). There is 
evidence that EGF receptors are expressed on brain-derived microglial cells. 
Furthermore these tissue macrophage-like cells respond chemotactically to EGF 
(Nolte et al., 1997). Some forms of malignancy are associated with an inflammatory 
response, and it has been shown that macrophages associated with this response in 
uveal melanoma express high levels o f EGFR (Scholes et al., 2001). Although 
Mograbi (Mograbi et al., 1997) found that the human monocytic cell line, THP-1 and 
activated human monocytes express HB-EGF, AR and HRG, they reported that 
mRNA for EGFR, c-erbB2 and c-erbB4 was undetectable. Nevertheless, the EGFR 
has been reported to be expressed on another human monocytic cell line, U937 using 
flow cytometry analysis with anti-EGFR antibodies (Eales-Reynolds et al., 2001). 
Furthermore, it has been shown that ErbBl is present on rabbit peripheral blood 
leukocytes, and co-localises with macrophages within lesions o f atherosclerosis in 
the cholesterol-fed rabbit (Lamb et al., 2004). In these experiments, EGFR mediated 
both chemotactic responses towards monocytes and mitogenic responses towards 
monocyte-derived macrophages in vitro. Although EGF was found to be a less 
potent chemotactic factor for peripheral blood monocytes than MCP-1, it was more 
potent than MCP-1 for monocyte-derived macrophages (Lamb et al., 2004). 
Therefore, ligands for ErbBl may only play a limited role in attracting monocytes to 
the atherosclerotic plaque, but they may be important in targeting macrophages to 
different areas o f the plaque, resulting in macrophage-rich areas, such as the shoulder
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region. Upon reaching their destination, the mitogenic effects o f EGF on monocyte- 
derived macrophages may result in proliferation at these sites (Lamb et al., 2004). 
Indeed, proliferating macrophages have been identified in atherosclerotic lesions 
from both humans (Gordon et al., 1990) and cholesterol-fed rabbits (Rosenfeld & 
Ross, 1990). Together, these data add to the potential importance of the EGFR 
during atherogenesis.
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1.6 Aims of Thesis
1.6.1 Hypothesis
Monocytes and macrophages are an important determinant of plaque growth and 
stability. The EGFR family of ligands modulate monocyte and macrophage function 
via activation of the EGF receptor.
1.6.2 Aim
To investigate the expression, cellular location and function of the epidermal growth 
factor receptor on human monocytes and macrophages using a wide range of 
molecular and immunochemical techniques.
In this study, EGFR expression will be assessed using THP-1 cells and peripheral 
blood-derived monocytes and the effect of cellular differentiation will be 
investigated. Gene expression and inducibility o f the EGFR will be assayed 
following EGF ligand family and cytokine treatment and the functionality o f the 
receptor in response to ligands will also be investigated within these cells. Finally, 
expression of the EGFR and its possible co-localisation with macrophages within 
human atherosclerotic plaques will be investigated.
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Chapter Two 
General Reagents & Methods
2.1 Tumour Cell Lines
The human monocytic cell line THP-1 was purchased from the European Collection 
of Cell Cultures. This cell line was established from the blood o f a 1 year old boy 
with acute monocytic leukaemia (Tsuchiya et al., 1980).
In addition to THP-1 cells, three human carcinoma cell lines expressing high (HN5), 
intermediate (EJ) and undetectable (MCF-7) levels o f EGFR were used in this study 
(Modjtahedi & Dean, 1996). Of these, the head and neck carcinoma cell line, HN5 
and the human bladder carcinoma cell line, EJ express 1.4xl07 and <2 xlO5 EGFR 
receptors per cell respectively. Expression in the human breast carcinoma cell line 
MCF-7 is undetectable.
2.1.1 Cell Culture Growth Media
THP-1 cells were cultured routinely in RPMI-1640 medium with GLUTAMAX 
(GIBCO Cell Culture Systems, Invitrogen Ltd., Paisley, UK) supplemented with 1% 
penicillin (50IU/ml) and streptomycin (50pg/ml) (GIBCO, UK).
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All adherent cell lines were cultured routinely in Dulbecco’s modified Eagle’s 
medium (DMEM; GIBCO, UK) supplemented with 1% penicillin (50IU/ml) and 
streptomycin (50pg/ml) (GIBCO, UK).
Both media were routinely supplemented with 10% heat inactivated foetal calf serum 
(FCS; GIBCO, UK) unless otherwise stated. All media was pre-warmed to 37°C 
prior to use unless otherwise stated.
2.1.2 Passaging o f  Tumour Cell Lines
All cells were routinely cultured in large (175cm2), medium (75cm2), or small 
(25cm2) tissue culture flasks at 37°C in a humidified atmosphere containing 5% CO2.
Monocytic THP-1 cells exist as a suspension culture. They were maintained at a cell 
density of 2-9x105 cells per ml, as described below. Non-adherent cells were 
transferred to a centrifuge tube and centrifuged at 1200rpm (400g) for 3 minutes 
(Fisherbrand 3R, Fisher Scientific UK, Loughborough, UK). After removal of the 
supernatant, the cell pellet was resuspended in warm (37°C) sterile phosphate 
buffered saline (PBS; BDH, UK) and centrifuged once again. After removal o f the 
PBS supernatant, the cell pellet was resuspended once again in PBS in preparation 
for determination o f cell viability. A 20pl aliquot of cell suspension was mixed with 
20jil of trypan blue solution (0.4% solution; Invitrogen Ltd., UK) and loaded onto a 
haemocytometer chamber (Neubauer). In each o f the four comer squares the number 
of clear viable cells and blue non viable cells was counted and the total cell number 
for that square was calculated. The average number o f viable cells and total cells
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from each of the four squares was then calculated. Percentage cell viability was also 
calculated using the equation below:
% Cell Viability = Average viable cell number 
Average total cell number
The number of viable cells per ml was calculated by multiplying the average viable 
cell number by any dilution factors that had been applied and then multiplying that 
number by lx l0 4. This whole process was repeated on the other side of the 
haemocytometer and the averages for viable cell number per ml and cell viability of 
both sides was calculated. The required aliquot o f viable cells was then removed, 
centrifuged, and resuspended in the required volume of growth medium to give a 
final concentration o f 2x105 cells per ml once seeded into a new tissue culture flask.
Adherent cell monolayers approaching confluency were washed thrice with PBS 
(37°C) prior to incubation with 0.25% trypsin/ethylenediaminetetraacetic acid 
(EDTA) (T4049; Sigma-Aldrich Company Ltd., Dorset, UK) at 37°C until the cells 
were dissociated. The trypsin was inactivated with an equal volume of growth 
medium and the cell suspension was centrifuged at 1200rpm (400g) for 3 minutes. 
The cell pellet was resuspended in pre-warmed growth medium and cells were 
seeded in new tissue culture flasks at the required density.
2.1.3 Long Term Storage o f Cells
All tumour cells were stored in liquid nitrogen for long term storage. Near confluent 
monocytic THP-1 cells were washed by centrifugation in PBS prior to cell re­
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suspension in FCS containing 10% sterile glycerol (Sigma Ltd., UK). One millilitre 
aliquots were transferred to 1.5ml cryovials (Nunc™, Fisher Scientific, UK) and 
stored at -80°C for 24 hours in a Cryo 1°C freezing vessel (Nalge (Europe) Limited, 
Hereford, UK) containing propan-2-ol. Cells were then transferred to liquid 
nitrogen. When required, cells were removed from liquid nitrogen, thawed rapidly at 
37°C and transferred to 10ml RPMI-1640 containing 20% FCS, 15mM N-(2- 
hydroxyethyl)-piperazine-N'-(2-ethanesulfonic acid) (HEPES; GIBCO, UK) and 1% 
penicillin (50IU/ml) and streptomycin (50pg/ml) (GIBCO, UK) in a 25cm2 tissue 
culture flask. The flask was stood upright and the cells were incubated at 37°C in 
this position for 7 days. Cells were then centrifuged and the cell pellet was 
resuspended in 7ml routine culturing RPMI-1640 growth medium. Cells were once 
again incubated at 37°C for 7 days or until the culture had become a sufficient cell 
suspension. Cells were then cultured as described in section 2.1.2.
Near confluent adherent tumour cells were dissociated using trypsin and centrifuged 
at 1200rpm (400g) for 3 minutes as described in section 2.1.2. Following removal of 
the supernatant, the cell pellet was resuspended and frozen as outlined above. When 
required, cells were removed from liquid nitrogen, thawed rapidly at 37°C and 
transferred to 10ml routine culturing DMEM medium. Following centrifugation, the 
cell pellet was resuspended in fresh routine culturing DMEM medium and cultured 
as described under section 2.1.2.
2.2 THP-1 Cell Differentiation
Monocytic differentiation was achieved by incubation of 4x105 cells per ml in 
routine culturing RPMI-1640 with lOnM Phorbol 12-myristate 13-acetate (PMA;
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Sigma-Aldrich, UK). Cells were incubated as described in section 2.1.2 for 72 
hours, and during this time developed into adherent macrophage-like cells 
(Basheeruddin et al., 1992; Auwerx, 1991; Rehfeldt et al., 1991; Tsuchiya et al., 
1982).
2.3 Primary Human Mononuclear Cell Culture
Human blood from a total o f nine individuals was used in this study (in accordance 
to the University of Surrey’s ethics policy on the donation and use of human 
specimens in teaching and research). Venous blood was collected via syringe from 
an antecubital vein into sterile 3.8% sodium citrate (Sigma-Aldrich, UK) in the ratio 
of 9 parts blood to 1 part citrate. The anticoagulated blood was then diluted 1:1 in 
warm PBS and carefully layered onto an equal volume of Histopaque-1077 (Sigma- 
Aldrich, UK). The blood was centrifuged at 1200rpm (400g) for 30 minutes at room 
temperature. The buffy mononuclear cell layer was removed along with the plasma 
and washed twice in PBS at 200g for 10 minutes. Isolated peripheral blood 
mononuclear cells (PBMCs) were resuspended in serum-free RPMI-1640 medium. 
Cells were counted using a haemocytometer, diluted to lxlO6 cells per ml in serum- 
free RPMI-1640 medium and incubated at 37°C to allow monocytes to adhere. After 
2 hours, the media containing the unattached cells was replaced with routine 
culturing RPMI-1640 medium. Primary monocytes were incubated as above into 
macrophage-like cells with a medium replacement at 24 and 48 hours and at every 48 
hour interval up to 8 days in culture.
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2.4 Serum Starvation of THP-1 Cells
THP-1 cell proliferation and viability was investigated in culture under different 
percentages of FCS. THP-1 cells were cultured to near confluency as described in 
section 2.1.2. Cells were centrifuged at 1200rpm (400g) for 3 minutes and the pellet 
resuspended in PBS (37°C). Cell number and viability was determined using trypan 
blue solution (0.4%; Invitrogen Ltd., UK) as described in section 2.1.2. Cells were 
diluted to lx l0 5 viable cells per ml in RPMI-1640 medium containing either 10%, 
5% or 2% FCS. Cells were cultured in a 12-well plate in triplicate wells with 2ml of 
cells (2xl05) per well. At 24 hour intervals, the cells were mixed to create a full 
suspension and an aliquot o f cells was collected and the cell count and viability was 
determined as described in section 2.1.2.
2.5 Growth Factors and Antibodies
Several cellular growth factors were used in this study (Table 2.1). Growth factors 
were reconsitiuted with 0.1% bovine serum albumin (BSA A9418; Sigma-Aldrich, 
UK.) in either PBS or lOnM acetic acid. All reconsitiuted growth factors were stored 
in working aliquots at -80°C and thawed as required. Once thawed the aliquot was 
kept at 4°C for up to 1 month.
Several commercial primary and secondary antibodies were used in this study (Table 
2.2). The rat monoclonal antibodies ICR62 (IgG2b) and ICR16 (IgG2a) used in this 
study were developed and characterised by Dr Helmout Modjtahedi (Modjtahedi et 
al., 1993). ICR62 and ICR16 were raised against the external domain of the EGFR
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on the human breast carcinoma cell line MDA-MB468 and the human head and neck 
carcinoma cell line HN5 respectively.
2.6 EGFR mRNA Analysis
2.6.1 Cell Culture Preparation
THP-1 cells were cultured to near confluency as described in section 2.1.2. THP-1 
cells were collected, centrifuged and resuspended in warm PBS. Cells number and 
viability was determined and THP-1 cells were diluted and seeded at 1.5xl06 viable 
cells per well (2ml) in a 24-well plate in RPMI-1640 media supplemented with 2% 
or 10% (control) FCS. Cells were incubated for 18 hours to acclimatise.
For differentiated THP-1 experiments, THP-1 cells were collected and counted as 
described above. Cells were seeded at 8xl05 viable cells per well (2ml) in a 24-well 
plate in routine culturing RPMI-1640 medium in the presence o f a final 
concentration o f lOnM PMA (Sigma-Aldrich, UK). Cells were incubated for 72 
hours into macrophage-like cells as described in section 2.2.
At the start of the experiment (0 hours), the previous medium was removed and 
replaced with 2ml RPMI-1640 medium containing 2% FCS supplemented with the 
four EGFR ligands (EGF, HB-EGF, TGFa or BTC) at 25nM or 50nM, or the 
monocyte activators IFNy (lOOU/ml), IL-ip (2.5ng/ml) and LPS (lOOng/ml) in 
duplicate or triplicate tissue culture wells. The treatment concentrations for the 
monocyte activators had been previously optimised for THP-1 cells within the
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Table 2.1 Commercial growth factors used in this study. PBS: Phosphate 
buffered saline; BSA: Bovine serum albumin
Growth Factor Reconstitution Stock Dilution Product Code/ 
Company
Betacellulin (BTC) 
Human Recombinant
0.22pm-filtered 
PBS containing 
0.1% BSA
lOpg/ml
B-3670 
Sigma-Aldrich 
Company Ltd., 
Dorset, UK
Epidermal Growth Factor 
(EGF)
Human Recombinant
0.22pm-filtered 
lOnM acetic acid 
containing 0.1% 
BSA
200pg/ml
E-9644 
Sigma-Aldrich 
Company Ltd., 
Dorset, UK
Heparin-Binding 
Epidermal Growth 
Factor-Like Growth 
Factor (HB-EGF) 
Human Recombinant
0.22pm-filtered 
PBS containing 
0.1% BSA 50 pg/ml
E-4643 
Sigma-Aldrich 
Company Ltd., 
Dorset, UK
Interleukin-1P (IL-1 p) 
Human Recombinant
0.22pm-filtered 
PBS containing 
0.1% BSA
lng/ml
201-LB 
R&D Systems 
Europe Ltd., 
Abingdon, UK
Interferon y (IFNy) 
Human Recombinant
0.22pm-filtered 
PBS containing 
0.1% BSA
lOOU/pl
285-IF 
R&D Systems 
Europe Ltd., 
Abingdon, UK
Monocyte Chemotactic 
Protein-1 (MCP-1) 
Human Recombinant
0.22pm-filtered 
PBS containing 
0.1% BSA
lOpg/ml
M-6667 
Sigma-Aldrich 
Company Ltd., 
Dorset, UK
Macrophage Colony 
Stimulating Factor 
(M-CSF)
Human Recombinant
0.22pm-filtered 
PBS containing 
0.1% BSA
5 pg/ml
216-MC 
R&D Systems 
Europe Ltd., 
Abingdon, UK
Transforming Growth 
Factor a (TGFa) 
Human Recombinant
0.22pm-filtered 
lOnM acetic acid 
containing 0.1% 
BSA
lOOpg/ml
239-A 
R&D Systems 
Europe Ltd., 
Abingdon, UK
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Table 2.2 Commercial primary and secondary antibodies used in this study.
FC: Flow Cytometry; IHC: Immunohistochemistry; ICC: Immunocytochemisty; WB: 
Western Blotting; RPE-Cy5: R-phycoerythrin-cyanine5; FITC: Fluorescein
isothiocyanate.
Antibody Stated Specificity Experimental Use 
and Dilution
Product Code/ 
Company
Primaries
Mouse anti-human 
CD14: RPE-Cy5 
conjugate (IgG2a; 
clone Tuk4)
Human CD 14 cell 
surface antigen
FC (1/20) MCA1568C 
Serotec Ltd., 
Oxford, UK
Rabbit anti-human 
EGFR (polyclonal, 
affinity purified)
C-terminus of 
human EGFR
WB (1/200) SC-03 
Santa Cruz 
Biotechnology 
Inc., Santa 
Cruz, CA, USA
Mouse anti-human 
smooth muscle cell 
actin (IgG2a, kappa; 
clone 1A4)
a-smooth muscle 
cell isoform of actin
IHC (1/500) M 0851 
DAKO Ltd., 
Ely, UK
Mouse monoclonal 
anti-human CD68, 
macrophage (IgGl, 
kappa; clone KP1)
Human CD68 cell 
surface antigen
IHC (1/100) M 0814 
DAKO Ltd., 
Ely, UK
Mouse monoclonal 
HAM56to 
macrophage (IgM, 
kappa; clone 
HAM56)
Human 
macrophages 
(specific antigen has 
not been 
characterised)
IHC (1/30) ab8186 
Abeam Ltd., 
Cambridge, UK
Mouse IgG2a 
negative control: 
RPE-Cy5 conjugate
Negative control in 
human tissues
FC (1/20) MCA929C 
Serotec Ltd., 
Oxford, UK
Mouse IgGl negative 
control
Negative control in 
human tissues
IHC (1/25) MCA928 
Serotec Ltd., 
Oxford, UK
Mouse IgM negative 
control (IgM, kappa; 
clone DAK-G08)
Negative control in 
human tissues
IHC (1/1000) X 0942 
DAKO Ltd., 
Ely, UK
Rat IgG2b negative 
control (IgG2b, clone 
LO-DNP-11)
Negative control in 
human tissues
FC (1/100) 
ICC (1/5)
MCA1125R 
Serotec Ltd., 
Oxford, UK
Rat IgG2a negative 
control (IgG2a, clone 
LO-DNP-16)
Negative control in 
human tissues
IHC (1/20) MCA1124R 
Serotec Ltd., 
Oxford, UK
Secondary
F(ab’)2 rabbit anti-rat 
IgG: FITC conjugate
Rat IgG FC (1/100) 
ICC (1/300)
STAR17B 
Serotec Ltd., 
Oxford, UK
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laboratory. Control cells in routine culturing RPMI-1640 medium had fresh medium 
re-applied. Cells were incubated at 37°C in a humidified 5% CO2 atmosphere.
At appropriate time points (6, 12, 24 and 48 hours), 1ml of THP-1 cells were 
transferred from the well to a 1.5ml microcentrifuge tube and centrifuged at 200g for 
3 minutes at room temperature. The supernatant was removed and the remaining 
lml of cells was transferred from the well to the microcentrifuge tube. The cells were 
once again centrifuged at 200g for 3 minutes at room temperature and the 
supernatant was removed. The pellet was resuspended in 500pl TRIzol (Invitrogen 
Ltd., UK) and mixed to ensure complete cell lysis. For differentiated THP-1 cells, 
the medium was removed at the appropriate times points (0, 6, 12, 24 and 48 hours) 
and 500pl TRIzol (Invitrogen Ltd., UK) was added. The TRIzol (Invitrogen Ltd., 
UK) was mixed to ensure complete cell lysis. All samples were stored at -20°C for 
short term storage or -80°C for long term storage prior to RNA extraction.
Mononuclear cells were isolated and cultured as described in section 2.3. Cells were 
cultured in 24-well plates at 2x106 cells (2ml) per well. At the required time points 
the medium was removed and 500pl TRIzol (Invitrogen Ltd., UK) was added. The 
TRIzol (Invitrogen Ltd., UK) was mixed to ensure complete cell lysis. All samples 
were stored as above prior to RNA extraction.
2.6.2 RNA Extraction & Quantification
TRIzol cell lysates were defrosted at room temperature and then mixed gently. Total 
cellular RNA was isolated as per manufactures instructions -  200jil chloroform was 
added per lm l TRIzol and shaken vigorously for 15 seconds. Samples were left to
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settle for 5 minutes at room temperature and subsequently centrifuged at 12,000g for 
15 minutes at 4°C. The top, aqueous layer was carefully removed, transferred to a 
fresh microcentrifuge tube and mixed by inversion with an equal volume of propan- 
2-ol. The sample was again centrifuged at 12,000g for 15 minutes at 4°C. The 
supernatant was removed and the RNA pellet was resuspended and vortexed in 500pl 
ice-cold 70% ethanol made in autoclaved diethylpyrocarbonate (DEPC; Sigma- 
Aldrich, UK)-treated MilliQ water. The RNA was centrifuged at 10,000g for 5 
minutes at 4°C. The supernatant was removed and the RNA pellet was left to air-dry. 
Pellets were resuspended in 20pl DEPC-treated MilliQ water per 500pl TRIzol and 
stored at -80°C prior to quantification.
RNA concentration was measured using a Nanodrop spectrophotometer (Agilent 
Technologies, Stockport, UK). RNA integrity was assessed by gel electrophoresis. 
2pg/10pl RNA in lOx loading dye (glycerol buffer containing bromophenol blue, 
Sigma-Aldrich, UK) was separated on a RNase-free 2% agarose (Invitrogen Ltd., 
UK) lx  Tris-Borate-EDTA (TBE) gel (lOx solution - 108g Tris base, 55g boric acid 
and 9.3g Na2EDTA to 1 litre with deionised water, pH 8.3) with 1% ethidium 
bromide (Promega, Southampton, UK). The gel was run at 120V for 30 minutes 
with appropriate ssRNA ladder (New England Biolabs (UK) Ltd., Hitchin, UK) to 
separate the 28 S, 18 S and 5 S ribosomal RNAs and visualised under ultra violet 
light (figure 2.1).
Samples were diluted to a concentration o f lOng/pl in autoclaved DEPC-treated 
MilliQ water. lOOng RNA was treated with RNase-Free DNasel (Promega) for 40 
minutes at 37°C. The reaction was terminated with the addition o f lp l DNase STOP
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Figure 2.1 Gel electrophoresis of isolated RNA. Isolated RNA was subjected to 
electrophoresis on a 2% RNase-free TBE agarose gel at 120V for 30 minutes to show 
integrity of the samples. The bands of the 28 S, 18 S and 5 S ribosomal RNAs are 
indicated. The example samples run are; Lane A -  no sample, B -  RNA ladder, C -  
EJ standard curve sample, D -  THP-1 standard curve sample, E -  human monocyte 
sample, F -  THP-1 sample, G -  differentiated THP-1 sample and H -  no sample.
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buffer and with incubation for 10 minutes at 65°C. Samples were then stored at - 
80°C.
2.6.3 Quantitative Real-Time PCR
Quantitative real-time PCR was performed using a one-step QuantiTect SYBR Green 
RT-PCR kit (Qiagen Ltd., West Sussex, UK). A QuantiTect Primer Assay 
(QT00085701, GeneGlobe, Qiagen Ltd., UK) was used to detect human EGFR, 
based upon the NCBI sequence NM_005228 (figure 2.2). Primers were reconstituted 
to a 1 Ox concentration in DEPC-treated MilliQ water.
Primers for the internal housekeeping gene MLN51 (Metastatic lymph node-51) 
(Degot et al., 2002; King & Cooper, 1986) were designed based on the NCBI 
sequence NM 007359; left-hand sequence CAA GAG TGC TGA GGA GTC GG, 
right-hand sequence TCA TTA GCT TCT GAT TTC AG by HA Khwaja (PhD 
Thesis University o f Oxford, 2005). The primer pair was synthesised by MWG- 
Biotech (MWG-Biotech Ltd., Milton Keynes, UK) and reconstituted to a 
concentration of 1 OOpmol/pl (lOOpM) in DEPC-treated MilliQ water.
Quantitative PCR (QPCR) reaction mixes were composed on ice and shown in Table 
2.3. 9.5pl reaction mix was loaded into appropriate wells of Thermo-Fast opaque 
white 96 well plates (Abgene, Epsom, UK). 20ng (3 pi) DNased RNA was added to 
appropriate wells in duplicate for EGFR and MLN51 reactions resulting in a final 
reaction volume per well o f 12.5pi. Plates were sealed with Absolute QPCR seals 
(Abgene, UK), centrifuged at 2000rpm for 1 minute, agitated to mix the components 
and centrifuged once again. The plates were kept on ice at all times.
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Figure 2.2 GeneGlobe EGFR primers. The location is based on NCBI sequence 
NM 005228. The primers are designed to cross the boundary of exon 1 and 2 based 
on the Ensembl Transcript ENST00000275493.
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Table 2.3 Composition of master mixes for EGFR and MLN51 QPCR reactions.
EGFR
Final
Component Volume Concentration
2x QuantiTect SYBR Green RT-PCR Master 6.25 pi lx/reaction
Mix (Qiagen Ltd., UK)
lOx QuantiTect EGFR Primer Assay (Qiagen 1.25 pi lx/reaction
Ltd., UK)
QuantiTect RT mix (Qiagen Ltd., UK) 0.125pl 0.125pl/reaction
RNase-free H2O (Qiagen Ltd., UK) 1.875pl -
TOTAL 9.5pl
MLN51
Final
Component Volume Concentration
2x QuantiTect SYBR Green RT-PCR Master 6.25 pi lx/reaction
Mix (Qiagen Ltd., UK)
Primer R (lOpmol/pl) 0.75pl 7.5pmol/reaction
Primer L (lOpmol/pl) 0.75pl 7.5pmol/reaction
QuantiTect RT mix (Qiagen Ltd., UK) 0.125pl 0.125pl/reaction
RNase-free H2O (Qiagen Ltd., UK) 1.625pi -
TOTAL 9.5pl
Table 2.4 Cycling conditions for the QPCR of EGFR and MLN51.
Step Time Temperature
Reverse Transcription 30 minutes 50°C
PCR initial activation step (cDNA denaturation) 15 minutes 95°C
3 step cycling (40 cycles)
Denaturation 15 seconds 95°C
Annealing 30 seconds 55°C
Data Collection 30 seconds
56
Chapter 2 -  Materials & Methods
QPCR analysis was performed using the ABI Prism 7000 (Applied Biosystems, 
Foster City, CA, USA) for the monocyte analysis or the 7500 Fast Real-Time PCR 
System (Applied Biosystems, USA) for THP-1 cell analysis. The cycling conditions 
for the QPCR reaction are shown in Table 2.4. QuantiTect Primer Assays are pre­
optimised to work with QuantiTect SYBR Green RT-PCR kits at an annealing 
temperature o f 55°C so no further optimisation of the reaction was necessary.
At the end of the QPCR reaction, Ct (Cycle Threshold) values were obtained by 
setting the baseline of the amplification and adjusting the threshold to the start o f the 
exponential region o f the amplification curves. For the 7500 Fast Real-Time PCR 
System (Applied Biosystems, USA) the baseline was set between cycles 3 and 15 
and the threshold was adjusted to 0.5. For the ABI Prism 7000 Real-Time PCR 
System (Applied Biosystems, USA) the baseline was set between cycles 6 and 15 
and the threshold was adjusted to 0.02. These settings were used consistently for 
each machine to ensure consistency between Ct values for each experiment.
Melt curve analysis o f the PCR products was performed over a range of 65°C - 95°C 
to verify their specificity and identity. Gel electrophoresis of the PCR products was 
also performed to confirm product specificity. Total PCR product (12.5pl) was 
mixed with lOx loading buffer (Sigma-Aldrich, UK) and loaded onto a 2% agarose 
gel (Invitrogen Ltd., UK) with 1% TBB buffer. The gel was run at 40V for 1 hour to 
ensure sufficient separation between the specific product and primer-dimer bands.
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2.6.4 Standard Curve Preparation
A standard curve for each gene o f interest was prepared from RNA extracted from 
the EJ cell line which expresses both MLN51 and EGFR mRNA. EJ RNA was 
prepared and measured as described in section 2.6.2. 5fig RNA was treated with 
DNase I (Promega, UK) as described previously. A serial dilution of RNA in 
RNase-free water was made covering the range from 0.0 lng to lOOng for each gene. 
Aliquots of each dilution were kept at -80°C and defrosted when necessary.
Separate standard curves were constructed for human peripheral blood monocyte 
analysis and THP-1 cell analysis as separate machines were used. The Ct values for 
each dilution were plotted against their corresponding log ng amounts o f RNA to 
create standard curves for each gene. Reference points were incorporated into each 
further plate analysis to create a compiled standard curve for a specific experiment 
and to ensure consistency between each QPCR plate.
The ng amount of EGFR and MLN51 for each test sample was calculated from the 
Ct value utilizing the equation of the prepared standard curve as shown below:
n g= 10((CtxA)+B)
where A is the gradient and B is the intercept of the specific standard curve
EGFR mRNA expression was normalised to MLN51 expression (ng EGFR divided 
by ng MLN51 for each individual sample) and reported as a fold induction over 
experimental plate control values.
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2.7 Immunoprecipitation
2.7.1 Preparation o f Whole Cell Lysates
A 175cm2 tissue culture flask of THP-1 cells, cultured as described in section 2.1.2,
n
were grown to near confluency (6.6x10 total cells) and transferred to a centrifuge 
tube. EJ cells were grown to near confluency in a 75cm tissue culture flask as 
described in section 2.1.2. The monolayer was washed with cold wash buffer [0.02% 
sodium azide (Sigma-Aldrich, UK) and ImM phenylmethanesulphonylfluoride 
(PMSF; Sigma-Aldrich, UK) in PBS] before the cells were detached into 5ml wash 
buffer using a cell scraper. The cells were then transferred to a centrifuge tube. All 
collected cells were then washed twice by centrifugation at 1200rpm (400g) for 3 
minutes in cold wash buffer and resuspended in cold lysis buffer (as wash buffer 
above containing 1% Triton-X 100 (Sigma-Aldrich, UK) in PBS) (4ml for near 
confluent 75cm2 flask of EJ cells; 1ml per 13xl06 THP-1 cells). Cell lysates were 
incubated on ice for 20 minutes and centrifuged at 30,000rpm for 30 minutes at 4°C 
(Beckman Ultra Centrifuge, Beckman Dickinson, UK). The supernatant was 
removed and stored at -80°C.
2.7.2 Preparation o f Protein-G Sepharose Bead and Antibody Conjugation
Protein-G sepharose beads (Pharmacia, UK) (50pl) were conjugated to lOpg of 
specific antibody (ICR62) or isotype control antibody (rat IgG2b) as described 
below. Protein-G sepharose beads were transferred to a 1.5ml microcentrifuge tube 
and centrifuged at a maximum of 500rpm for 30 seconds. The ethanol supernatant 
was removed and the beads resuspended in 1ml wash buffer (as above) and
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centrifuged once again as before. This was repeated twice. After the final wash, the 
protein-G sepharose beads were resuspended in wash buffer.
About 10pg of antibody or equal volume of wash buffer (no antibody control) was 
added to every 50pl prepared protein-G sepharose beads in a microcentrifuge tube. 
Tubes were rotated for 1 hour at room temperature or at 4°C overnight. The 
conjugated beads were washed thrice with wash buffer as before and resuspended in 
lml wash buffer and stored upright at 4°C.
2.7.3 Cell Lysate Incubation
Antibody conjugated beads were centrifuged as before and supernatant removed. 
Beads were resuspended in original bead volume and lm l of cell lysate was added to 
every 50pl of protein G sepharose bead conjugate. Beads were rotated as described 
above and washed thrice in lm l wash buffer by centrifugation as before. After last 
wash, the supernatant was removed and an equal volume o f NuPAGE® lithium 
dodecyl sulphate (LDS) sample buffer (details in section 2.8) to beads was added. 
The sample-buffer mix was heated at 75°C for 10 minutes, cooled and stored at - 
20°C.
2.8 SDS-PAGE and Western Blotting
The expression of the EGFR was investigated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blotting. Table 2.5 details the products 
purchased from Invitogen Ltd. (UK). A temporal list of working dilutions for this 
system is detailed below.
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Lysis Buffer (lx): For lOOpl solution - 25 pi NuPAGE® LDS sample buffer (4x; 
Invitrogen Ltd., UK), lOpl NuPAGE® reducing agent (lOx; Invitrogen Ltd., UK) 
and 65 pi distilled H2O. The lysis buffer was supplemented with lp l protease 
inhibitor cocktail (Sigma-Aldrich, UK) containing 104nM 4-(2-aminoethyl) 
benzenesulfonyl fluoride hydrochloride (AEBSF), 80pM aprotinin, 2nM leupeptin, 
4nM bestatin, 1.5mM pepstatin A and 1.4mM E-64.
Running Buffer (lx): Consisted of 50ml NuPAGE® 4-morpholine propanesulfonic 
acid (MOPS) sodium dodecyl sulphate (SDS) running buffer (20x; Invitrogen Ltd., 
UK) and 950ml distilled water. This is enough for one XCell II™ Surelock™ Mini- 
Cell tank.
Transfer Buffer (lx): Consisted of 50ml NuPAGE® transfer buffer (20x; 
Invitrogen Ltd., UK), 200ml methanol (100ml per gel), lm l antioxidant and 750ml of 
distilled water. This is enough for one XCell II™ Surelock™ Mini-Cell tank.
Blocking Solution: Consisted of 2ml blocker/diluent A (Invitrogen Ltd., UK), 3ml 
of blocker/diluent B (Invitrogen Ltd., UK) and 5ml of distilled water. This is enough 
for one PVDF membrane.
Primary Antibody Diluent: Consisted o f 2ml blocker/diluent A (Invitrogen Ltd., 
UK), lml o f blocker/diluent B (Invitrogen Ltd., UK) and 7ml o f distilled water. This 
is enough for one PVDF membrane.
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Antibody Wash (lx): Consisted of 10ml antibody wash solution (16x; Invitrogen 
Ltd., UK) and 150ml distilled water. This is enough for one PVDF membrane over 
two steps.
2.8.1 SDS-PAGE
SDS-PAGE was performed using the XCell II™ Surelock™ Mini-Cell system 
(Invitrogen Ltd., UK). The prepared immunoprecipitated cell lysates were removed 
from -20°C and defrosted on ice. 15pi cell lysate was loaded per well o f a 1mm 10% 
Bis-Tris gel (Invitrogen Ltd., UK) with 5 pi o f multi-coloured molecular weight 
standard (Invitrogen Ltd., UK). Gel electrophoresis was performed at a constant 
200V for 55 minutes in lx  NuPAGE® MOPS SDS running buffer (Invitrogen Ltd., 
UK) with added antioxidant (400pl; Invitrogen, Ltd., UK).
2.8.2 Western Blotting
Following SDS-PAGE, the proteins were transferred from the gel to a 0.45pm pore 
polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA, USA). This 
was performed in at a constant 30V for 2 hours in lx  NuPAGE® transfer buffer, 
using the XCell™ Mini-Cell Blot Module kit (Invitrogen Ltd., UK). Effective 
transfer was indicated by the presence of all coloured bands of the multi-coloured 
standard (Invitrogen Ltd., UK) on the PVDF membrane post-transfer. Following 
Western transfer, the membrane was washed briefly in deionised H2O before 
incubation with 10ml blocking solution (Invitrogen Ltd., UK) for 30 minutes at room 
temperature or overnight at 4°C on a rotary shaker set at 1 revolution per second.
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Table 2.5 Reagents purchased from Invitrogen Ltd., UK for SDS-PAGE and 
Western Blotting.
REAGENT DESCRIPTION
WestemBreeze® 
chemiluminescent 
western blot 
immunodetection kit
Blocker/diluent A and B; secondary antibody solution; 
wash solution (16x); chemiluminescent substrate
Blocker/diluent A Buffered saline containing detergent
Blocker/diluent B Concentrated Hammerstein casein solution
Secondary antibody 
solution
Alkaline phosphate-conjugated, affinity purified, anti­
rabbit IgG
Wash solution (16x) Buffered saline containing detergent
Chemiluminescent
substrate
CDP-Star® substrate for alkaline phosphatase
MultiMark® 
multicoloured standard
On NuPAGE® 10% Bis-Tris Gels/MOPS: Myosin 
188kDa; Phosphorylase B 97kDa; Glutamic 
Dehydrogenase 52kDa; Carbonic Anhydrase 33kDa; 
Myoglobin Red 21kDa; Myoglobin Blue 19kDa; 
Lysozyme 12kDa; Aprotinin N/A; Insulin N/A
NuPAGE® antioxidant Constituents not specified
NuPAGE® Gels 10% Bis-Tris 1mm, 15 well gels
NuPAGE® LDS 
sample buffer (4x)
106mM Tris HC1; 141mM Tris base; 2% LDS; 10% 
Glycerol; 0.5ImM EDTA; 0.22mM SERVA® Blue G250; 
0.175mM Phenol Red; pH 8.5
NuPAGE® MOPS SDS 
running buffer (2x)
50mM MOPS; 50mM Tris base; 0.1% SDS; ImM EDTA;
pH 7.7
NuPAGE® transfer 
buffer (20x)
25mM Bicine; 25mM Bis-Tris (free base); ImM EDTA;
pH 7.2
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Membranes were washed three times for 5 minutes with 20ml deionised water prior 
to incubation with primary antibody made up in 10ml o f antibody diluent (Invitrogen 
Ltd., UK). Following one hour incubation at room temperature, the membrane was 
washed three times for 5 minutes with antibody was solution (Invitrogen Ltd., UK), 
and then incubated with 10ml o f secondary antibody solution (Invitrogen Ltd., UK) 
for 30 minutes at room temperature. Following three more 5 minutes washes in 
antibody wash solution and two 3 minute washes in deionised water, 2.5ml of 
chemiluminescent substrate (CDP-Star®; Invitrogen Ltd., UK) was evenly added to 
the membrane. Following 5 minutes incubation, the excess CDP-Star® was blotted 
from the membrane using filter paper and the membrane was wrapped in cling film 
in preparation for luminography.
For visualisation of the transferred proteins the membrane blot was exposed to 
Kodak BioMax XAR scientific imaging film (Sigma-Aldrich, UK). The film was 
developed in CD 18 manual developer and then fixed in CF42 non-hardening fixer 
(both 1/5 in water; Photosol Ltd., Brentwood, UK).
2.9 Flow Cytometry Analysis
2.9.1 Flow Cytometry Analysis o f  EGFR Expressing Tumour Cells 
Human tumour cells were cultured as described in section 2.1.2 and dissociated using 
0.25% trypsin. Following trypsin inactivation as described in section 2.1.2, the cells 
were washed by centrifugation at 1200rpm (400g) for 3 minutes in PBS and 
resuspended at lx l0 6 cells per ml o f DMEM with 2% FCS. Cells were incubated by 
rotation with primary antibody or matched isotype control for 1 hour at 4°C. Cells
64
Chapter 2 -  Materials & Methods
were subsequently washed by centrifugation at 1200rpm (400g) for 3 minutes in lml 
DMEM with 2% FCS three times. After last wash cells were resuspended in lml 
DMEM with 2% FCS and incubated by rotation with FITC-conjugated F(ab’)2 rabbit 
anti-rat IgG secondary antibody (Table 2.2) for 1 hour at 4°C. Cells were washed 
once in lml DMEM with 2% FCS and twice more in PBS by centrifugation. The 
cells were then transferred to flow cytometry tubes (BD Falcon™, Becton Dickinson 
UK Ltd., Oxford, UK), centrifuged once again and the cell pellet was resuspended in 
lml FACS Flow™ buffer (Becton Dickinson UK Ltd.) prior to analysis. A 
minimum of 10,000 events were recorded by excitation with an argon laser at 
488nm, and analysed using the FL-1 detector (FITC detector; 525nm) using a 
FACScan flow cytometer (Becton Dickinson UK Ltd.) and CellQuest™ software. 
Subsequent fluorescent histogram analysis was obtained using Windows Multiple 
Document Interface (WinMDI) flow cytometry application version 2.9 
(facs.scripps.edu).
2.9.2 Flow Cytometry Analysis o f  THP-1 and Differentiated THP-1 Cells
THP-1 cells were grown to near confluency in a 75cm2 tissue culture flask as 
described in section 2.1.2. THP-1 cells were centrifuged at 1200rpm (400g) for 3 
minutes and the pellet was resuspended in cold PBS. Differentiated THP-1 cells 
were created as described in section 2.2. After 72 hours the medium was removed 
and the adhered cells were washed with sterile PBS. Adhered cells were dissociated 
using cold sterile lOmM lidocaine hydrochloride (Sigma-Aldrich, UK)/ lOmM 
EDTA (pH 8; Sigma-Aldrich, UK) in PBS (Schafer et al., 2004; Nielsen, 1987). 
Cells were incubated on ice for 5 minutes and periodically agitated to assist 
dissociation. Dissociated cells were then collected into a centrifuge tube.
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Both THP-1 and differentiated THP-1 cells were then centrifuged at 1200rpm (400g) 
for 3 minutes and resuspended in cold flow cytometry buffer (1% BSA (A9418, 
Sigma, UK), 0.05% sodium azide (Sigma-Aldrich, UK) in PBS) and counted. Cells 
were diluted to lxlO7 cells per ml and aliquots o f lOOpl cells (lxlO 6 cells) were 
dispensed per flow cytometry tube. Cells were incubated for 30 minutes in darkness 
at 4°C with primary antibody or appropriate isotype control, along with FITC- 
conjugated F(ab’)2 rabbit anti-rat secondary antibody {Table 2.2). A final 
concentration of 2% human serum was added to reduce non-specific FcyR binding. 
Cells were washed with flow cytometry buffer by centrifugation and the resulting 
pellet was resuspended in 4% paraformaldehyde (Sigma-Aldrich, UK) in PBS and 
stored at 4°C to await analysis. Cells were analysed as described in section 2.9.1.
2.9.3 Flow Cytometry Analysis o f  Primary Human Mononuclear Cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood as 
described previously in section 2.3. After 2 hours adherence in serum-free media the 
non-adherent cells were removed. Adhered cells were dissociated using cold sterile 
lOmM lidocaine hydrochloride (Sigma-Aldrich, UK)/10mM EDTA (pH 8; Sigma- 
Aldrich, UK) in PBS (Schafer et al., 2004; Nielsen, 1987). Cells were incubated on 
ice for 5 minutes and periodically agitated to assist dissociation. Dissociated cells 
were then collected into a tube and centrifuged at 1200rpm (400g) for 3 minutes. 
The pellet was resuspended in flow cytometry buffer (as in section 2.9.2) and the 
cells were counted. Cells were diluted to lx l 07 cells per ml and aliquots o f lOOpl 
cells (1 xlO6 cells) were dispensed per flow cytometry tube. Cells were incubated for 
30 minutes in darkness at 4°C with primary antibody or appropriate isotype control, 
along with FITC-conjugated F(ab’)2 rabbit ant-rat IgG secondary antibody where
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appropriate (Table 2.2). A final concentration of 2% human serum was added to 
reduce non-specific FcyR binding. Cells were washed with flow cytometry buffer by 
centrifugation and the resulting pellet was resuspended in 4% paraformaldehyde 
(Sigma-Aldrich, UK) in PBS and stored at 4°C to await analysis. Events (20,000) 
were recorded by excitation with a 20mW argon laser at 488nm, and emission 
collected at 525nm for FITC (FL-1) and 682nm (for the PerCP fluorochrome) for 
RPE-Cy5 (FL-3) using a BD FACSCanto™ flow cytometer (BD Biosciences UK 
Ltd., Oxford, UK) and BD FACSDiva™ v.4.0 software (BD Biosciences UK Ltd.). 
Compensation between RPE-Cy5 and FITC was set at 2.18.
2.9.4 Flow Cytometry Analysis o f  8 Day Monocyte Derived Macrophages
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and 
cultured in 6-well plates (1x10 cells per well) into monocyte-derived macrophage 
cells as described previously in section 2.3. After 8 days in culture, the growth 
medium removed and replaced with RPMI-1640 medium with 2% FCS containing 
0.1 nM, lOnM or 25nM HB-EGF. After 2 hours the medium was removed and the 
adhered cells were dissociated and prepared for flow cytometry analysis as described 
in section 2.9.3.
2.10 Immunocytochemistry
2.10.1 Cytospin Preparation
THP-1 cells were grown to near confluency as described in section 2.1.2. THP-1 
cells were differentiated as described in section 2.2 and dissociated with lOnM 
lidocaine hydrochloride/EDTA as described in section 2.9.2. EJ cells were grown to
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near confluency and dissociated as described in section 2.1.2. All cells were washed 
in PBS, counted and diluted to 2x105 cells per ml in routine culturing RPMI-1640 or 
DMEM media. Aliquots of200pl cells (4x104 cells) were loaded into the funnels of 
a ThermoShandon Cytospin 4 machine (Thermo Electron Corporation, Cheshire, 
UK). Cells were spun onto pre-washed, uncoated glass slides at lOOOrpm for 5 
minutes. The cells were left to air dry on the slides for 1 hour at room temperature 
and were subsequently wrapped in tin foil and stored at -20°C until staining.
2.10.2 Staining Procedure
Slides were removed from -20°C storage and air-dried for 1 hour at room 
temperature. Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich, UK) in PBS 
for 15 minutes then washed three times in cold PBS. Cells were then permeabilised 
with cold 0.5% Triton-X 100 (Sigma-Aldrich, UK) in PBS for 15 minutes at room 
temperature. Slides were washed three times in cold PBS containing 0.5% BSA 
(A9418, Sigma-Aldrich, UK). Primary antibodies and appropriate matched isotype 
controls were diluted to their working concentrations in cold 0.5% BSA in PBS. 
Slides were incubated for 1 hour in darkness at 4°C. Slides were washed three times 
in cold 0.5% BSA in PBS before application o f the FITC-conjugated F(ab’)2 rabbit 
anti-rat IgG secondary antibody (Table 2.2) for 30 minutes in darkness at 4°C. Slides 
were again washed three times in cold PBS. The nuclear Hoechst 33258 stain 
(B2883, Sigma) was diluted to 2pg/ml in PBS and applied to the cells for 5 minutes 
in darkness at room temperature. Slides were washed in cold PBS and mounted with 
a coverslip in Vectashield mounting medium (H1000; Vector Laboratories Ltd., 
Peterborough, UK). Slides were wrapped in tin-foil and stored at 4°C until analysis. 
Cells were visualised using a Leica DMLB microscope with Leica Qwin image
68
Chapter 2 -  Materials & Methods
analysis software (Leica Microsytems Ltd., Milton Keynes, UK). The microscope 
was equipped with a colour JVC TK-C1380 video camera with the integration times 
set at 3 frames for FITC fluorescence and 0 frames for Hoechst fluorescence.
2.11 Chemotaxis Assay
THP-1 cells were grown to near confluency in a 75cm2 tissue culture flask as 
described in section 2.1.2. THP-1 cells were collected and centrifuged at 1200rpm 
(400g) for 3 minutes and the pellet was resuspended in cold PBS. Cells were once 
again centrifuged and the cell pellet was resuspended in RPMI-1640 medium 
containing 1% IgG-free BSA (A2058, Sigma-Aldrich, UK). Cells were counted 
using a haemocytometer and subsequently diluted to lx l0 6 cells per ml.
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and 
cultured as described previously in section 2.3. Monocytes were cultured in 25cm2 
tissue culture flasks at lxlO6 cells per ml. For monocyte experiments, after 2 hours 
incubation in serum-free RPMI-1640 medium the non-adherent cells were 
dissociated as described below. For experiments involving 48 hour monocytes and 8 
day monocyte-derived macrophages, after 2 hours incubation the serum-free RPMI- 
1640 medium was replaced with routine culturing RPMI-1640 medium. The 
medium was replaced again at 24 and 48 hours, and at every 48 hour interval up to 8 
days in culture. At 48 hours and 8 days the cells were dissociated as described 
below.
All adhered cells were dissociated using cold sterile lOmM lidocaine hydrochloride 
(Sigma-Aldrich, UK)/ lOmM EDTA (pH 8; Sigma-Aldrich, UK) in PBS. Cells were
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incubated on ice for 5 minutes and periodically agitated to assist dissociation. 
Dissociated cells were then collected into a tube and centrifuged at 1200rpm (400g) 
for 3 minutes. The cell pellet was resuspended in RPMI-1640 with 1% IgG-free 
BSA (A2058; Sigma-Aldrich, UK). Cells were counted using a haemocytometer and 
subsequently diluted to lx l0 6 cells per ml.
A microBoydon chemotaxis chamber (Neuroprobe, Bethseda, MD, USA) was 
assembled with 28pl control medium (RPMI-1640/1% IgG-free BSA) or the 
chemokine of interest (prepared in RPMI-1640/1% IgG-free BSA) being placed in 
triplicate wells in the lower reservoir. A polycarbonate polyvinyl pyrrolidone (PVP)- 
free membrane with 5pm pores (Poretics Corp, Livermore, CA, USA) was placed on 
top and the top section o f reservoirs was assembled. 50pl of cell suspension (5x104 
cells) was placed into each well in the upper reservoir. The chamber was incubated 
for 2-4 hours at 37°C in a humidified 5% CO2 atmosphere. The chamber was 
disassembled and the membrane removed, fixed and stained using Diff-Quik 
solutions; fixative (2 minutes), stain I (2.5 minutes) and stain II (1 minute) (Dade, 
Gamidor Technical Services, UK). The membrane was washed in deionised water to 
rinse off excess stain and mounted on a microscope slide so that the cells faced 
down. The membrane top was wiped with a damp cotton bud to remove unmigrated 
cells and another microscope slide was placed on top to keep the membrane in place. 
It was then left to air dry. Total migrated cells were counted in 10 fields o f view at 
x400 magnification within each well using a Leica DMLB microscope (Leica 
Microsystems Ltd., Milton Keynes, UK). Chemotactic activity was normalised by 
expressing it as fold migratory increase over control cells.
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2.12 Proliferation Assay (MTT)
THP-1 cells were cultured to near confluency as described in section 2.1.2. Cells 
were collected and washed by centrifugation in PBS at 1200rpm (400g) for 3 
minutes. The cell pellet was resuspended in PBS and cells were counted using a 
haemocytometer. Cell viability was also checked using trypan blue solution (0.4%; 
Invitrogen Ltd., UK) as described in section 2.1.2. Cells were subsequently diluted 
to 2x105 cells per ml in RPMI-1640 medium with 2% FCS. Cells were distributed in 
lOOpl aliquots (2x104 cells) to each well o f a 96-well plate (Thermo-Fisher 
Scientific, Denmark) and incubated for 4 hours at 37°C in a humidified 5% CO2 
atmosphere. For differentiated THP-1 cell experiments, THP-1 cells, after being 
counted, were diluted to 4xl05 cells per ml in routine culturing RPMI-1640 medium 
containing a final concentration o f lOnM PMA (Sigma-Aldrich, UK). Cells were 
distributed in lOOpl aliquots (4x104 cells) to each well of a 96-well plate and 
incubated for 72 hours at 37°C in a humidified 5% CO2 atmosphere. After the 
incubation period, the medium was replaced with RPMI-1640 medium with 2% FCS 
in preparation for treatment.
The EGFR ligands (EGF, HB-EGF, BTC and TGFa), the monoclonal antibody 
ICR62 and the tyrosine kinase inhibitor gefitnib (IRESSA) ((Ciardiello et al., 2000); 
a kind gift to Dr Helmout Modjtahedi from Astra Zenica, UK) were diluted in RPMI- 
1640 medium with 2% FCS and lOOpl aliquots were added to triplicate wells. Cells 
were incubated for 72 hours at 37°C in a humidified 5% CO2 atmosphere. For 
analysis, 50pl of sterile MTT (5mg/ml, thiazolyl blue tetrazolium bromide; Sigma- 
Aldrich, UK) was added to each well and incubated for 4 hours. Plates were 
centrifuged at 400g for 5 minutes and the supernatant removed. The water-insoluble
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MTT-formazan blue crystals were solubilized with 200pl dimethyl sulfoxide 
(DMSO) and the plates were shaken vigorously to ensure proper dissolution. Colour 
intensity/absorbance was read at 540nm using a Labsystems MultiSkan RC plate 
reader (Thermo Electron, UK).
2.13 Statistical Analysis
A P value equal to or less than 0.05 was considered statistically significant. Data are 
expressed as mean ± SEM or SD where indicated for each variable. Statistical 
analysis was performed using an unpaired t test or a one- or two-way analysis of 
variance (ANOVA) followed by Dunnett’s multiple comparison or Bonferroni post 
hoc tests where appropriate using GraphPad Prism (version 4.03 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com).
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Chapter Three
The Expression o f EGFR by THP-1 Cells & Human 
Peripheral Blood Monocytes
3.1 Introduction
The epidermal growth factor receptor has been found to be expressed on a wide 
variety of cell types and tissues throughout the human body and is important for 
embryogenesis and development, mediating cellular events such as differentiation, 
migration, proliferation and apoptosis (Casalini et al., 2004; Yano et al., 2003). 
Tissues expressing EGFR include those from epithelial, mesenchymal and neuronal 
origins (Normanno et al., 2006; Yano et al., 2003), as well as cells within the 
vasculature, particularly intimal (Tamura et a l, 2001) and medial (Nakata et al., 
1996) smooth muscle cells and endothelial cells (Styren et al., 1993). There is 
however, limited evidence of its expression on the human mononuclear cell lineage. 
Only two examples exist: brain derived microglial cells (Nolte et al., 1997) and 
macrophages associated with the inflammatory response in uveal melanoma (Scholes 
et al., 2001).
To date only one human monocytic cell line, U937, has been found to express the 
EGFR on its cell membrane (Eales-Reynolds et al., 2001). The receptor in this case 
was detected with flow cytometry using the monoclonal antibody ICR62. 
Furthermore, the phorbol ester phorbol 12-myristate 13-acetate (PMA) was shown to 
significantly increase the percentage of EGFR-positive cells.
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3.1.1 Aim
This study aimed to investigate whether the EGFR is expressed on other human 
mononuclear cells, either primary cells or the cell line THP-1. Expression of the 
EGFR was established on monocytic THP-1 cells using flow cytometry and 
immunocytochemistry techniques. The effect of differentiation into a macrophage­
like cell was also investigated. The detection o f protein within THP-1 cells was 
performed using SDS-PAGE and western blotting techniques. Similarly, human 
peripheral blood monocytes and human macrophage-like cells were investigated.
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3.2 The Cell Surface Expression of EGFR on Human Tumour Cells 
by Flow Cytometry
Three human carcinoma cell lines that express EGFR were used to validate the use of 
the anti-EGFR rat monoclonal antibody ICR62 in the flow cytometry system used for 
THP-1 cells. The three cell lines have different levels o f EGFR expression. MCF-7 
cells have an undetectable expression, EJ cells display medium expression (<2 x 105 
receptors per cell) and HN5 cells display extensive expression (1.4 x 107 receptors 
per cell) (Modjtahedi & Dean, 1996).
The cell surface expression levels of EGFR as determined by flow cytometry in the 
three tumour cell lines is presented in figure 3.1. MCF-7 cells had a mean 
fluorescence intensity (MFI) of 3.44, which was barely above the MFI o f the 
unstained control cells at 3.14. The EJ cells had a MFI of 179.11 and the high 
expressing HN5 cell line had a MFI of 4057.5. Controls for both the antibody 
isotype and secondary antibody showed no non-specific binding (data not shown).
In order to validate the use of ICR62 with the flow cytometry protocol designed for 
cells of the monocytic lineage, the level o f EGFR expression in the EJ cell line was 
determined using the method described in section 2.9.2. This method had been 
previously optimised within the laboratory (Lamb et al., 2004). EJ cells were 
incubated with ICR62 along with the F(ab’)2 rabbit anti-rat IgG FITC conjugated 
secondary antibody for 1 hour at 4°C (figure 3.2). Although the resulting MFI of 
21.68 was considerably lower than for the previous method, the THP-1 flow
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cytometry method was still considered a suitable method of detecting cell surface 
EGFR expression.
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Figure 3.1 EGFR expression on the human carcinoma cell lines. The three 
tumour cell lines MCF-7 (A), EJ (B) and HN5 (C) were labelled as described in 
section 2.9.1 with the rat monoclonal antibody ICR62 (lOpg/ml) (iii) for 1 hour at 
4°C. Cells were then washed prior to incubation with the F(ab’)2 rabbit anti-rat IgG 
FITC conjugated secondary antibody (10pg/ml) for 1 hour at 4°C. Unstained cells 
are shown in forward versus side scatter dot plot (i) and FL1-H FITC (ii) histogram 
form. The mean fluorescence intensity (MFI) of each sample is shown as the figures 
in the top left hand comer of each histogram. These are representative plots of two 
experiments.
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Figure 3.2 EGFR expression on the EJ cell line using the same flow cytometry 
method used to stain THP-1 cells. The EJ tumour cell line was incubated with the 
rat monoclonal antibody ICR62 (lOpg/ml) or IgG2b isotype control (10|ig/ml) and 
the F(ab’)2 rabbit anti-rat IgG FITC conjugated secondary antibody (lOpg/ml) for 1 
hour at 4°C as described in section 2.9.2. Unstained cells (A) were gated in a 
forward versus side scatter dot plot with the resulting FL1-H (FITC) histograms of 
unstained cells (B), IgG2b isotype control (C) and ICR62 (D). The mean 
fluorescence intensity (MFI) of each sample are shown as the figures in the top left 
hand comer of each histogram. This is a representative result of three experiments.
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3.3 The Cellular Surface Expression of EGFR on the Monocytic 
THP-1 Cell by Flow Cytometry
Monocytic THP-1 cells were incubated in the presence of the anti-EGFR monoclonal 
antibody ICR62 and the appropriate isotype control as described in section 2.9.2. 
For flow cytometry analysis, THP-1 cells were gated in a forward versus side scatter 
dot plot and transformed into a FL1-H fluorescence histogram. An example is 
shown in figure 3.3A. Here, unstained cells had a MFI o f 2.67 and the IgG2b isotype 
control had a MFI o f 3.23. THP-1 cells incubated with ICR62 had a MFI 19.32. The 
table (figure 3.3B) shows the MFI o f THP-1 cells incubated with ICR62 from repeat 
experiments. THP-1 cells had an average MFI of 21.62 ± 2.92 (mean ± SD) and 
therefore could be considered to express EGFR on their cell surface.
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Figure 3.3 The cell surface expression of the EGFR on THP-1 cells. Monocytic 
THP-1 cells were incubated for 1 hour at 4°C in the presence of the monoclonal 
antibody ICR62 (lOpg/ml) and the F(ab’)2 rabbit anti-rat IgG FITC conjugated 
secondary antibody (10pg/ml) as described in section 2.9.2. Unstained control THP- 
1 cells were gated in a forward versus side scatter dot plot (Ai) with the resulting 
FL1-H (FITC) histogram of ICR62 (Aii). Histogram populations in the example 
shown are for unstained (black), IgG2b isotype control (blue) and ICR62 (red). The 
mean fluorescence intensity of each population is shown on the histogram. This is a 
representative result of six experiments as shown in the table (B).
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3.4 The Cell Surface Expression of EGFR on the Differentiated 
THP-1 Cell by Flow Cytometry
THP-1 cells were differentiated into macrophage-like cells with lOnM PMA over 72 
hours and examined for their EGFR cell surface expression by flow cytometry 
analysis as described in section 2.9.2. Differentiated THP-1 cells were incubated in 
the presence of the anti-EGFR monoclonal antibody ICR62 and the appropriate 
isotype control. Differentiated THP-1 cells were gated in a forward versus side 
scatter dot plot (figure 3.4A) and transformed into a fluorescence histogram (figure 
3.4B). Unstained control cells had a MFI of 3.61 and the IgG2b isotype control had a 
MFI of 3.47. THP-1 cells incubated with ICR62 had a MFI 3.96 and therefore did 
not express EGFR on their cell surface.
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Figure 3.4 The cell surface expression of the EGFR on differentiated THP-1 
cells. Monocytic THP-1 cells were differentiated into macrophage-like cells in the 
presence of lOnM PMA over 72 hours as described in section 2.2. Differentiated 
THP-1 cells were incubated for 1 hour at 4°C in the presence of the monoclonal 
antibody ICR62 (lOpg/ml) and the F(ab’)2 rabbit anti-rat IgG FITC conjugated 
secondary antibody (10pg/ml) as described in section 2.9.2. Unstained control 
differentiated THP-1 cells were gated in a forward versus side scatter dot plot (A) 
with the resulting FL1-H (FITC) histogram of ICR62 (B). Histogram populations 
shown are for unstained (black), IgG2b isotype control (blue) and ICR62 (red). The 
mean fluorescence intensity of each population is shown on the histogram. This is a 
representative result of four experiments.
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3.5 The Cell Surface Expression of the EGFR by Human Peripheral 
Blood-Derived Monocytes
Human peripheral blood monocytes were isolated from whole blood from one 
healthy individual and cultured as described in section 2.3. Isolated human 
peripheral blood monocytes were incubated with an antibody to the monocyte marker 
CD 14 and ICR62 to establish the presence of EGFR as described in section 2.9.3.
The suspected monocyte population was gated on a forward versus side scatter dot 
plot and is shown as the red cells within PI (figure 3.5A). 21.3% of the total cell 
population was located within this gated population. Confirmation that these gated 
cells were monocytes was achieved by plotting the total cell population in a forward 
versus RPE-Cy5 dot plot (figure 3.5B). Cells which stained positive with the anti- 
CD14 antibody are shown as the blue population (figure 3.5Bi). The percentage of 
CD 14 positive cells within the whole cell population was 16.9%. Cells stained with 
the mouse IgG2a isotype control are also shown (figure 3.5Bii). The percentage of 
cells stained in P3 with the isotype control was 1.5% of the total cell population. 
When the CD 14 positive cells from P3 were gated on the original forward verses side 
scatter dot plot they were located within PI.
The gated CD 14 positive monocyte cells within PI (figure 3.5A) were transformed 
into a FL1-H (FITC) versus FL3-H (RPE-Cy5) dot plot (figure 3.6). When the cells 
were double stained for CD14 and EGFR 55.2% of the gated cell population 
expressed both markers (figure 3.6aQ2). The double stained isotype control cells 
only showed 0.5% of the gated population in this same region (figure 3.6bQ2).
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However, cells were still located within sector Q4 (13.2%) indicating non-specific 
binding from the matched isotype control for EGFR.
When cells were singly stained for CD14, 58.9% of cells in the gated population 
were found to be positive (figure 3.6cQl). This percentage was reduced to 0.1% 
when the isotype control for CD 14 was used (figure 3.6dQl). Therefore, non­
specific binding of the CD 14 antibody was minimal. When the cells were singly 
stained for EGFR using ICR62, 9.8% of PI were considered positive (figure 
3.6eQ4). However, when the cells were singly stained with the rat IgG2b isotype 
control for ICR62, 11.4% of PI were located within sector Q4 (figure 3.6/Q4). This 
would suggest that the positive result seen with ICR62 may be non-specific. 
Although the double stained cells (figure 3.6aQ2) are positive for CD 14 and can be 
considered monocytes, it is not clear whether these cells are really EGFR positive.
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Figure 3.5 Isolation of the CD 14 positive monocyte population. Isolated human 
peripheral blood monocytes from one healthy individual were incubated in the 
presence of antibodies against the monocyte marker CD 14 and ICR62 (EGFR) for 1 
hour at 4°C as described in section 2.9.3. (A) The suspected monocyte population 
(PI -  red population; 21.3% of total cell population) was gated within a forward 
verses side scatter dot plot containing the total cell population (20,000 events). (B) 
The CD 14 positive population (monocytes) within the whole cell population was 
identified by plotting cells in a forward versus RPE-Cy5 dot plot. Positively 
expressing CD 14 monocytes (P3 -  blue population; 16.9% total cell population) (i) 
and isotype control (1.5% of total cell population) (ii). The CD 14 positive cell 
population in P3 was located within the whole cell population on the forward versus 
side scatter dot plot (A). These cells are represented as the blue population, with the 
majority of them falling within PL
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Figure 3.6 The cell surface expression of the EGFR on human peripheral blood 
monocytes. Human peripheral blood monocytes from one healthy individual were 
double stained for the monocyte marker CD 14 and EGFR with ICR62 as described in 
section 2.9.3. Gated cells in PI {figure 3.5A) were transformed into a FL1-H (FITC) 
for EGFR versus FL3-H (RPE-Cy5) for CD 14 dot plot. The dot plots show double 
CD14/EGFR positive (a), double isotype control (b), single CD 14 positive (c), single 
CD 14 isotype control (IgG2a) (d), single EGFR (ICR62) positive (e), single EGFR 
isotype control (IgG2b) (f) and unstained cells (g). Figures in each quadrant show 
the percentage of stained cells from PI.
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3.6 The Cell Surface Expression of the EGFR on Monocyte-Derived 
Macrophages
Human peripheral blood monocytes were isolated from whole blood from one 
healthy individual and cultured as described in section 2.3. Monocyte-derived 
macrophages were incubated with an antibody to the monocyte marker CD 14 and 
ICR62 to establish the presence of EGFR as described in section 2.9.3.
Monocyte-derived macrophages were gated within a forward versus side scatter dot 
plot based upon their CD14 expression as described previously in section 3.5. This 
gated population (PI) contained 27% of cells from the total cell population (figure 
3.7a). Cells within PI were transformed into a FL1-H (FITC) versus FL3-H (RPE- 
Cy5) dot plot (figure 3.7b, c &d).
Human monocytes showed an extremely low expression of EGFR following 
maturation into monocyte-derived macrophages (figure 3.7d). The percentage of 
cells in Q2, positive for both CD 14 and EGFR, was 1% of the cells gated in PI. This 
is equivalent to 54 cells out of the 5420 cells in PI, or 0.27% of the total 20,000 cell 
population. When stained with the double isotype controls, only 0.4% of cells in PI 
were located in sector Q2 (figure 3.7c). Also, only 0.3% of cells in PI were located 
in sector Q4, which would indicate positive EGFR expression and therefore non­
specific binding o f that isotype of antibody. Therefore it could be suggested that out 
of the 1% of double positive cells, 0.7% are actually positive (1% total - 0.3% non­
specific = 0.7% specific EGFR). This is equivalent to 37 cells out o f the 5420 cells 
in PI, or 0.19% of the total 20,000 cell population.
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Figure 3.7 The cell surface expression of the EGFR on human peripheral blood 
monocyte-derived macrophages. Peripheral blood monocytes were isolated from 
whole blood from one healthy individual and cultured for 8 days for maturation into 
monocyte-derived macrophages as described in section 2.3. Cells were assessed for 
the expression of CD 14 (RPE-Cy5) and the EGFR (FITC) with the rat monoclonal 
antibody ICR62 as described in section 2.9.3. Monocyte-derived macrophages were 
gated as PI (a), and transformed into FL-1H (FITC) versus FL-3H (RPE-Cy5) dot 
plots for unstained cells (b), double isotype control (c) and double CD 14 & EGFR 
(d). Figures in each quadrant show the percentage of stained cells from P I.
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HB-EGF is one o f the EGFR ligands (Higashiyama et al., 1991). Treatment of 
monocyte-derived macrophages from one healthy individual with HB-EGF was 
carried out to investigate any changes in cell surface EGFR expression. A slight 
increase in EGFR expression was observed in Q2 when the cells were treated with 
lOnM HB-EGF (figure 3.8c). The percentage o f cells within this quadrant increased 
from 1% in untreated cells (figure 3.8a) to 1.9% in the lOnM treated cells. This 
increase in percentage within Q2 was combined with an observed increase in MFI 
within Q l, indicating a shift in the population. Untreated cells had an MFI of 377, 
whereas lOnM HB-EGF treated cells had an MFI o f 515. O.lnM and 25nM treated 
cells had MFI values o f 321 and 306 respectively. Indeed, on visual inspection of the 
dot plots a cell population shift to the right is clearly seen.
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Figure 3.8 The effect of HB-EGF on the cell surface expression of the EGFR on 
human peripheral blood monocyte-derived macrophages. Peripheral blood 
monocytes were isolated from whole blood from one healthy individual and cultured 
for 8 days for maturation into monocyte-derived macrophages as described in section 
2.3. Cells were treated for 2 hours with 0.1 nM, lOnM or 25nM HB-EGF and then 
assessed for the expression of CD 14 (RPE-Cy5) and EGFR (FITC) with the rat 
monoclonal antibody ICR62 as described in section 2.9.3. Monocyte-derived 
macrophages were gated as PI (figure 3.7a), and transformed into FL-1H (FITC) 
versus FL-3H (RPE-Cy5) dot plots for untreated cells (a), 0.1 nM (b), lOnM (c) and 
25nM HB-EGF (d). Figures in each quadrant show the percentage of stained cells 
from PI.
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3.7 Localization of EGFR in Monocytic and Differentiated THP-1 
Cells
Monocytic and differentiated THP-1 cells were immunocytochemically stained with 
ICR62 as described in section 2.10 to determine the location of their EGF receptors. 
Monocytic THP-1 cells showed EGFR reactivity within their cytoplasm with slight 
cell membrane staining (figure 3.9A). There was minimal reactivity following 
incubation with the isotype control IgG2b or control buffer (figure 3.9B & C). When 
the images for ICR62 and nuclei were combined the EGFR positive regions could 
clearly be seen to surround the nuclei (figure 3.9D).
EJ cells in comparison have a more honey comb-like appearance in their pattern of 
staining with ICR62 (figure 3J0A). This is consistent with the knowledge that this 
cell line expresses many EGF receptors on its cell surface (Modjtahedi & Dean, 
1996).
The staining pattern for the differentiated THP-1 cells was different. Not only are 
the cells much larger but the EGFR appeared to be located within the cell nucleus as 
well as within the cytoplasm (figure 3.11A). When both the images for ICR62 and 
Hoechst were combined it became clear that the blue nuclear staining did overlap the 
green FITC staining for EGFR (figure 3.1 ID). Once again, there was no reactivity 
following incubation with the isotype control IgG2b or control buffer (figure 3.1 IB 
&C).
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Figure 3.9 Localisation of the EGFR in monocytic THP-1 cells. Monocytic THP- 
1 cells were spun onto microscope slides using a Cytospin and subjected to 
immunocytochemical staining as described in section 2.10. Cells were air-dried, 
fixed in 4% paraformaldehyde and permeabilised in 0.5% Triton X-100. 
Immunofluorescent staining was conducted with the rat monoclonal antibody ICR62 
(20pg/ml) (A) and a rat IgG2b isotype control (20pg/ml) (B) as described in section 
2.10.2. Control cells (C). Representative staining for FITC staining (left panels) and 
Hoechst 33258 nuclear staining (right panels) are shown. All images are at xlOO 
magnification. The location of the nuclei is shown in the combined image (D).
92
Chapter 3 -  EGFR Expression
Figure 3.10 Localisation of the EGFR in the EJ tumour cell line. EJ tumour cells 
were dissociated with trypsin and spun onto microscope slides using a Cytospin and 
subjected to immunocytochemical staining as described in section 2.10. Cells were 
air-dried, fixed in 4% paraformaldehyde and permeabilised in 0.5% Triton X-100. 
Immunofluorescent staining was conducted with the rat monoclonal antibody ICR62 
(20pg/ml) as described in section 2.10.2. Representative staining for FITC staining 
(A) and Hoechst 33258 nuclear staining (B) are shown. All images are at xlOO 
magnification. The location of the nuclei is shown in the combined image (C).
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Figure 3.11 Localisation of the EGFR in differentiated THP-1 cells. Monocytic 
THP-1 cells were incubated in the presence of lOnM PMA for 72 hours to produce 
differentiated THP-1 cells as described in section 2.2. The cells were dissociated and 
spun onto microscope slides using a Cytospin and subjected to immunocytochemical 
staining as described in section 2.10. Cells were air-dried, fixed in 4% 
paraformaldehyde and permeabilised in 0.5% Triton X-100. Immunofluorescent 
staining was conducted with the rat monoclonal antibody ICR62 (20pg/ml) (A) and a 
rat IgG2b isotype control (20pg/ml) (B) as described in section 2.10.2. Control cells 
(C). Representative staining for FITC staining (left panels) and Hoechst 33258 
nuclear staining (right panels) are shown. All images are at x 100 magnification. The 
location of the nuclei is shown in the combined image (D).
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3.8 THP-1 Cell EGFR Protein Expression
EJ cells are known to express easily detectable levels of EGFR. Therefore, these 
cells were used as a positive control for the immunoprecipitation reaction. Cell 
lysates were incubated with Protein-G sepharose beads conjugated with ICR62. 
Following SDS-PAGE and western transfer, the resulting membrane was 
investigated for the presence of EGFR protein with a commercial antibody SC-03 
(Table 2.2). A positive EGFR band is seen in the ICR62 lane after a 3 minute 
exposure (figure 3.12). No bands are seen in the IgG2b or control lanes indicating 
that the immunoprecipitation reaction is specific and that the EGFR protein is only 
being isolated when incubated with ICR62.
The reaction was then carried out with THP-1 cell lysates. An EGFR band can be 
seen in the ICR62 lane (figure 3.13) however, there is high background on this blot 
as the film had to be exposed for 30 minutes which can cloud the positive result. 
There are however no bands of the same molecular weight visible in the IgG2b or 
control columns which strongly suggests that the band seen is due to EGFR.
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Figure 3.12 Immunoprecipitation of EGFR in EJ cells. EJ cells were lysed and 
subjected to immunoprecipitation with the monoclonal antibody ICR62 as described 
in section 2.7. As controls, equal volumes of the EJ lysate were also 
immunoprecipitated with the isotype control IgG2b and buffer. Equal volumes 
(15pl) of the resulting samples were subjected to SDS-PAGE, transferred to PVDF 
membrane and probed for the presence of EGFR with rabbit anti-human polyclonal 
antibody SC-03 (1/200) with a chemiluminescent detection system as described in 
section 2.8. The membrane was exposed to photographic film for 3 minutes. A 
positive EGFR band is seen in the ICR62 lane.
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Figure 3.13 EGFR protein expression in THP-1 cells. THP-1 cells were lysed and 
subjected to immunoprecipitation with the monoclonal antibody ICR62 as described 
in section 2.7. As controls, equal volumes of the THP-1 lysate were also 
immunoprecipitated with the isotype control IgG2b (dilution) and buffer. Equal 
volumes (15pl) of the resulting samples were subjected to SDS-PAGE, transferred to 
PVDF membrane and probed for the presence of EGFR with the rabbit anti-human 
polyclonal antibody SC-03 (1/200) and a chemiluminescent detection system as 
described in section 2.8. The membrane was exposed to photographic film for 30 
minutes. A slight positive EGFR band is seen in the ICR62 lane.
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3.9 Discussion
The expression of EGF receptor was investigated in monocytic THP-1 cells, 
differentiated THP-1 cells, human peripheral blood-derived monocytes and human 
monocyte-derived macrophages. Receptor expression was investigated using flow 
cytometry, immunocytochemistry and western blotting techniques.
Validation of the rat monoclonal antibody ICR62 for use with the monocyte flow 
cytometry protocol was first established with the EGFR expressing human tumour 
cell lines HN5, EJ and MCF-7 (figure 3.1). EJ cells, characterised as having a mid­
range cell surface expression of EGFR had a mean fluorescence intensity of 179.11 
when using the human carcinoma flow cytometry protocol described in 2.9.1. 
However, when analysed using the monocyte flow cytometry protocol as described 
in 2.9.2, the EJ mean fluorescence intensity fell to 21.68 (figure 3.2). This drop in 
detection could be attributable to the lack o f rotation within the antibody incubation 
steps which is included in the first protocol. Rotation enables the cells to be 
constantly free floating in the antibody, whereas without rotation cells naturally form 
a pellet at the bottom o f the incubation tube under the influence o f gravity. This 
could mean that cells within or on the underside o f the pellet would have a reduced 
exposure to the antibodies.
Analysis o f THP-1 cells for EGFR expression using the monocyte flow cytometry 
protocol resulted in an average mean fluorescence intensity of 21.62 ± 2.92 (figure 
3.3). This was comparable to the expression on the EJ cells under the same flow  
cytometry protocol. It could therefore be suggested at this early stage that THP-1 
cells express the EGF receptor to the same extent as EJ cells.
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The expression of EGFR was subsequently investigated on differentiated THP-1 
cells. Monocytic THP-1 cells, when incubated with the phorbol ester PMA for at 
least 48 hours in culture are considered to become macrophage-like with respect to 
both morphology and gene expression (Auwerx, 1991; Tsuchiya et al., 1982). 
Following incubation with lOnM PMA for 72 hours the macrophage-like 
differentiated THP-1 cells were analysed for EGFR expression. Results from four 
flow cytometry experiments indicated that there was no EGFR expression on the 
cellular surface of these differentiated cells (figure 3.4).
Further analysis of the receptor expression on THP-1 cells with 
immunocytochemistry indicated that the EGFR, present on the cell surface and 
within the cytoplasm of the monocytic cell (figure 3.9), was located in the nucleus in 
the differentiated cell (figure 3.11). This provided an explanation for the observed 
result following the flow cytometry analysis where there was no cell surface 
reactivity for EGFR with ICR62. What possible role therefore could the EGFR have 
for being in the cell nucleus of the differentiated THP-1 cell?
All members o f the EGFR family have been detected in nuclei (Wang et al., 2004; 
Offrerdinger et al., 2002; Lin et al., 2001; Ni et al., 2001; Marti & Hug, 1995; Xie & 
Hung, 1994) as well as other PTKs including nerve growth factor receptor (NGFR), 
fibroblast growth factor receptor (FGFR), vascular endothelial growth factor 
receptor-2 (VEGFR-2) and type 1 TGFp receptor. Inflammatory cytokine receptors 
for IL-1, IL-5 and IFNy have also been located in the nuclear compartment (Lo & 
Hung, 2006). Since its first discovery in human adrenocortical carcinoma (Kamio et 
al., 1990), the nuclear localisation of EGFR has been detected in various tissues and
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carcinoma cell types including hepatocytes (Marti et al., 1991), placenta (Cao et al., 
1995), thyroid (Marti et al., 2001), breast (Lo et al., 2006), bladder (Lipponen & 
Eskelinen, 1994), and oral cavity (Psyrri et al., 2005).
The nuclear EGFR pathway can be initiated by ligand binding, and nuclear 
localisation signals (NLSs) have been identified in all four members o f the EGFR 
family. EGFR’s NLS is located within the juxtamembrane region (Hsu & Hung, 
2007; Lo & Hung, 2006). As EGF receptors lack a putative DNA binding domain, it 
is suspected that they first associate with DNA-binding transcription factors to then 
enhance target gene transcription via their intrinsic transactivational activity (Lo & 
Hung, 2006). It is therefore thought that EGFR interacts with STAT3 and E2F1 to 
upregulate expression of inducible nitric oxide synthase (iNOS) and B-Myb 
respectively (Hanada et al., 2006; Lo et al., 2005). Nuclear EGFR has also been 
found to upregulate cyclin D1 expression leading to Gl/S cell cycle progression (Lin 
et al., 2001). All of these factors are associated with increased proliferation in 
cancerous cells.
The nuclear import o f EGFR can also occur in ligand-independent situations, such as 
exposure to irradiation, heat shock, H2O2 and cisplatin (Lo & Hung, 2006). In these 
situations, EGFR interacts with DNA-dependent protein kinase (DNA-PK) leading to 
DNA damage repair and ultimately the radioresistance o f tumours (Chen & Nirodi, 
2007; Dittmann et al., 2005).
The above evidence strongly suggests that the role for the nuclear localisation of 
EGFR is to drive cellular proliferation. However, one of the characteristics o f a
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PMA differentiated THP-1 cell is its inability to proliferate (Schwende et al., 1996; 
Auwerx, 1991). What, therefore is its role in an essentially non-proliferating cell? It 
must not be forgotten that THP-1 cells are of leukaemic origin (Tsuchiya et al., 
1980) and that the observed result may be due to their oncogenic status rather than 
their leukaemic origin. Peripheral blood-derived monocytes and macrophage-like 
cells should be investigated as to whether they also have nuclear localisation of the 
EGF receptor.
Following the flow cytometry result with the THP-1 cells, isolated peripheral blood 
monocytes were investigated for their EGFR expression. Since isolated monocytes 
were investigated from only one individual, care must be taken in the interpretation 
of these results. The monocytes initially appeared to express the EGF receptor 
(figure 3.6a) as cells were present in the quadrant representing double staining for 
both CD 14 (monocytes) and ICR62 (EGFR). However, a similar result was obtained 
with the matched isotype control antibody which would indicate that the result with 
ICR62 could be due to non-specific binding of the antibody (figure 3.6e & J). In 
order to confirm the result with ICR62 further experiments with more individuals are 
needed to investigate any gender or genetic differences in expression and perhaps the 
use of an alternative isotype control antibody could be investigated.
It is interesting that THP-1 cells express EGFR on their cell surface whereas 
peripheral blood-derived monocytes from one individual do not. It could be possible 
that during the oncogenic process, the THP-1 cell developed the expression of the 
EGFR and now relies in part on it to maintain its growth. Other differences have 
been observed in the gene expression profiles between monocytic cell lines and
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human primary monocytes. For example, the top three genes most highly expressed 
in THP-1 cells, cathepsin G, neutrophil elastase 2 and proteinase 3 are not generally 
associated with monocytes. Similarly, ficolin 1, MHC class II DRal and interferon 
y-inducible protein 30 which are highly expressed in monocytes are not expressed in 
THP-1 cells. The results o f the above study suggested that although THP-1 cells are 
morphologically similar to monocytes, the two are very different from a 
transcriptomic point of view (Kohro et al., 2004).
It was subsequently investigated to see whether blood-derived monocyte maturation 
into a macrophage-like cell would result in EGFR expression. Isolated human 
peripheral blood-derived monocytes from the same one individual were cultured for 
8 days into macrophage-like cells. A very low expression of the EGFR was observed 
in monocyte-derived macrophages (figure 3.7). However, when these cells were pre­
incubated with the EGFR ligand HB-EGF (lOnM) there was a slight increase in 
receptor expression (figure 3.8). It could be suggested that any increase in receptor 
expression on the cellular surface is immediately counteracted by ligand binding and 
subsequent internalisation o f the receptor. Therefore no extra receptor would be 
seen.
It could be considered that peripheral blood-derived monocyte maturation into the 
macrophage-like cell in culture is a very rudimentary process. The main stimulus for 
monocyte maturation within the tissue culture environment is the presence of a 
plastic ‘surface’. Within the plaque environment the invading monocyte is exposed 
to many other different types of ‘surface’ such as other cells and extra cellular matrix 
components (Ross, 1993). Added to this is the myriad o f growth factors and
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cytokines which can initiate maturation and activation down specific pathways for 
example IFNy and IL-lp (Mosser, 2003; Ma et al., 2003). Perhaps it should be 
considered that the artificial maturation o f cell culture monocytes should occur in the 
presence of a variety of stimuli such as collagen or fibronectin coated flasks so as to 
get a representation of the plaque environment. A variety o f studies have shown that 
adherence o f monocytes to different surfaces results in the upregulation of different 
genes such as IL-6, PDGF and IL-8 (Standiford et al., 1991; Shaw et al., 1990; 
Navarro et al., 1989). Perhaps with a specific activatory stimulus, for example IFNy 
the maturing macrophage-like cell may be ‘persuaded’ to express the EGF receptor.
After discovering that THP-1 cells express the EGFR through flow cytometry and 
immunocytochemical analysis the expression was also investigated using 
immunoprecipitation and western blotting techniques. Following a negative result 
solely with SDS-PAGE and western blotting, the THP-1 cells were subjected to 
immunoprecipitation with ICR62 to specifically isolate the EGFR protein prior to 
electrophoresis and western blotting with a commercial anti-EGFR antibody. The 
technique was optimised with EJ cells in order to demonstrate that indeed ICR62 was 
capable of precipitating out EGFR (figure 3.12). However, when analysing THP-1 
cells, a very low specific EGFR expression was observed following a 30 minute 
chemiluminescent exposure to photographic film (figure 3.13). Further to this, a 
total of 6x10 cells were required to obtain this result. This made the further study of 
the protein expression difficult. The low expression of the EGFR in THP-1 cells 
maybe outside the detectable range of this system and therefore a more sensitive 
system has to be employed.
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3.10 Conclusions
The main aim of this chapter was to investigate the expression of the EGFR on the 
THP-1 cell line and peripheral blood-derived monocytes. Flow cytometry analysis 
of the THP-1 cell line with the monoclonal antibody ICR62 revealed expression of 
the EGFR which was comparable to the bladder carcinoma cell line EJ which is an 
intermediate EGFR expresser. When incubated with PMA to induce cellular 
differentiation, the macrophage-like THP-1 cells displayed no EGFR expression. 
The EGFR was subsequently shown to be localised within the nucleus o f these cells. 
The purpose of this nuclear localisation remains unclear and blood-derived 
monocytes and macrophage-like cells should be investigated for their receptor 
localisation. SDS-PAGE and subsequent western blotting techniques did show 
specific reactivity to the EGFR following immunoprecipitation with the monoclonal 
antibody ICR62. However, vast numbers of cells were harvested for this analysis 
which made future experiments involving primary cells inconceivable.
Peripheral blood-derived monocytes were also investigated for their expression of 
EGFR by flow cytometry. Minimal receptor expression was observed which was 
inconsistent with the results seen with the THP-1 cell line. However, although the 
two types o f cell are very similar morphologically, they do exhibit large differences 
in terms of transcription. Care must be taken in the interpretation o f observed results 
with the THP-1 cell line when referring to a possible role of a blood monocyte. 
Monocyte-derived macrophages also displayed minimal receptor expression by flow 
cytometry and this expression increased only slightly following pre-incubation with 
the EGFR ligand HB-EGF. However, this result was obtained through analysis of
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only one individual. More individuals should be investigated to account for any age, 
gender or genetic differences.
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Chapter Four 
Analysis o f EGFR Gene Expression
4.1 Introduction
The EGFR gene spans llOkb on chromosome 7pl2-14 and contains 26 exons with 
several long introns (Haley et al., 1987; Merlino et al., 1985). The EGFR promoter 
lacks a characteristic TATA and CAAT box, but is enriched in G + C residues 
(Haley et al., 1987; Ishii et al., 1985). G + C rich promoters mainly demonstrate 
transcription from multiple start sites, whereas some, like the TATA-box promoters 
initiate from a single start site (Hudson et al., 1990).
The four GC boxes bind the ubiquitous, positive transcription factor Spl which is 
essential for EGFR gene transcription (Safe & Abdelrahim, 2005; Kageyama et al.,
1988). Three GC rich regions bind the factor EGFR-specific transcription factor-1 
(ETF1), which specifically stimulates transcription from promoters without a TATA 
box (Kageyama et al., 1989). The positive transcription factor ETF2 binds to a 
single promoter site (Johnson et al., 1988a). The promoter also contains four SI 
nuclease-sensitive regions with the motif o f TCCTCCTCC. These regions bind Spl, 
EGF responsive DNA binding protein (ERDP-1) and the factor TCF (Chen et al., 
1993; Johnson et al., 1988b; Ishii et al., 1985). TCF is essential for optimal EGFR 
gene transcription.
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Two repressor proteins have been identified that bind to the EGFR promoter. GCF 
(GC factor) is a 91kDa protein that binds with high affinity to three GC-rich regions 
which overlap a ETF1 binding site (Kageyama & Pastan, 1989) and ETR (EGFR 
transcriptional repressor) is a 128kDa protein which binds to one site on the promoter 
(Hou et al., 1994).
Regulation of the expression of the EGFR has been extensively studied, but is still 
not completely understood (Merlino, 1990). A number of agents have been 
suggested to upregulate the EGFR at a transcriptional level. These include phorbol 
esters (Bjorge & Kudlow, 1987), IFNy (Chang et al., 1987), retinoic acid (Oberg & 
Carpenter, 1991), TGFp (Femandez-Pol et al., 1987), and cAMP (Hudson et al.,
1989). The ligands EGF and TGFa are also known to stimulate the synthesis o f the 
EGFR (Burgess, 1989; Kudlow et al., 1986).
In this chapter, EGFR gene expression was analysed in monocytic and differentiated 
THP-1 cells following treatment with four o f the EGFR ligands EGF, HB-EGF, 
TGFa and BTC, as well as three monocyte activators IFNy, IL-lp and LPS. Human 
peripheral blood-derived monocytes were also analysed for their gene expression 
changes during maturation into macrophage cells. Changes in gene expression were 
determined by analysing mRNA expression using quantitative real-time PCR.
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4.2 Effect of Serum Concentration on THP-1 Cells
In order to execute assays in which the effect of the EGFR ligands was being 
determined, the serum concentration in the experimental medium had to be reduced, 
in effect, cells were serum starved. This was to ensure that any change in gene 
expression seen within the experiment was due to the addition of that particular 
ligand.
THP-1 cells were cultured over a period of 96 hours in RPMI-1640 media containing 
10%, 5% and 2% FCS and their growth was investigated. Cells were seeded at lx l0 5 
per ml and a steady increase in cell number was seen with all three serum 
concentrations (figure 4.1). A drop in cellular proliferation was observed at 96 hours 
with the cells incubated in 2% FCS (P<0.05). Therefore if  cells were to be grown in 
2% serum for experimental procedures, the maximum duration time of the 
experiment should be set at 72 hours.
Cell viability was also investigated using the trypan blue exclusion method. At no 
point during the experiment did viability drop below 95% under any treatment (data 
not shown).
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Figure 4.1 THP-1 cell proliferation under different medium serum 
concentrations. THP-1 cells were grown in 12-well plates in RPMI-1640 media 
supplemented with 10%, 5% or 2% foetal calf serum. Total cell counts per ml were 
taken at 24 hour intervals using a haemocytometer as described in section 2.1.2. 
Data shown are the mean ± SEM (n = 3). Data were analysed using a two-way 
analysis of variance (ANOVA) followed by Bonferroni post hoc test. *P<0.05 (10% 
and 5% serum versus 2% serum at 96 hours)
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4.3 Preparation of EGFR and MLN51 Standard Curves
Standard curves for both EGFR and MLN51 genes were created with RNA from 
THP-1 and EJ cells in order to establish the expression range for each cell type. 
RNA from both EJ and THP-1 cells was diluted to a range of O.Olng to lOOng. The 
cycle threshold (Ct) value for each RNA amount was established from the resulting 
amplification curves (figure 4.2) by setting the cycle threshold to 0.5 and the baseline 
between cycles 3 and 15. The cycle threshold values for each cell line and gene were 
then plotted against the log ng o f RNA (figure 4.3).
Detection of EGFR gene expression in EJ cells could be obtained at the lowest 
amount o f O.Olng RNA. However, this quantity of RNA for the THP-1 cells did not 
yield a detectable product, as demonstrated by the amplification curve (figure 4.2Bi). 
Both cell lines produced consistent amplification over the range o f the diluted 
amounts as demonstrated by the r2 values on the standard curves (figure 4.3). 
However, the THP-1 cells had lower expression of EGFR as shown by the higher Ct 
values (figure 4.3Bi). MLN51 detection in both cell lines was comparable (figure 
4.3Aii & Bii).
Based on these results, the EJ cell line was chosen to produce the standard curves for 
both EGFR and MLN51 genes. This would enable very low quantities o f EGFR 
gene expression to be confidently detected in the test/treatment samples from THP-1 
cells and human primary monocytes.
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Figure 4.2 Amplification plots for EGFR and MLN51 expression in EJ and 
THP-1 cells. RNA extracted from EJ cells (A) and THP-1 cells (B) was isolated as 
described in section 2.6.3, diluted to the indicated amounts per reaction and 
amplified using a one-step SYBR Green real-time PCR reaction as described in 
section 2.6.3. Cycle threshold (Ct) values for each amount were obtained for EGFR
(i) and MLN51 (ii) expression by manually setting the cycle threshold to 0.5 and the 
baseline between cycles 3 and 15.
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Figure 4.3 Standard curves for EGFR and MLN51 with EJ and THP-1 RNA.
Standard curves were created with RNA covering the range of O.Olng to lOOng from 
EJ cells (A) and THP-1 cells (B) for EGFR (i) and MLN51 (ii). Cycle threshold (Ct) 
values derived from the amplification curves were plotted against the log ng amounts 
of RNA. The correlation between the points was analysed by linear regression and r2 
values were obtained to demonstrate ‘best fit’. Points represent the mean (n = 2) Ct 
value ± SD.
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Standard curves were constructed for both human peripheral blood-derived 
monocytes and THP-1 cells from each analysis QPCR amplification plate with EJ 
RNA (figure 4.4). Linear regression analysis on each of the curves produced r2 
values of greater than 0.9.
Following the cycling reaction, melt-curve analysis was performed to establish the 
melting point of the specific PCR product (figure 4.5). Melt curves are plotted as 
temperature (°C) against the change in the rate o f dissociation (derivative, -dF/dT) of 
the primers and the template cDNA (Pryor & Wittwer, 2006; Ririe et al., 1997). In 
EJ cells both EGFR and MLN51 have melting point temperature (Tm) values of 
78.7°C. The non template control (NTC) for EGFR runs at the bottom o f the graph 
as there is no template for the primers to anneal to. The NTC for the MLN51 
reaction contains a peak at 71.3°C which either demonstrates a contaminant in the 
reaction or a primer dimer due to the primer sequence.
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Figure 4.4 Compiled standard curves for human peripheral blood-derived 
monocytes and THP-1 cells for EGFR and MLN51. Standard curve reference 
points with EJ RNA were run on each analysis QPCR plate to compile standard 
curves for monocytes (A) and THP-1 cells (B) for both EGFR (i) and MLN51 (ii). 
Ct values obtained from the amplification curve were plotted against the log ng 
amounts o f RNA. The correlation between the points was analysed by linear 
regression and r2 values were obtained to demonstrate ‘best fit’. Points represent the 
mean (n = 4-24) Ct value ±  SEM.
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Figure 4.5 Dissociation melt curves in EJ cells for EGFR and MLN51 gene 
expression. Following the PCR reaction, PCR products were subjected to melt 
curve analysis. Each standard curve ng value are plotted as temperature (°C) against 
the change in the rate of dissociation (-dF/dT). Tm values for EJ cells for both 
EGFR (A) and MLN51 (B) was 78.7°C. NTC -  non template control.
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4.4 EGFR mRNA Expression in Monocytic and Differentiated THP- 
1 Cells
Monocytic THP-1 cells were found to have a very low level o f EGFR mRNA 
expression when normalised to the housekeeping gene MLN51 (0.003 ± 0.0004) 
(figure 4.6). When differentiated with lOnM PMA for 72 hours into macrophage­
like cells, EGFR mRNA expression increased three-fold (0.01 ± 0.001). This 
increase was found to be highly statistically significant (P0.0001).
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Figure 4.6 Expression of EGFR mRNA in monocytic and differentiated THP-1 
cells. The expression of EGFR mRNA in monocytic and differentiated THP-1 cells 
was established by real-time QPCR analysis and expression was normalised to the 
housekeeping gene MLN51. Data shown are the mean ± SEM (THP-1 n = 10; 
dTHP-1 n = 7). Data were analysed using an unpaired t test. ***P<0.0001 (dTHP-1 
versus THP-1).
117
Chapter 4 -  EGFR Gene Expression
Due to the vast number of samples generated in a preliminary experiment with 
monocytic and differentiated THP-1 cells treated with four o f the EGFR ligands and 
three monocyte activators at four time points in duplicate tissue culture wells, the 
tissue culture samples for each condition were pooled prior to DNase treatment. 
This, therefore, gave an n of 1. The preliminary experiment of pooled samples gave 
an indication of possible activity which led on to a more detailed investigation into 
TGFa, HB-EGF, IFNy and IL-lp at 12 and 24 hours. In the follow up experiment, 
each treatment at the two time points was investigated in triplicate tissue culture 
wells. This ultimately gave an n of 1 for all EGF, BTC and LPS data bars and an n 
of 4 for HB-EGF, TGFa, IFNy and IL-lp at 12 and 24 hours and an n of 1 at 6 hours.
Data presented on the graphs are the combination of both the preliminary 
investigation and the more detailed follow-up investigation for 6, 12 and 24 hours. 
As no significant data were recorded at 48 hours, these data have been omitted from 
the graphs.
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4.4.1 HB-EGF Induces the Expression o f EGFR mRNA in Monocytic THP-1 Cells 
Monocytic THP-1 cells were treated with physiologically relavent levels of EGF, 
HB-EGF, TGFa and BTC for 6, 12 and 24 hours. EGFR mRNA expression in 
response to EGF treatment remained low (figure 4.7A). The greatest induction (1.6 ± 
0.41 fold) in expression occurred with 50nM EGF at 24 hours treatment. Peak 
EGFR expression following HB-EGF treatment occurred at 12 hours with 50nM with 
a 2.7 ± 0.66 fold induction over control cells (figure 4.7B). This induction in 
expression was statistically significant (P<0.01). EGFR expression following 
treatment with TGFa (figure 4.7C) and BTC (figure 4.7D) showed no significant 
increases. Peak fold induction occurred with 50nM TGFa following 6 hours 
treatment (1.7 ± 0.39 fold) and with 50nM BTC following 24 hours treatment (1.4 ± 
0.58 fold).
The most notable result with monocytic THP-1 cells was that they responded most 
following treatment with 50nM of each ligand albeit at different time points.
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Figure 4.7 EGFR mRNA expression in monocytic THP-1 cells following 
treatment with EGFR ligands. THP-1 cells were incubated in the presence of EGF 
(A), HB-EGF (B), TGFa (C) and BTC (D) at 25nM and 50nM. Cells were harvested 
after 6 , 12 and 24 hours treatment. Bars represent the mean ± SEM of the fold 
induction over untreated control cells of PCR plate duplicates of tissue culture wells 
(n = 1,6 hours; n = 4, 12 and 24 hours). Data were analysed using one-way analysis 
of variance (ANOVA) followed by Dunnett’s multiple comparison post hoc test. 
**P<0.01 (50nM HB-EGF at 12 hours versus control).
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4.4,2 IFNy and IL-lp Induce the Expression o f EGFR mRNA in Monocytic THP- 
1 Cells
Monocytic THP-1 cells were treated with physiologically relevant levels o f IFNy, IL- 
lp and LPS for 6, 12 and 24 hours. EGFR mRNA expression following IFNy 
treatment increased 3.7 ± 0.63 fold over control cells at 12 hours (figure 4.8A). This 
induction was found to be statistically significant (PO.Ol). Expression remained at 
baseline at 6 hours and 24 hours treatment. A similar induction of expression profile 
was observed following IL-lp treatment (figure 4.8B). EGFR mRNA expression 
increased 3.6 ± 1.13 fold at 12 hours and this induction was found to be statistically 
significant (PO.Ol). Once again, expression remained at baseline at 6 hours and 24 
hours treatment.
No statistical analysis could be performed on the LPS treatments (figure 4.8C) as 
they were representative results from one preliminary experiment.
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Figure 4.8 EGFR mRNA expression in monocytic THP-1 cells following 
treatment with IFNy, IL-ip and LPS. THP-1 cells were incubated in the presence 
of IFNy (lOOU/ml) (A), IL-lp (2.5ng/ml) (B) and LPS (lOOng/ml) (C). Cells were 
harvested after 6 , 12 and 24 hours treatment. Bars represent the mean ± SEM of the 
fold induction over untreated control cells of PCR plate duplicates of tissue culture 
wells (IFNy & IL-lp: n = 1, 6  hours; n = 4, 12 and 24 hours; LPS: n = 1). Data were 
analysed using one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparison post hoc test. **P<0.01 (IFNy and IL-1 p at 12 hours versus 
control).
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4.4.3 TGFa Induces the Expression o f EGFR mRNA in Differentiated THP-1 
Cells
Differentiated THP-1 cells were treated with physiologically relavent levels o f EGF, 
HB-EGF, TGFa and BTC for 6, 12 and 24 hours. EGFR mRNA expression in 
response to EGF treatment remained low (figure 4.9A). Peak induction in expression 
(1.4 ± 0.03 fold) occurred following 6 hours treatment with 25nM EGF. HB-EGF 
treatment at 50nM resulted in a 1.5 ± 0.30 fold induction over control cells at 12 
hours (figure 4.9B). Treatment with TGFa resulted in the largest induction in EGFR 
mRNA expression out o f all the EGFR ligands tested. EGFR mRNA expression was 
induced 2 ± 0.39 fold when treated with 50nM for 12 hours (figure 4.9C). This 
induction was found to be very statistically significant (PO.Ol). EGFR mRNA 
expression following treatment with BTC remained low with a peak induction of 1.3 
± 0.34 fold seen with 50nM at 6 hours (figure 4.9D).
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Figure 4.9 EGFR mRNA expression in differentiated THP-1 cells following 
treatment with EGFR ligands. After incubation with lOnM PMA for 72 hours, the 
differentiated THP-1 cells were incubated in the presence of EGF (A), HB-EGF (B), 
TGFa (C) and BTC (D) at 25nM and 50nM. Cells were harvested after 6 , 12 and 24 
hours treatment. Bars represent the mean ± SEM of the fold induction over untreated 
control cells of PCR plate duplicates of tissue culture wells (n = 1, 6  hours; n = 4, 12 
and 24 hours). Data were analysed using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparison post hoc test. **P<0.01 (50nM TGFa at 
1 2  hours versus control).
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4.4,4 IFNy and IL-lp Induce the Expression o f EGFR mRNA in Differentiated 
THP-1 Cells
Differentiated THP-1 cells were treated with physiologically relavent levels o f IFNy, 
IL-lp and LPS for 6, 12 and 24 hours. EGFR mRNA expression following IFNy 
treatment increased 1.8 ± 0.19 fold over control cells after 12 hours (PO.Ol) (figure 
4.10A). Expression remained low at 6 hours and 24 hours treatment. As with the 
monocytic THP-1 cells, the same expression profile was seen following treatment 
with IL-lp (figure 4.10B). EGFR mRNA expression increased 1.7 ± 0.22 fold at 12 
hours. This induction was found to be statistically significant (PO.05). Once again, 
expression remained low at 6 hours and 24 hours treatment. LPS treatment had no 
effect on the expression of EGFR mRNA (figure 4.10C). However, it should be 
considered that these data are from the preliminary experiment and therefore are only 
representative of one experiment.
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Figure 4.10 EGFR mRNA expression in differentiated THP-1 cells following 
treatment with IFNy, IL-lp and LPS. After incubation with lOnM PMA for 72 
hours, the differentiated THP-1 cells were incubated in the presence of IFNy 
(lOOU/ml) (A) IL-ip (2.5ng/ml) (B) and LPS (lOOng/ml) (C). Cells were harvested 
after 6, 12 and 24 hours treatment. Bars represent the mean ± SEM of the fold 
induction over untreated control cells of PCR plate duplicates of tissue culture wells 
(IFNy & IL-lp: n = 1, 6 hours; n = 4, 12 and 24 hours; LPS: n = 1). Data were 
analysed using one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparison post hoc test. **P<0.01 (IFNy at 12 hours versus control); 
*P<0.05 (IL-lp at 12 hours versus control).
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4.5 EGFR mRNA Expression in Human Blood-Derived Monocytes
Isolated human monocytes from five healthy individuals were incubated and 
harvested over a period of 8 days and analysed for changes in EGFR mRNA 
expression (figure 3.11). Gene expression in the monocytes remained very low for 
the first 24 hours. Between 48 and 96 hours, EGFR mRNA expression varied greatly 
between individuals with one individual having a 10-fold increased expression. 
From 7 days, EGFR expression had returned to the original low levels in all 
individuals.
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Figure 4.11 EGFR expression in peripheral blood monocytes and blood derived 
macrophages. Isolated human blood monocytes from five healthy individuals were 
incubated over a period of 8 days into macrophages-like cells as described in section 
2.3. Cells were harvested at the times shown and analysed for their EGFR mRNA 
expression using real-time QPCR analysis as described in section 2.6. EGFR 
expression was normalised to the house-keeping gene MLN51. Each dot represents 
the mean o f the QPCR well duplicate for each tissue culture well duplicate for each 
individual. Bars represent the mean of all results for that time point.
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With a very low level of mRNA expression the validity o f the results was 
investigated by analysing the product dissociation. The results indicated that the 
majority o f the QPCR results were non-valid (figure 4.12). For example sample Xa, 
dissociation melt curve analysis revealed dominant Tm peaks under 70°C. 
Dissociation peaks at this temperature indicate primer dimer formation and therefore 
no specific primer binding to the target sequence. This can occur when there is a 
very low amount or no target sequence available. This result was confirmed by gel 
electrophoresis o f the PCR products (figure 4.12B). The double band on the gel for 
sample Xa corresponds to the double peaks seen on the dissociation curve (figure 
4.12A). The top band corresponds to the small dissociation peak at 78°C, and this 
lies in line with the EJ cell EGFR standards. This indicates that there is some 
specific binding o f the primers to the target sequence, however the peak and band for 
non-specific binding is larger, resulting in the Ct value for that sample being 
considered void.
Corresponding analysis of MLN51 expression in sample Xa was investigated. 
Dissociation melt curve analysis produced a specific Tm peak at 79°C (figure 4.13A). 
This result was confirmed by gel electrophoresis. A strong band can be observed in 
line with the EJ cell MLN51 standards (figure 4.13B). This result confirms that, 
although there is a very low copy number o f the EGFR gene, there is sufficient 
mRNA to be analysed.
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Figure 4.12 Melt curve dissociation and gel electrophoresis analysis of monocyte 
EGFR PCR products. (A) The PCR product of sample Xa was subjected to melt 
curve analysis. The melt curve is plotted as temperature (°C) against the change in 
rate of dissociation (-dF/dT). Specific product formation is represented by a 
prominent peak and Tm value of 78.6°C to 79°C. (B) The PCR product of sample Xa 
was also subjected to gel electrophoresis to confirm product specificity.
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Figure 4.13 Melt curve dissociation and gel electrophoresis analysis of monocyte 
MLN51 PCR products. (A) The PCR product of sample Xa was subjected to melt 
curve analysis. The melt curve is plotted as temperature (°C) against the change in 
rate of dissociation (-dF/dT). Specific product formation is represented by a 
prominent peak and Tm value of 78.6°C to 79°C. (B) The PCR product of sample Xa 
was also subjected to gel electrophoresis to confirm product specificity.
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With the valid PCR products for each individual established, the results were re­
plotted (figure 4.14). At 2 hours, EGFR mRNA expression was low, as seen 
originally. There were no valid data points at the 12 hour or 24 hour time points. 
Remaining data for the 48 hour time point again indicated an increase in EGFR 
mRNA expression in two different individuals. At 72 hours, EGFR mRNA 
expression decreased to low levels and remained at this level for up until 9 days in 
culture. With the low number of valid results it is not possible to make a valid 
conclusion on the EGFR mRNA expression in these samples.
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Figure 4.14 Viable results for EGFR expression in peripheral blood monocytes 
and blood derived macrophages. PCR products were checked for their validity and 
unvalid results were removed. Each dot represents the mean of the QPCR well 
duplicate for each tissue culture well duplicate for each individual. Bars represent 
the mean of all results for that time point.
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4.6 Discussion
One of the aims of this chapter was to investigate the gene expression of the EGF 
receptor following treatment with four of the EGFR ligands EGF, HB-EGF, TGFa 
and BTC, as well as three monocyte activators IFNy, IL-lp and LPS.
Baseline mRNA expression of the EGFR on monocytic THP-1 cells, when 
normalised to the housekeeping gene MLN51, was very low at 0.003 (figure 4.6). 
Equivalent gene expression to MLN51 would have resulted in a ratio of 1. When the 
THP-1 cells were differentiated into macrophage-like cells, EGFR gene expression 
increased 3-fold. This could either have been as a result o f the differential status of 
the cell or due to the PMA treatment. Indeed, PMA has been shown to stimulate 
EGFR synthesis (Bjorge & Kudlow, 1987). Further studies showed that the effects 
of phorbol esters are mediated via the transcription factors Activator Protein 1 and 2 
(API and AP2) (Angel et al., 1987; Chiu et al., 1987) and that the EGFR promoter 
contains sequences similar to API and AP2 binding sites. Indeed, EGFR gene 
transcription has been found to be activated by PMA and that this process was in 
part, mediated via AP2 in prepared nuclei and nuclear extracts from KB cells 
(Johnson, 1996).
EGFR mRNA expression was increased significantly (2.7 ±  0.66; P<0.01) when the 
THP-1 cells were incubated with 50nM HB-EGF for 12 hours (figure 4.7). No other 
significant effects resulting from the treatment with the other ligands was seen. HB- 
EGF has a higher affinity for binding to the EGFR and this is aided by its heparin 
binding capabilities (Higashiyama et al., 1993). This could, therefore, explain why 
only HB-EGF evoked a response in the THP-1 cells. On the other hand, EGF and
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TGFa are capable of stimulating the synthesis of the EGF receptor in cell lines from 
human breast cancer and rat hepatic epithelial cells (Burgess, 1989; Bjorge & 
Kudlow, 1987; Kudlow et al., 1986; Earp et al., 1986). To date, HB-EGF has not 
been associated with EGFR mRNA up-regulation. However, this observed effect of 
HB-EGF may only occur in cells of the monocytic lineage and so has remained 
uninvestigated.
When the THP-1 cells were differentiated into macrophage-like cells, 50nM TGFa 
significantly (PO.Ol) induced EGFR mRNA expression following 12 hours 
treatment (figure 4.9). This is interesting as previous experiments within this thesis 
have shown that the EGFR is not expressed on the cell membrane o f differentiated 
THP-1 cells. How, therefore, is TGFa inducing this response? Both PMA and EGF 
have been shown to stimulate EGFR mRNA expression in human KB cells. 
However, EGF was actually shown to stabilize the EGFR mRNA, whereas PMA did 
not affect mRNA stability (Jinno et al., 1988). Further to this, EGF and TGFa have 
been shown to be equipotent in stabilizing EGFR mRNA and increasing expression 
of EGFR protein in KB cells (McCulloch et al., 1998) and prostate cancer cells lines 
(Seth et al., 1999). It could be suggested that in monocytic THP-1 cells EGFR 
mRNA levels were so low that any stabilization effects could not be seen. However, 
in the differentiated THP-1 cells, PMA had increased overall receptor gene 
expression and therefore the stabilizing effects o f TGFa could be observed as an 
increase in gene expression. Why the possible stabilizing effect is not seen at 6 
hours is unclear. However, it should be noted that the result at 6 hours is 
representative of only one result. Due to the fact that EGF produced no notable 
results throughout these sets of experiments it could be considered that this source of
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growth factor was biologically inactive. Perhaps it would have been wise to include 
a positive control, for example a cell line which is responsive to all four EGFR 
ligands used.
Monocytic THP-1 cells were also investigated for their EGFR gene expression 
following treatment with the inducers of monocyte activation IFNy, IL-lp and LPS. 
Both IFNy and IL-lp significantly (P<0.01) induced EGFR mRNA expression at 12 
hours (figure 4.8). LPS also induced mRNA induction of EGFR but at 6 hours and 
24 hours. However, as this result was from the preliminary experiment, no statistical 
tests could be undertaken. When THP-1 cells were differentiated into macrophage­
like cells, EGFR mRNA expression was significantly induced by IFNy (P<0.01) and 
IL-ip (P<0.05), once again, at 12 hours treatment (figure 4.10). However, fold 
induction for both cytokines was half that seen when the THP-1 cells were 
monocytic suggesting that the cytokines have more influence on monocytes. As the 
response to LPS was completely abolished in the differentiated THP-1 cell, focus 
was set on IFNy and IL-lp as both these cytokines are influential players in the 
atherosclerotic plaque environment (Ross, 1993).
IFNy appears to be an important activating stimulus for macrophages and has been 
known to upregulate EGFR gene expression for some time (Ma et al., 2003; Chang 
et al., 1987). In addition to the rapid JAK/STAT la-mediated priming response, in 
macrophage activation IFNy also induces the expression of a set o f transcription 
factors known as interferon regulatory factors (IRF-1 to IRF-9). IFNy is now known 
to regulate EGFR gene expression via the induction in the expression o f IRF-1. IRF-
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1 is a regulatory factor that binds to the interferon stimulated response element 
(ISRE) sequences (Schroder et al., 2004; Rubinstein et al., 1998).
IL-lp also plays a role in modulating macrophage activation. The binding of IL-lp 
to IL-1R1 activates both mitogen-activated protein kinase (MAPK)-AP1 (activator 
protein kinase-1) and I-kB kinase (IKK)-NFkB pathways via MYD88 (myeloid 
differentiation factor 88), IRAK (interleukin-1 receptor associated kinase) and 
TRAF6 (tumour necrosis factor receptor-associated factor 6) (Ma et al., 2003). It is 
unclear how IL-lp signalling could lead to the upregulation of EGFR mRNA as up 
until this point IL-lp has only been associated the EGFR protein (Wan et al., 2001; 
Murthy et al., 2000; Kracht et al., 1994; Bird & Saklatvala, 1990). One possibility 
could be that TRAF6 associates with various effector molecules, ultimately resulting 
in activation of transcription factors such as NF-kB and AP-1 (Boch et al., 2001). It 
has also been proposed that IRF-1 expression can been induced by IL-ip (Fujita et 
al., 1989).
LPS is a typical pathogen-associated molecular patterns (PAMPs) which 
macrophages use to recognise a range of bacteria, virus, parasite and fungi. In order 
to signal, LPS must complex with LPS-binding protein prior to being recognised by a 
cell membrane-bound high-affmity LPS PRR (pattem-recognition receptor) known 
as CD 14. CD 14 then cooperates with the PRR coreceptor TLR4 (toll-like receptor 4) 
which shares the signal transduction pathway with IL-1 receptor (Ma et al., 2003). It 
could be via this signal transduction pathway that LPS induces EGFR expression.
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EGFR expression in human peripheral monocytes and macrophage-like cells from 
five individuals was very low (figure 4.14). This was consistent with the low 
expression seen following flow cytometry analysis. There was however a peak in 
expression after 48 hours in culture. A possible explanation for this could be that the 
EGFR has an increased expression as the monocyte matures into a macrophage in 
order to prepare it for possible exposure to EGFR ligands as that type of cell. If no 
activation of the EGFR protein occurs then perhaps gene expression is returned to 
baseline levels. If activation of the EGFR protein does occur then maybe increased 
EGFR gene expression is sustained. A further extension to this investigation would 
be to incubate the monocytes after 48 hours with EGFR ligands and monocyte 
activators as carried out in the THP-1 cell investigation.
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4.7 Conclusions
The main aim of this chapter was to investigate the gene expression o f the EGF 
receptor using quantitative real-time PCR techniques. Initial investigations with the 
THP-1 cell line showed that the levels of EGFR gene expression were very low when 
normalised to the housekeeping gene MLN51. As a comparison, the EJ tumour cell 
line has a gene expression ratio of 1 when normalised to MLN51 (data not shown). 
Following differentiation into macrophage-like cells, the differentiated THP-1 cells 
had increased EGFR gene expression. This could either be as a result of the 
maturation status of the cell or due to the differentiation procedure as PMA is a 
known inducer of EGFR gene transcription.
Following incubation with the EGFR ligands, HB-EGF was found to significantly 
increase EGFR gene expression in the monocytic THP-1 cells. Interestingly, to date 
out of all the ligands only EGF and TGFa have been shown to increase EGFR gene 
expression. Perhaps, the gene induction seen here with HB-EGF is solely associated 
with THP-1 cells. When the THP-1 cells were differentiated into macrophage-like 
cells gene expression was significantly increased following treatment with TGFa. 
Instead of an actual increase in expression, it was suggested that this result was due 
to the stabilizing effects TGFa can have on EGFR mRNA.
When incubated in the presence of IFNy and IL-ip, EGFR gene expression in both 
monocytic and differentiated THP-1 cells was significantly induced. IFNy primes 
and activates monocytes to act as effector cells in pro-inflammatory Thl cellular 
response. Perhaps if  exposed to IFNy, the monocyte upregulates the EGFR to aid in 
a specific process, i.e. the migration of the cell to sites of inflammation.
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Interestingly, IL-lp has not previously been shown to upregulate the EGFR as it is 
usually associated with its downregulation as a protein.
EGFR gene expression in human peripheral blood-derived monocytes from five 
individuals was very low. As they matured into macrophage-like cells in culture 
their EGFR expression spiked at 48 hours. Increased EGFR expression could be 
initiated during the maturation process in anticipation of ligand exposure to the cell. 
If no ligand activates the EGFR protein then gene expression is reduced back down 
to baseline. Perhaps incubation after 48 hours with the EGFR ligands or IFNy in 
culture could sustain the increased EGFR gene expression.
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Chapter Five
The Functional Properties o f the EGFR Ligands on THP-1 
Cells and Human Monocytes
5.1 Introduction
Monocytes and macrophages play a crucial role in the development and stability of 
the atherosclerotic plaque. Monocytes are initially attracted to the developing plaque 
environment under the influence of MCP-1 (Ikeda et al., 2002). Once inside the 
plaque, mature macrophages migrate within the lesion under the influence of MIP- 
la , MIP-lp and RANTES (Osterud & Bjorklid, 2003; Reape & Groot, 1999; Cross 
et ah, 1997; Uguccioni et al., 1995). LysoPC, oxLDL, TGFp and the CSFs are also 
potent chemoattractants (Resat et al., 2003; Ross, 1993; Quinn et al., 1988; Quinn et 
al., 1987). Macrophages may be transformed into sub-populations of cells with 
different properties depending on the different stimuli they encounter in the plaque. 
Although IFNy and the interleukins play a major role in the activation of 
macrophages, many other factors including lipids, growth factors and extracellular 
matrix proteins can influence the process. These sub-populations influence the 
plaque environment further by either being highly microbicidal and inflammatory or 
immunosupressive (Ma et al., 2003). The apoptosis o f macrophages within the 
plaque is highly influential to its stability and is almost certainly multifactorial. 
Inefficient clearance o f the apoptotic macrophage leads to the generation of the 
necrotic core, increased inflammation and plaque instability (Tabas, 2005).
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With respect to atherosclerosis, HB-EGF is a potent VSMC mitogen and 
chemoattractant in vitro (Higashiyama et al. 1993; Higashiyama et a l 1991). It is 
capable of upregulating PDGF, bFBF and M-CSF receptor mRNA in SMCs and can 
mediate the transactivation of the EGFR by G-protein coupled receptors for 
angiotensin II and thrombin (Kalmes et al., 2001; Raab & Klagsbrun, 1997; Peifley 
et al., 1996). Both BTC and EGF have been shown to possess mitogenic activity for 
rat SMCs and cultured human aortic SMCs (Tamura et al., 2001; Shing et al., 1993; 
Thyberg et al., 1990).
With respect to monocyte and macrophages, EGF has been found to be chemotactic 
for microglial cells and rabbit peripheral blood-derived monocytes and macrophage­
like cells (Lamb et al., 2004; Nolte et al., 1997). EGF was also been found to be 
mitogenic for rabbit monocyte-derived macrophages (Lamb et al., 2004).
5.1,1 Aim
The aim of this chapter therefore was to investigate the function o f the EGFR and its 
ligands EGF, HB-EGF, TGFa and BTC in monocytic and differentiated THP-1 cells. 
The possible function was also investigated in human peripheral blood-derived 
monocytes and monocyte-derived macrophages. Functional analysis was determined 
using proliferation and chemotaxis assays.
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5.2 The Effect of EGFR Ligands on THP-1 Cell Growth
THP-1 cells were assessed for their cellular proliferation with the MTT assay 
following treatment with EGF, HB-EGF, TGFa and BTC for 72 hours at the 
concentrations shown (figure 5.1 A). Untreated control cells had an average 
absorbance of 1.162 ± 0.03. Treatment of the cells with EGF, HB-EGF and BTC 
resulted in no change in their growth as their absorbances remained around the 
control cell absorbance. Interestingly, TGFa caused a significant (P<0.05) drop in 
absorbance following 0.4nM treatment (0.818 ± 0.03) when compared to control 
untreated cells. This could indicate either an inhibition in cellular proliferation or 
activation of cellular apoptosis.
Differentiated THP-1 cells were also investigated using the MTT assay. Monocytic 
THP-1 cells were differentiated with lOnM PMA for 72 hours followed by treatment 
with EGF, HB-EGF, TGFa and BTC for a further 72 hours at the concentrations 
shown (figure 5.IB). Once again, untreated control cells were analysed and they had 
an average absorbance of 1.050 ± 0.05. Results for each ligand were extremely 
variable with no clearly defined trend seen.
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Figure 5.1 The effect of EGFR ligands on the growth of monocytic and 
differentiated THP-1 cells. Monocytic (A) and differentiated THP-1 (B) cells were 
grown in RPMI-1640 with 2% FCS containing EGF, HB-EGF, TGFa, BTC at the 
indicated concentrations or control medium for a period of 72 hours. Cell density 
was analysed by MTT assay as described within section 2.12. Each point represents 
the mean ± SEM (control n = 6 ; EGFR ligands n = 3). Data were analysed using 
one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison 
post hoc test. */><0.05 (0.4nM TGFa versus untreated control)
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5.2.1 The Monoclonal Antibody ICR62 Inhibits the Growth o f THP-1 Cells but not 
Differentiated THP-1 Cells
Monocytic THP-1 cells were grown in the presence of varying concentrations of the 
monoclonal antibody ICR62 (figure 5.2A). Untreated control cells had an average 
absorbance of 1.346 ± 0.08. When treated with ljig/ml ICR62, the absorbance was 
0.833 ± 0.04, 38% lower than untreated control cells. This inhibition in growth was 
found to be statistically significant (P<0.01) and continued with further more 
concentrated treatments.
Differentiated THP-1 cells were also investigated, but as seen with the ligand 
treatments the results were extremely scattered with no clearly defined trend seen.
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Figure 5.2 The effect of the monoclonal antibody ICR62 on the growth of 
monocytic and differentiated THP-1 cells. Monocytic and differentiated THP-1 
cells were grown in RPMI-1640 with 2% FCS containing ICR62 or control medium 
for a period of 72 hours. Cell density was analysed by MTT assay as described 
within section 2.12. Each point represents the mean ± SEM (control n = 6 ; ICR62 n 
= 3). Data was analysed using a one-way analysis of variance (ANOVA) followed 
by Dunnett’s multiple comparison post hoc test. **/><0.01 (1,2 and 16pg/ml ICR62 
versus untreated control).
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5.3 Chemotactic Effects of the EGFR Ligands
5.3.1 THP-1 Cells Migrate in Response to MCP-1
THP-1 cells were investigated for their chemotactic activity towards the well 
characterised monocyte chemokine MCP-1. THP-1 cells were exposed to MCP-1 
over a range of 0.0InM to 30nM in a microBoydon chemotaxis chamber for 2 hours 
as previously investigated by Lamb et al., 2004. Migrated cells were counted in 10 
fields of view for each test well and the fold migratory increase over unstimulated 
control cells was calculated.
Peak chemotactic activity was observed at InM where an average of 255 ± 47.52 
cells migrated (figure 5.3). This was equivalent to a 2.3 ± 0.19 fold increase in 
migration over unstimulated control cells and was found to be statistically significant 
(PO.05).
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Figure 5.3 THP-1 cells migrate in response to MCP-1. THP-1 cells were assessed 
for their chemotactic activity towards MCP-1 over 2 hours in a mircoBoyden 
chemotaxis chamber. Total cells were counted in 10 fields of view per treatment 
well. Data shown are the mean ± SEM (n = 9) of the fold increase over unstimulated 
control cells. Data were analysed using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparison post hoc test. *P<0.05 (InM MCP-1 
versus unstimulated control).
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5.3.2 THP-1 Cells Migrate in Response to the EGFR Ligands 
Monocytic THP-1 cells were assessed for the chemotactic activity towards the EGFR 
ligands EGF, HB-EGF, TGFa and BTC. The cells were exposed to physiological 
concentrations of EGF over a range of O.lnM to 300nM, and HB-EGF, TGFa and 
BTC over a range o f O.OlnM to 30nM in a microBoydon chemotaxis chamber for 2 
hours as previously investigated by Lamb et al., 2004. Migratory cells were counted 
in 10 fields o f view for each test well and the fold migratory increase over 
unstimulated control cells was calculated. For each ligand, the migratory response to 
MCP-1 is shown for comparison.
THP-1 chemotactic activity towards EGF was minimal with the peak observed at 
InM with an average of 79 ± 17.67 migrated cells (figure 5.4A). This was equivalent 
to a 1.04 ± 0.23 fold induction over the unstimulated control cells. Chemotactic 
activity towards HB-EGF was much greater. Peak activity was observed at O.lnM
\
with an average of 344 ± 41.50 migrated cells, equivalent to a 3 ± 0.36 fold increase 
over control cells (figure SAB). This migratory effect was found to be statistically 
significant (P<0.01). The response at 0.3nM (2.6 ± 0.24 fold) was also found to be 
statistically significant (P<0.01), as were O.OlnM (2.2 ±  0.06 fold, P<0.05) and 
0.03nM (2.1 ± 0.35 fold, P<0.05). TGFa also resulted in some chemotactic activity 
with the peak being observed at 0.3nM with a 2 ± 0.06 fold induction over 
unstimulated control cells (figure 5.5A). This was found to be statistically significant 
(P<0.05). As seen with EGF, the chemotactic response to BTC was also minimal 
with a 1.4 ± 0.13 fold induction in chemotactic activity at 0.3nM (figure 5.5B).
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Figure 5.4 The chemotactic response of THP-1 cells to EGF & HB-EGF. THP-1 
cells were assessed for their chemotactic ability in response to EGF (A) and HB-EGF 
(B), over 2 hours in a mircoBoyden chemotaxis chamber. Total cells were counted 
in 10 fields of view per treatment well. THP-1 response to MCP-1 is shown as a 
comparison with each ligand. Data shown are the mean ± SEM (n = 3) of the fold 
increase over each ligand’s unstimulated control cells. Raw cell count data were 
analysed using one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparison post hoc test. **P<0.01 (O.lnM & 0.3nM HB-EGF versus 
unstimulated control), *P<0.05 (O.OlnM & 0.03nM HB-EGF versus unstimulated 
control; InM MCP-1 versus unstimulated control).
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Figure 5.5 The chemotactic response of THP-1 cells to TGFa & BTC. THP-1 
cells were assessed for their chemotactic ability in response to TGFa (A) and BTC 
(B), over 2 hours in a mircoBoyden chemotaxis chamber. Total cells were counted 
in 10 fields of view per treatment well. THP-1 response to MCP-1 is shown as a 
comparison with each ligand. Data shown are the mean ± SEM (n = 3) of the fold 
increase over each ligand’s unstimulated control cells. Raw cell count data were 
analysed using one-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple comparison post hoc test. *P<0.05 (0.3nM TGFa versus unstimulated 
control; InM MCP-1 versus unstimulated control).
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5.3.3 Monocyte Chemotaxis in Response to MCP-1 Following Incubation with 
Different Blood Anticoagulants
Peripheral blood was collected from the same healthy individual and anticoagulated 
with either EDTA (BD Vacutainer® EDTA blood tube, BD Diagnostics, UK) or 
3.8% sodium citrate as described in section 2.3. Isolated monocytes were then 
assessed for their chemotactic activity towards MCP-1 over a range of O.OlnM to 
30nM (figure 5.6). Between O.lnM and 30nM MCP-1, monocytes exposed to citrate 
anticoagulation had a consistently greater chemotactic activity compared to 
monocytes which had been exposed to EDTA anticoagulation. Peak response to 
MCP-1 following EDTA anticoagulation occurred at O.lnM with an average of 292 ± 
50.86 migrated cells. This equated to a statistically significant (P<0.01) 3.1 ± 0.52 
fold increase in migration over the unstimulated control cells. Peak response to 
MCP-1 following citrate anticoagulation occurred at 0.3nM with an average of 669 ± 
100.2 migrated cells. This equated to a statistically significant (P<0.01) 5.3 ± 0.81 
fold increase in migration over the unstimulated control cells. In fact, all responses 
between O.lnM and lOnM MCP-1 with citrate anticoagulated cells had statistically 
significant (P<0.01) increases in their activity when compared to their unstimulated 
control cells.
Therefore, all blood collected for further monocyte chemotaxis experiments was 
anticoagulated with citrate as it was felt that this anticoagulant provided the cells 
with the best opportunity for maximal chemotactic activity to other chemoattractants.
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Figure 5.6 The chemotactic response of human peripheral blood monocytes to 
MCP-1 with different anticoagulants. Human peripheral blood was collected from 
the same healthy individual via antecubital vein and anticoagulated in the presence of 
either EDTA or 3.8% sodium citrate. Isolated monocytes were assessed for their 
chemotactic ability in response to MCP-1 over 2 hours in a mircoBoyden chemotaxis 
chamber. Total cells were counted in 10 fields of view per treatment well. Data 
shown are the mean ± SEM (Citrate, n = 9; EDTA, n = 3) of the fold induction over 
unstimulated control cells. Raw cell count data were analysed using one-way 
analysis of variance (ANOVA) followed by Dunnett’s post hoc test. **P<0.01 
(Citrate O.lnM, 0.3nM, InM, 3nM & lOnM versus citrate unstimulated control; 
EDTA O.lnM versus EDTA unstimulated control).
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5.3.4 Population Control & MCP-1 Responses
From each monocyte chemotaxis experiment with four different healthy individuals 
the unstimulated control and MCP-1 (O.lnM) treatment data were compiled to 
produce total population values (figure 5.7). The mean cell count for control cells 
was 146 ± 11.44. Mean MCP-1 cell count was 345 ±  41.33. This corresponds to a
2.4 ± 0.28 fold increase in migration compared to control cells when exposed to 
MCP-1. This fold increase was found to be extremely statistically significant 
(PO.OOl) using an impaired t test.
The total population control was subsequently used to normalise all the experimental 
data between individuals in calculating the folds over the control. The total 
population MCP-1 response was subsequently used as a reference point against 
which experimental data could be compared.
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Control MCP-1
Figure 5.7 Total population control and MCP-1 responses. All experimental data 
for the control and MCP-1 (0.1 nM) responses was consolidated from individual 
monocyte chemotaxis experiments from four healthy individuals. Total cells were 
counted in 10 fields of view per treatment well. Data shown are the mean ± SEM 
fold chemotactic response for MCP-1 over the population control. Mean cell count 
was 146 ± 11.44 for control cells and 345 ± 41.33 for MCP-1 exposed cells. The 
population was 2.4 ± 0.28 fold. Raw cell count data (control, n = 37; MCP-1 n = 30) 
were analysed using an unpaired t test. ***P<0.0001 (MCP-1 versus unstimulated 
control).
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5.3.5 Human Monocytes Migrate Significantly in Response to HB-EGF but not 
EGF
As a result of HB-EGF evoking the greatest migratory response in THP-1 cells, this 
ligand was focused upon in order to investigate the migratory responses of human 
peripheral blood monocytes. EGF was also investigated due to its role as the major 
EGFR ligand.
Using the blood from three healthy individuals, EGF was investigated over a range 
of 0.1 to lOOnM and HB-EGF was investigated over a range of 0.01 to lOnM. 
Monocytes showed their peak chemotactic response to EGF at 0.1 nM (figure 5.8A) 
with an average of 230 ± 33.75 cells migrating. This response was 1.6 ± 0.23 fold 
over the control cells. Peak monocyte chemotactic response to HB-EGF was seen at 
lOnM (figure 5.8B). The average cell count of 355 ± 41.16 corresponded to a 2.4 ± 
0.28 fold increase in chemotactic response over control cells. The chemotactic 
response of monocytes to HB-EGF at lOnM was found to be very statistically 
significant (P<0.01). Further to this, the response seen with HB-EGF at lOnM was 
comparable to that seen with the population response for MCP-1 at O.lnM.
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Figure 5.8 The chemotactic response of human peripheral blood monocytes to 
EGF and HB-EGF. Human peripheral blood monocytes isolated from three healthy 
individuals were assessed for their chemotactic response to EGF and HB-EGF in a 
microBoydon chemotaxis chamber for 2 hours. Total cells were counted in 10 fields 
of view per treatment well. Data shown are the mean ± SEM (control n = 37; MCP-1 
n = 30; EGF/HB-EGF n = 6 ). Raw cell count data were analysed using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison post hoc 
test. **P<0.01 (lOnM HB-EGF versus unstimulated control).
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5,3,6 Blood Monocyte Response to MCP-1 Decreases with Cellular Maturation
Peripheral blood monocytes from four healthy individuals were assessed for their 
ability to respond to MCP-1 during differentiation/maturation into monocyte-derived 
macrophages. Control unstimulated cells did not alter their chemokinetic activity 
over the period of maturation (figure 5.9A). Mean control cell count for monocytes 
was 146 ± 11.44. This reduced to 94 ± 9.52 cells after 48 hours and increased to 110 
± 29.00 cells at 8 days. As there was no statistical difference between the control 
cells over the maturation period it could be assumed that the cells were healthy and 
capable of chemotaxis if  induced to migrate.
In order to assess if  the cellular migratory response to MCP-1 (O.lnM) changed 
during maturation, data from each individual experiment was compiled at each time 
point (figure 5.9B). Monocytes had the largest response to MCP-1 with an average 
of 345 ± 41 cells migrating which equates to a 2.4 ± 0.28 fold increase in migration 
over control unstimulated cells. After 48 hours the number migrating cells dropped 
slightly to 304 ± 28. However, as the number of control cells migrating also 
decreased, the fold increase in migration increased to 3.2 ± 0.29. At 8 days the 
number o f cells migrating in response to MCP-1 dropped dramatically to 106 ± 16, 
equal to the unstimulated control cells at this time point. When compared to 48 hour 
monocytes this decrease in migration was found to be statistically significant 
(P<0.05). This indicated that 8 day monocyte-derived macrophages no longer 
responded chemotactically to MCP-1 at O.lnM.
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Figure 5.9 The effect of monocyte maturation on the chemotactic response to 
MCP-1. Peripheral blood monocytes from four healthy individuals were cultured 
and their chemotactic ability to MCP-1 (O.lnM) was assessed as 2 hour monocytes, 
48 hour monocytes and 8 day monocyte-derived macrophages. Total cells were 
counted in 10 fields of view per treatment well. (A) Unstimulated control cells were 
compared at the three time points. Data shown are the mean ± SEM (monocytes n = 
37; 48 hours n = 11; 8  days n = 6 ). (B) Migratory response of cells at each time 
point to MCP-1 (O.lnM). Data shown are the mean ± SEM (monocytes n = 30; 48 
hours n = 1 2 ; 8 days n = 6 ) of the fold increase in migration over each time point 
control. Data were analysed using one-way analysis of variance (ANOVA) followed 
by Bonferroni’s multiple comparison post hoc test. *P<0.05 (8  day macrophages 
versus 48 hour monocytes).
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5.3.7 Chemotactic Response to HB-EGF Increases with Cellular Maturation
As seen in section 5.3.5, peak monocyte chemotactic response to HB-EGF was seen 
at lOnM (figure 5.10A). The average cell count of 355 ± 41.16 corresponded to a 2.4 
± 0.28 fold increase in chemotactic response over unstimulated control cells. The 
chemotactic response of monocytes to HB-EGF at lOnM was found to be very 
statistically significant (P<0.01). Further to this, the response seen with HB-EGF at 
lOnM was comparable to that seen with the population response for MCP-1 at 
O.lnM.
After 48 hours adherence in tissue culture, the monocytes showed their peak 
chemotactic activity at InM HB-EGF (figure 5.1 OB). The average cell count of 190 
±25.01 corresponded to a 2 ± 0.27 fold induction in chemotaxis over unstimulated 
control cells. This response was two-thirds of that seen for MCP-1 at this time point 
(3.2 ± 0.29 fold over control cells). At 8 days, the monocyte-derived macrophages 
showed their peak response at O.lnM HB-EGF with an average cell count of 228 ± 
44.14 (2 ± 0.40 fold induction over unstimulated control cells) (figure 5.10C). This 
response was 2 fold higher than the response seen with MCP-1 with these cells, 
however, this difference was not found to be statistically significant. Therefore, HB- 
EGF resulted in being the major chemotactic factor for monocyte-derived 
macrophages.
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Figure 5.10 The effect of monocyte maturation on chemotactic response to HB- 
EGF. The chemotactic response to HB-EGF of monocytes (A), 48 hour old 
monocytes (B) and 8 day monocyte-derived macrophages (C) from four healthy 
individuals was investigated in a microBoydon chemotaxis chamber for 2 hours. 
Total cells were counted in 10 fields of view per treatment well. Data shown are the 
mean ± SEM (HB-EGF monocytes n = 6; 48 hours n = 3; 8 days n = 3) of the fold 
increase over unstimulated control cells. See figure 5.9 for control and MCP-1 (n) 
numbers. Raw cell count data were analysed using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparison post hoc test. **/><0.01 
(monocyte lOnM HB-EGF versus monocyte unstimulated control).
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5,3,8 The Monoclonal Antibody ICR62 Inhibits Monocyte Chemotaxis
Having already established that human peripheral blood monocytes migrate in 
response to HB-EGF it was investigated whether this could be inhibited by the 
monoclonal antibody ICR62 (figure 5.11). Peak monocyte migratory response to 
HB-EGF (O.lnM) from one healthy individual was 1.6 ± 0.21 fold higher over 
control cells (average cell count of 232 ± 30.21). This was consistent for the 
population HB-EGF response at this concentration.
Monocytes incubated with ICR62 (50nM) showed a reduced migratory response with 
an average cell count of 164 ± 47.64, only 1.1 ± 0.33 fold over control cells. When 
monocytes were incubated with ICR62 (lOOnM) the drop in migratory response 
compared to HB-EGF was found to be significant (P<0.05). Mean cell count at this 
treatment was 96 ± 15.59 which corresponded to a fold of 0.66 ± 0.11; less migration 
than control cells. Similar reductions in chemotaxis were also observed with the 
IgG2b isotype control at 50nM and lOOnM. However, they were not found to be 
statistically significant.
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Figure 5.11 The inhibition of monocyte chemotaxis with ICR62. Isolated 
peripheral blood monocytes from one healthy individual were incubated with ICR62 
or IgG2b isotype control at 50nM and lOOnM and their chemotactic response to HB- 
EGF (O.lnM) was assessed after 2 hours. Total cells were counted in 10 fields of 
view per treatment well. Data shown are the mean ± SEM (control n = 37; MCP-1 n 
= 6; HB-EGF treatments n = 6) of the fold increase in migration over unstimulated 
control cells. Raw cell count data were analysed using one-way analysis of variance 
(ANOVA) followed by Bonferroni’s post hoc test. *P<0.05 (lOOnM ICR62 versus 
HB-EGF).
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5.4 Discussion
Within this chapter the functional role o f the EGFR and its ligands was investigated 
on monocytic THP-1 cells, differentiated THP-1 cells, human peripheral blood- 
derived monocytes and human macrophage-like cells. Functionality was assessed 
using the MTT assay for cell growth and the chemotaxis assay for migration.
The MTT assay may be used in the measurement of cell proliferation studies that 
traditionally use the incorporation o f radioisotopes as a measurement of cell division 
(Mosmann, 1983). The yellow MTT solution is converted to a water-soluble MTT- 
formazan of a dark blue colour by the mitochondrial dehydrogenases o f living cells. 
The blue crystals are solubilized with the addition of acidified isopropanol and the 
intensity is measured colourimetrically at a wavelength of 570nm. The assay has 
been modified since its original development and has been found to have enhanced
*5
sensitivity compared to methods based on [ H]thymidine incorporation (Gieni et al., 
1995; Twentyman & Luscombe, 1987; Denizot & Lang, 1986; Davis & Czech, 
1984). It has also been validated for use with cells o f the monocytic lineage (Gebre- 
Hiwot et al., 1992; van de Loosdrecht et al., 1991; Ferrari et ah, 1990).
The treatment of monocytic THP-1 cells with EGF, HB-EGF, TGFa or BTC 
produced no discemable change in THP-1 cell growth, be it proliferative or apoptotic 
(figure 5.1 A). However, the THP-1 cells were growing within the system as the 
initial absorbance at the time of treatment was an average of 0.320 ± 0.02 (data not 
shown). When the untreated control cells were assayed 72 hours later, their 
absorbance had increased 3.6 fold to an average o f 1.162 ± 0.03. This increase was 
found to be statistically significant (P<0.001). A difference in cellular growth was
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perhaps not observed with the ligand treatments due to the fact that the cells were not 
maintained in serum-free media. There were perhaps sufficient quantities of 
endogenous growth factors remaining to drive THP-1 cell proliferation.
When the differentiated THP-1 cells were investigated, results for each ligand were 
scattered and no clear trend for either a proliferative or apoptotic response was 
observed (figure 5. IB). The differentiated THP-1 cells were assayed for their initial 
absorbance before treatment. This average absorbance was 0.810 ± 0.02 (data not 
shown). When the untreated control cells were assayed 72 hours later, their 
absorbance had significantly (PO.OOl) increased by 1.3 fold to an average of 1.050 
± 0.05. This again suggested that the cells had been proliferating within those 72 
hours but not to the same extent as the monocytic THP-1 cells. This reduction or 
lack of proliferative ability in the differentiated THP-1 cell is well documented 
(Schwende eta l., 1996; Auwerx, 1991).
Inhibition of the growth of the monocytic THP-1 cells was also investigated. The 
monoclonal antibody ICR62 is known to inhibit ligand binding to the EGF receptor. 
During characterisation, the antibody was found to bind to epitope ‘C’ located within 
the ligand binding domain of the EGFR (Modjtahedi et al., 1993). Incubation of 
THP-1 cells with lpg/ml ICR62 resulted in a statistically significant (P<0.01) 
decrease in cell growth compared to untreated control cells (figure 5.2A). This 
inhibition was sustained up through the more concentrated treatments. The head and 
neck tumour cell line HN5 has complete inhibition of proliferation following 5nM 
treatment with ICR62 (Modjtahedi et al., 1993). The complete loss of proliferation 
in the HN5 cell line is probably due to the fact that the cells heavily rely on the
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EGFR for continued proliferation. Only partial loss o f proliferation is seen with the 
THP-1 cell line probably because the EGFR only plays a part in the cells 
proliferation. It could be investigated in the future to determine whether ICR62 is 
actually inhibiting growth or whether it is inducing apoptosis in THP-1 cells at that 
concentration. It should be noted that without specific antibody isotype control data 
this result should be interpreted with caution as the decrease in cellular growth could 
be due to non-specific binding of the antibody. Further experiments into the 
inhibition of growth o f cells o f the monocytic lineage with ICR62 should include a 
matched isotype control.
Other studies have shown that although treatment of an ovarian cancer cell line with 
varying concentrations of TGFa did not show significant growth promotion, 
monoclonal antibodies against TGFa and EGFR significantly inhibited cell growth 
(Morishige et al., 1991).
As seen with the previous ligand treatments, no effect in growth was seen when 
differentiated THP-1 cells were incubated with ICR62 (figure 5.2B). This is 
probably due to the fact that there are no receptors on the cell surface as 
demonstrated by flow cytometry and immunocytochemical analysis.
HB-EGF and the EGFR have been shown to be responsible for the chemotaxis of 
smooth muscle cells within the developing plaque resulting in the migration of 
medial smooth muscle cells in to the intimal space therefore adding to the further 
developing the plaque (Higashiyama et al., 1993). When THP-1 cells were assessed 
for their chemotactic activity towards the EGFR ligands tested, HB-EGF proved to
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be the most affective chemokine (figure 5.4B). This response was found to be 
greater than that seen with the well characterised monocyte chemokine MCP-1. 
Interestingly, peak chemotactic activity towards HB-EGF was observed at a ten-fold 
lower concentration than that seen with MCP-1 and equivalent peak activity towards 
TGFa was at a third lower concentration than MCP-1. EGFR ligands may have a 
higher affinity for their receptor compared to MCP-1 and its receptor CCR2, 
therefore this may explain why the EGFR ligands exhibit their chemotactic activity 
at lower concentrations. The differential effects o f the ligands could be due to their 
different affinities for the EGFR. HB-EGF has been shown to have a much greater 
affinity for the EGFR than EGF on smooth muscle cells (Higashiyama et al., 1991). 
This could be due to the requirement of cell surface heparin sulphate proteoglycan 
(HSPG) to aid in the binding of HB-EGF to the EGFR (Aviezer & Yayon, 1994; 
Higashiyama et al., 1993). This may explain why HB-EGF is a more efficient 
chemokine than the other ligands tested. When investigating whether differentiated 
THP-1 cells were chemotactic towards the EGFR ligands no responses were seen 
(data not shown). Further to this the cells were also non responsive to MCP-1. 
Studies have shown that THP-1 cell maturation mediated by high concentrations of 
PMA (50nM to lpM) resulted in the down-regulation o f the MCP-1 receptor CCR2 
(Phillips et al., 2005; Denholm & Stankus, 1995). This is consistent with previous 
observations in this thesis as no receptor expression has been observed.
On the basis o f the results observed with the THP-1 cells, HB-EGF was used to 
assess the chemotactic activity of peripheral blood-derived monocytes and 
monocyte-derived macrophages. Peripheral blood-derived monocytes had a 
statistically significant (P<0.01) 2.4 ± 0.28 fold increase in their chemotactic
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response compared to unstimulated control cells when exposed to lOnM HB-EGF 
(figure 5.8B). This was equivalent to the response seen for O.lnM MCP-1 with these 
same cells. Interestingly, as the monocyte matured into an 8 day old monocyte- 
derived macrophage the chemotactic response to O.lnM MCP-1 decreased, whereas 
peak chemotactic activity to HB-EGF occurred at lower concentrations (figure 5.10). 
The decrease in monocyte responsiveness to MCP-1 with maturation has been 
previously observed with a downregulation of CCR2 (Phillips et al., 2005), however, 
why monocyte-derived macrophages should become responsive to HB-EGF at lower 
concentrations is unclear. One explanation could be that in the circulation the 
monocytes are designed to be responsive to MCP-1 and not HB-EGF which explains 
why the monocytes were only chemotactically responsive to HB-EGF at a high 
concentration (lOnM). However, when they enter the tissues and mature into 
macrophages they may change their responsiveness to HB-EGF as the requirement to 
respond to MCP-1 decreases. This would enable the fine tuning of macrophage 
migration within the tissue at very low levels of HB-EGF. Staining for cell markers 
in serial sections showed macrophages to be the main cell type expressing HB-EGF 
mRNA (Reape et al., 1997). Studies have shown that there is increased production 
of HB-EGF protein by macrophages and SMCs in aortic atherosclerotic plaques 
(Miyagawa et al. 1995). This could mean that macrophages contained in certain 
areas within an early lesion could produce HB-EGF in order to guide new 
macrophages to the areas where they are needed, for example areas o f high lipid. It 
has been suggested that lysoPC, a component o f oxidatively modified low-density 
lipoprotein, could up-regulate HB-EGF production in macrophages in human 
atherosclerotic lesions (Reape et al., 1997). This could mean that the regulation or 
modulation of HB-EGF protein synthesis in macrophages might be related to the
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metabolism of oxidized LDL in the intima (Nakata et al., 1996). Infiltration of 
macrophages into the intima appeared to be closely associated with the lesion of 
pathological thickening suggesting that macrophage-derived HB-EGF may play a 
crucial role in the process of coronary atherogenesis at a time when macrophages 
would potentially become a more dominant cell type than SMCs (Nakata et al., 
1996).
The monoclonal antibody ICR62 is known to decrease the binding o f ligand to the 
EGFR and subsequently inhibit tumour growth (Modjtahedi et al., 1993). When 
peripheral blood-derived monocytes were incubated with ICR62 in the chemotaxis 
chamber their activity towards HB-EGF significantly (P<0.05) reduced in a dose 
dependent manner (figure 5.11). This meant that ICR62 was possibly blocking the 
binding of HB-EGF to the EGFR thereby inhibiting chemotaxis. This showed that it 
was indeed the EGFR that was responsible for the chemotaxis o f the blood 
monocytes. The IgG2b isotype control was also investigated alongside ICR62 and 
was also found to inhibit chemotaxis, but not significantly. Information gained 
subsequently concerning this particular antibody revealed that it had become 
contaminated with ICR62 antibody. Therefore another source of isotype control 
should be used in future experiments. Other studies by Chan et al. have shown that 
blockade o f the EGFR with a monoclonal antibody (151-IgG) reduced intimal 
hyperplasia induced by balloon injury in the rat carotid artery. They hypothesised 
that this effect was due to the inhibition of medial SMC proliferation (Chan et al.,
2003).
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5.5 Conclusions
The main aim of this chapter was to discover a potential functional role o f EGF, HB- 
EGF, TGFa and BTC on THP-1 cells and human peripheral blood-derived 
monocytes and macrophage-like cells. Investigation of THP-1 cells with the MTT 
assay showed that the ligands played no role in the survival status o f these particular 
cells. However, when incubated in the presence of the monoclonal antibody ICR62 
THP-1 cell proliferation was significantly inhibited. This would indicate that the 
EGF receptor does indeed play a role in the maintenance of THP-1 cell growth, and 
warrants further investigation in serum-free media.
Chemotaxis experiments showed that monocytic THP-1 cells were chemotactic 
towards the EGFR ligands, most notably HB-EGF and TGFa. The result seen with 
HB-EGF was perhaps due to the heparin-binding domain located within this ligand. 
Interestingly, the chemotactic response to HB-EGF was greater than that observed 
for the major monocyte chemokine MCP-1. However, when these same experiments 
were conducted with differentiated THP-1 cells no such chemotactic activity was 
exhibited. This result ties in with the discovery that the EGFR is not expressed on 
the cell membrane of differentiated THP-1 cells as shown through flow cytometry 
and immunocytochemical analysis in chapter 3. Peripheral blood-derived monocytes 
were also significantly chemotactic towards HB-EGF but not EGF. This may again 
be due to the heparin-binding domain located within the growth factor which aides 
it’s binding to the receptor. This chemotactic response to HB-EGF was found to be 
comparable to the response observed with MCP-1. Interestingly, as the monocyte 
matured into a macrophage-like cell the chemotactic activity towards MCP-1 
decreased and the activity towards HB-EGF increased. This could lead to the
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hypothesis that monocytes are initially attracted to the developing plaque under the 
influence of MCP-1. However, as they mature into tissue macrophages and lose their 
ability to respond to MCP-1, HB-EGF may take over as the major chemokine 
responsible for internal plaque macrophage movement and rearrangement. When 
incubated with the monoclonal antibody ICR62, monocyte chemotactic activity 
towards HB-EGF was significantly inhibited in a dose dependent manner indicating 
that the EGFR was indeed responsible for the chemotactic ability o f monocytes.
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Chapter Six 
Expression of EGFR Within Macrophages ofHuman Arterial 
Sections
6.1 Introduction
The EGFR has been shown to be expressed within the atherosclerotic plaques of 
humans and experimental animals (Tamura et al., 2001; Nanney et al., 1988; Tomita 
et al., 1986). This expression is usually associated with smooth muscle cells 
(Miyagawa et al., 1995) and endothelial cells (Styren et al., 1993). Interestingly the 
expression of the EGFR on SMCs seems to be solely related to the plaque 
environment as the EGFR is not expressed in uie normal artery wall (Miyagawa et 
al., 1995). Furthermore, in the coronary and abdominal arteries o f adults, strong 
EGFR immunostaining has been localized to the SMCs on the border between the 
intima and the media (Nakata et al., 1996; Miyagawa et al., 1995).
Recently the expression of the EGFR has been found to co-localise with 
macrophages in the atherosclerotic lesions of cholesterol-fed rabbits (Lamb et ah,
2004).
6.1.1 Aim
This study aimed to investigate clinical sections o f lesions from patients undergoing 
abdominal aortic aneurism (AAA) repairs of femoral bypass surgery using
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immunohistochemical techniques. Within these samples, the expression of EGFR 
was investigated in relation to monocytes and macrophages within the lesions.
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6.2 Materials & Methods
6.2.1 Sample Collection & Fixation
Samples were collected from patients undergoing abdominal aortic aneurism repairs 
or femoral arterial bypasses at the Royal Surrey County Hospital, Guildford, Surrey, 
UK (ethical approval obtained from South West Surrey Local Research Ethics 
Committee and the University of Surrey Ethics Committee). Tissue samples were 
fixed in 4% paraformaldehyde (Sigma-Aldrich, UK) for 24 hours. Once fixed, 
tissues were washed and placed in 70% ethanol for storage prior to embedding.
6.2.2 Tissue Processing & Sectioning
Samples were processed in a histokinette prior to paraffin embedding. Blocks were 
soaked in 5% formic acid prior to sectioning. Five-micron sections were cut, floated 
onto Superfrost Plus slides (BDH, UK) and air dried over night.
6.2.3 Immunohistochemical Staining & Light Microscopy
Sections were heated at 50°C for 1 hour and then rehydrated in xylene (10 minutes), 
100% ethanol (10 minutes), 95% ethanol (5 minutes), 70% ethanol (3 minutes), 50% 
ethanol (2 minutes) and water. Antigen retrieval was carried out by microwaving 
sections in lOmM tri-sodium citrate in H2O (pH6) for 3 minutes on high and 7 
minutes on medium/low. Sections were washed twice in PBS containing 0.05% 
Tween-20 (Sigma-Aldrich, UK) (PBST) for 5 minutes before endogenous peroxidase 
activity was quenched by incubating sections with 0.3% H2O2 in methanol at room 
temperature for 30 minutes. Sections were again washed in PBST and subsequently
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immunostained using the Vectorstain ABC Elite Reagent kit for mouse or rat 
primary antibodies (Vector Laboratories Inc., Burlingame, CA, USA) following the 
manufacturer’s instructions. All primary antibodies (ICR16, a-SMC actin, HAM56 
and matched isotype controls) were diluted in PBT (0.1% BSA, 0.01% Tween-20 in 
PBS) and incubated on the sections overnight at 4°C in a humidified chamber. 
Sections were washed in PBST between each staining step. The colour peroxidase 
reaction was visualised either using Vector VIP (diluted in PBS) or DAB 
(diaminobenzidine) (diluted in MilliQ H2O) (both Vector Laboratories, USA). 
Sections were then washed in water and dehydrated through an alcohol series; 50% 
ethanol (3 minutes), 70% ethanol (3 minutes), 95% ethanol (5 minutes) and 100% 
(10 minutes). Sections were then cleared in xylene and mounted in DPX (BDH, 
UK).
Sections were visualised using a Leica DMLB microscope equipped with a colour 
JVC TK-C1380 video camera with Qwin image analysis software (Leica, Luton).
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6.3 The Expression of the EGFR within Human Atherosclerotic 
Lesions
The lesion of a male undergoing an AAA repair was investigated for its expression 
of the EGFR. Sections were stained with the monoclonal antibody ICR16 and a 
matched isotype control (figure 6.1A&B). Positive EGFR staining was localised to 
areas of cells with the morphology similar to that of macrophages. Smooth muscle 
cells were localised to the surrounding area around the clump of macrophages (figure 
6.1C).
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Figure 6.1 EGFR staining within human atherosclerotic lesion of a male 
abdominal aortic aneurism. Tissue was collected from a male undergoing an 
abdominal aortic aneurism repair. The sample was fixed, processed and sectioned as 
described in sections 6.2.1 and 6.2.2. Sections were stained as described in section 
6.2.3 with the monoclonal antibody ICR16 (5pg/ml) (A), IgG2a isotype control 
(5pg/ml) (B) or a-SMC actin (1/500 dilution) (C) and visualised with a DAB 
peroxidase system. Sections shown are under x400 (i) and xlOOO (ii) magnification 
for EGFR staining or x 100 (i) and x400 (ii) for SMC staining.
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6.4 The EGFR Co-localises with Macrophages in Human 
Atherosclerotic Lesions
Sections from a female undergoing femoral bypass surgery were double stained for 
EGFR expression with ICR16 and for macrophages with HAM56. Using a single 
stain a macrophage-rich area was identified within the lesion (figure 6.2A). On an 
associate section the presence o f EGFR within this macrophage-rich region was 
investigated. Within the macrophages (pink) the EGFR is clearly expressed (brown) 
as demonstrated by the cell identified by the arrow (figure 6.2B).
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Figure 6.2 EGFR and macrophage staining within human atherosclerotic lesion 
of a female femoral artery. Tissue was collected from a female undergoing a 
femoral bypass. The sample was fixed, processed and sectioned as described in 
sections 6.2.1 and 6.2.2. Sections were stained as described in section 6.2.3 with the 
HAM56 (macrophage) (1/30 dilution) and the monoclonal antibody ICR 16 (EGFR) 
(5pg/ml) and visualised with the Vector VIP (pink) or a DAB (brown) peroxidase 
system. Sections shown are stained with HAM56 and Vector VIP (A), and double 
staining with HAM56 (Vector VIP) and ICR16 (DAB) (B). Samples are shown 
under xlOOO magnification. A HAM56 positive cell expressing EGFR (ICR16) is 
identified by the arrow.
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6.5 Discussion
The aim of this chapter was to establish whether the EGFR co-localises with 
macrophages in human atherosclerotic lesions. Samples of atherosclerotic lesions 
were collected from patients undergoing AAA repairs (average age, 75 years) and 
femoral arterial bypasses (average age, 77 years) at the Royal Surrey County 
Hospital, Guildford, UK. Patients undergoing either type of procedure generally 
have advanced calcified lesions which make the histological process difficult (Stary 
et al., 1995). As a result of this, only a selection of the samples from the 12 patients 
could be sufficiently investigated.
The EGFR was found to be expressed within the lesions of a male AAA with the 
monoclonal antibody ICR16. The positively stained cells had macrophage 
morphology. Smooth muscle cells were also stained for within this lesion (data not 
shown). They were also positive for the EGFR.
Within the sections from a femoral arterial lesion, macrophages were identified using 
the macrophage-specific antibody HAM56. This antibody has been previously used 
for the detection of EGFR in human atherosclerotic plaques (Gown et al., 1986). 
Again, the detection of EGFR expression was carried out using ICR16. Double 
staining techniques revealed that the EGFR was expressed within those cells also 
positive for macrophages. Co-localisation of the EGFR with macrophages has 
previously been observed in uveal melanomas (Scholes et al., 2001).
The main difficulty experienced with this study was the quality o f the lesional 
sample. Many samples were highly calcified which made sectioning extremely
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difficult even following decalcification treatment with formic acid. Perhaps in the 
future in order to confirm the results obtained from this study, tissues could be 
collected from recently deceased individuals. Samples obtained in this fashion may 
provide better examples of earlier more easily analysed plaques. Samples could also 
be obtained from a broad age range from infants to the elderly, as well as from 
different vessels. It is possible that there could be different expression patterns and 
possible roles within different plaques i.e. carotid versus aortic.
In summary, this study aimed to provide evidence that macrophages within 
atherosclerotic plaques express the EGFR. Although the evidence is limited, staining 
for the EGFR was found to co-localise with cells stained positively for macrophages. 
Further investigations would need to be executed, perhaps using more sensitive 
confocal microscopy techniques to confirm the results obtained from this study.
181
Chapter 7 -  Final Conclusions
Chapter Seven 
General Discussion and Concluding Remarks
In this thesis the expression and potential function of the epidermal growth factor 
receptor (EGFR) was investigated in the monocytic THP-1 cell line and human 
peripheral blood-derived monocytes. The EGFR is known to play a role in the 
atherogenic process by mediating the proliferation and migration of smooth muscle 
cells (Higashiyama et al., 1993; Higashiyama et al., 1991). The EGF family of 
ligands, most notably HB-EGF, BTC, TGFa and EPR are also elaborated by smooth 
muscle cells (Tamura et al., 2001; Taylor et al., 1999; Higashiyama et al., 1994; 
Mueller et al., 1990), monocytes/macrophages (Tamura et al., 2001; Mograbi et al., 
1997; Toyoda et ah, 1997; Nakano et al., 1994; Higashiyama et al., 1991; Madtes et 
al., 1988), endothelial cells (Yoshizumi et al., 1992), T lymphocytes (Blotnick et al., 
1994) and platelets (Oka & Orth, 1983). Therefore, it can be concluded that the 
EGFR family plays an important role in the development of atherosclerosis.
Previous studies had reported the expression of the EGFR on human cells of the 
monocytic linage most notably brain-derived microglial cells (Nolte et al., 1997), 
uveal melanoma macrophages (Scholes et al., 2001) and the monocytic cell line 
U937 (Eales-Reynolds et al., 2001). Based on this evidence the expression o f the 
EGFR on rabbit peripheral blood leukocytes was investigated (Lamb et al., 2004). 
These cells were found to express the EGFR and activation resulted in both 
chemotactic and mitogenic responses. The EGFR was also found to co-localise with 
macrophages within the atherosclerotic plaques o f cholesterol-fed rabbits. However,
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to date, no study had investigated the expression of the EGFR on human monocytes 
and macrophages within the context o f atherosclerosis.
The EGFR was found to be minimally expressed on peripheral blood monocyte- 
derived macrophages and to a greater extent on the monocytic cell line THP-1 with 
flow cytometry techniques (figures 3.7 and 3.3 respectively). The THP-1 cell line 
was established from the blood o f a 1 year old boy with acute monocytic leukaemia 
(Tsuchiya et al., 1980). Although characterisation studies concluded that it 
resembled the human monocyte with respect to numerous criteria such as 
morphology, secretory products, oncogene expression, expression of membrane 
antigens and genes involved in lipid metabolism (Auwerx, 1991), recent studies into 
the gene expression of the two cell types have concluded that they are very different 
from a transcriptomic point o f view (Kohro et al., 2004). This could also be a reason 
as to why with quantitative real-time PCR analysis, THP-1 cells demonstrated higher 
levels o f EGFR mRNA than the peripheral blood-derived monocytes and 
macrophages (figures 4.6 and 4.14 respectively). The difference in EGFR expression 
could be due to the transformed nature of the THP-1 cell in that the EGFR 
participates in the normal proliferation status of the cell. The EGFR is often over­
expressed in human carcinomas and amplification o f gene expression has been 
demonstrated to occur in carcinoma patients (Normanno et al., 2006). Care should 
therefore be taken when interpreting the results o f experiments carried out with THP- 
1 cells in which it is otherwise assumed that they are representative of the 
macrophage (Kohro et al., 2004). It should also be noted that a very small number if  
individuals were used to provide monocytes for this study, especially for the flow  
cytometry experiments. These individuals differed in gender, age and genetic
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background, therefore for future experiments, an increased number of individuals 
should be used to provide a more complete picture o f the status of EGFR expression 
on peripheral blood monocytes.
Immunocytochemical studies into the localization of the EGFR within THP-1 cells 
revealed that monocytic THP-1 cells expressed the receptor on their cellular surface 
and within the cytoplasm (figure 3.9). Cells treated with PMA demonstrated nuclear 
localisation o f the EGFR (figure 3.11). This result corroborated the discovery that 
differentiated THP-1 cells did not express the EGFR on their cellular surface with 
flow cytometry and that no functionality could be established following proliferation 
and chemotaxis assays. The purpose of the EGFR nuclear localisation within 
differentiated THP-1 cells is unclear, although in other cells it is associated with 
increased proliferation and DNA damage repair leading to the radioresistance of 
tumours (Chen & Nirodi, 2007; Lin et al., 2001). The nuclear localisation could 
either be a characteristic of the macrophage-like cell or be a specific result of PMA 
treatment within the THP-1 cell. The interaction between the phorbol ester PMA and 
the EGFR is well documented. PMA has been shown to decrease the high-affinity 
binding of EGF to the EGFR and is responsible for its internalisation but not 
degradation in KB cells (Beguinot et al., 1985). PMA is an activator of PKC which 
is known to phosphorylate the EGFR at threonine 654 leading to receptor 
deactivation (King & Cooper, 1986). The loss o f EGFR cell surface expression of 
differentiated THP-1 cells could therefore be due to PMA treatment. It would be 
interesting to investigate the nuclear localisation o f the EGFR following treatment 
with other initiators o f THP-1 cell differentiation for example 1,25-dihydroxyvitamin 
D3, which do not activate PKC (Schwende et al., 1996). PMA has also been found
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to activate EGFR gene transcription via the transcription factor AP-2 (Johnson, 
1996). This confirms the finding that differentiated THP-1 cells had a greater EGFR 
gene expression when compared to monocytic THP-1 cells (figure 4.6).
Investigations into the functionality of the EGFR on THP-1 cells and peripheral 
blood-derived monocytes revealed that the receptor mediated baseline cellular 
proliferation and cellular motility. A decrease in the proliferation of THP-1 cells was 
only observed following treatment with the monoclonal antibody ICR62 (figure 5.2). 
This antibody binds with high affinity to a distinct epitope (termed ‘C’) on the 
extracellular domain o f the human EGFR and is known to inhibit ligand binding and 
completely inhibit cellular proliferation at 5nM (Modjtahedi et al., 1993). Although 
incubation of THP-1 cells with the EGFR ligands failed to increase cellular 
proliferation, ICR62 significantly reduced cell growth, indicating that the EGFR is 
indeed required in part for THP-1 cell growth. This effect was also seen with ICR16, 
another antibody of a different isotype which binds epitope C and is capable of 
inhibiting tumour growth (data not shown). To fully confirm that this inhibitory 
result is due to the functional F(ab’)2 region of the antibody, both experiments 
should be repeated with the appropriate antibody isotype controls. Interestingly, 
when THP-1 cells were incubated with the tyrosine kinase inhibitor gefitnib no 
growth inhibition was observed (data not shown). Gefitnib is a member o f the first 
generation of EGFR tyrosine kinase inhibitors that bind to their target, the catalytic 
site in the intracellular kinase domain, through classic competitive binding with ATP 
(Sequist, 2007; Wakeling et al., 2002). Perhaps no growth inhibition was observed 
because THP-1 cells are not solely dependent on the EGFR for proliferation. It 
might be interesting to repeat the experiment with a second generation tyrosine
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kinase inhibitor. Many of the second-generation compounds form covalent, and 
therefore permanent, bonds with their target, which should theoretically increase their 
effectiveness by prolonging the inhibition of EGFR signalling to the entire lifespan of 
the drug-bound receptor molecule (Sequist, 2007). Examples o f these inhibitors 
include EKB-569 (Wissner et al., 2003), HKI-272 (Rabindran et al., 2004) and CI- 
1033 (Allen et al., 2003).
HB-EGF was found to be the most functionally active of the EGFR ligands 
investigated. It induced EGFR gene expression in THP-1 cells (figure 4.7) and was 
the predominant chemokine for both THP-1 cells (figure 5.4) and peripheral blood- 
derived monocytes and macrophages (figures 5.8 and 5.10 respectively). This 
functional activity could be due in part to its ability to bind cell surface heparin 
sulphate which leads to a higher binding affinity to the EGFR (Higashiyama et al., 
1993). One possible explanation for increased EGFR gene expression following HB- 
EGF treatment could be that if HB-EGF is being released in the vicinity, monocytes 
will be chemotactic towards it. However, in order to increase this response, HB-EGF 
could also stimulate the increased expression o f EGFR in order to allow the cells to 
respond more effectively to the chemotactic stimulus. Both EGF and TGFa are 
capable of stimulating the synthesis o f the EGFR (Burgess, 1989; Bjorge & Kudlow, 
1987) but until now this has not been documented with HB-EGF. However, it is 
important that this phenomenon was observed within the THP-1 cell line and may 
not be representative o f the blood monocyte. EGFR gene expression within blood- 
derived monocytes was extremely low with only an increase seen at 48 hours 
incubation (figure 4.14) which could indicate that the EGFR is required for 
maturation or that with no activation o f the receptor via ligand binding, the gene
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expression is switched off. If the cells were maintained in HB-EGF or another 
stimulus such as a macrophage activator like IFNy perhaps the EGFR would 
continue to have increased expression. It was demonstrated that IFNy increased 
EGFR gene expression in both monocytic and differentiated THP-1 cells (figures 4.8 
and 4.10 respectively). Perhaps within the plaque environment where monocytes are 
in contact with such activating stimuli they may express the EGFR. This hypothesis 
could be supported by the fact that within this study the EGFR has been found to co- 
localise with macrophages in human atherosclerotic plaques (figure 6.2).
Interestingly, as peripheral blood-derived monocytes matured into monocyte-derived 
macrophages and MCP-1 chemotactic activity was lost, the cells developed an 
increased sensitivity or affinity to HB-EGF (figure 5.10). It is known that MCP-1 is 
responsible for the recruitment and infiltration o f monocytes to the developing 
lesion. However, as the monocyte matures into a tissue macrophage and the MCP-1 
receptor is downregulated (Phillips et al., 2005) it could be suggested that HB-EGF 
and the EGFR are involved in the directed migration of macrophages within the 
plaque perhaps to areas o f high lipid content where activated macrophages already 
exist, which elaborate HB-EGF. Importantly, the monoclonal antibody ICR62 
seemed to inhibit the migration o f peripheral blood-derived monocytes in response to 
HB-EGF (figure 5.11) although a more appropriate isotype control antibody should 
be used to confirm this result. Perhaps this could provide a novel therapeutic avenue 
in the prevention or treatment o f atherosclerosis.
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7.1 Future Work
As the expression of the EGFR has only clearly been demonstrated on the THP-1 cell 
by flow cytometry it would be valuable to investigate routes in which the EGFR 
could be upregulated on the surface o f peripheral blood-derived monocytes and 
macrophages. This thesis has clearly demonstrated that receptors are present on 
these cells through functional studies but it is unfortunate that they cannot be ‘seen’ 
to be expressed. Incubation of peripheral blood-derived monocytes and macrophages 
with IFNy. IL-ip, LPS and HB-EGF or combinations of them, could result in the 
upregulation of EGFR gene and protein expression from which signalling pathways 
could be elucidated. Further studies into the functionality o f the EGFR could involve 
investigating the phosphorylation status of the receptor following exposure to the 
different ligands.
Immunocytochemical analysis should also be carried out to determine the 
localisation of the receptors both in blood monocytes and monocyte-derived 
macrophages. This would provide a clear understanding as to the location of the 
receptors in mature macrophages and whether they are also localised within the 
nucleus as seen in differentiated THP-1 cells. Confocal microscopy could be utilised 
for this as it enables visualisation deep within cells to create sharply defined optical 
sections from which three-dimensional images can be created. Radioligand binding 
assays could also be attempted to investigate receptor number and ligand affinity on 
all monocyte cell types. Perhaps the expression of the other receptor family 
members should be investigated. After all, smooth muscle cells will proliferate and 
migrate in response to HB-EGF binding to the EGFR, but only migrate in response to 
HB-EGF binding to ErbB4 (Elenius et al., 1997). Peripheral blood-derived
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monocytes and monocyte-derived macrophages should also be investigated for their 
proliferation or apoptosis following treatment with the ligands and the inhibitory 
antibody ICR62. Inhibition of the receptor at the mRNA level could be achieved 
with siRNA techniques in order to ascertain the basal functionality o f the receptor 
within THP-1 cells and peripheral blood-derived monocytes and macrophages.
EGF receptor expression could also be investigated in lipid laden foam cells. This 
may provide an insight into the functioning o f the macrophage in an advanced plaque 
scenario. Activation of the EGFR by different ligands may result in the gene 
expression o f other important players in the advanced atherosclerotic environment 
such as MMPs. It could be interesting to investigate whether the EGFR is involved 
in the apoptosis o f macrophage foam cells which would o f course lead to the 
development of the necrotic core of the lesion.
Other receptors involved in the progression of atherosclerosis are known to 
transactivate the EGFR such as the PDGF receptor (Saito et al., 2001) and the G- 
protein coupled receptors (GPCRs) for thrombin (Kanda et al., 2001), endothelin 
(Iwasaki et al., 1998) and angiotensin II (Ushio-Fukai et al., 2001).
Since discovering that the EGFR co-localises with macrophages within human 
atherosclerotic lesions o f patients undergoing vascular surgery for advanced 
atherosclerotic lesions the next stage should be to investigate the expression within 
plaques at different stages o f progression. Clinical samples o f this type are usually 
obtained during autopsy. These would give an insight into the role the EGFR has on
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the monocyte or macrophage throughout the progression of the disease and also the 
location of expressing macrophages within the plaque environment
An extension to the study performed by Lamb et al., in 2004 could be carried out. 
Injection of the inhibitory antibody ICR62 into the cholesterol-fed rabbit could 
provide in vivo evidence that the progression of athererosclerosis does depend in part 
on the EGFR and its family o f ligands. Inhibition of the EGFR on monocytes and 
macrophages could result in a decrease in the migration or proliferation of these cells 
and thereby potentially halt or decelerate the development of the atherosclerotic 
plaque.
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